Membrane-related tyrosine and threonine-specific CDC2 inhibitory kinase (PKMYT1) inhibitors and uses thereof

By developing compounds or pharmaceutical compositions that inhibit PKMYT1 and WEE1 kinases, the problems of cell cycle disorders and tumor cell resistance are solved, and effective killing of tumor cells and chemotherapy effects are improved.

CN118900840AActive Publication Date: 2024-11-05INSILICO MEDICINE IP LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202380028691.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-18
Filing Date
2023-02-17
Publication Date
2024-11-05
Estimated Expiration
2043-02-17

AI Technical Summary

Technical Problem

The prior art is difficult to effectively inhibit PKMYT1 kinase, resulting in cell cycle disorders and increased drug resistance of tumor cells to chemotherapy.

Method used

Develop a compound or pharmaceutical composition that interferes with cell cycle regulation by inhibiting PKMYT1 and WEE1 kinases, promotes mitosis and DNA damage repair, thereby enhancing the killing effect on tumor cells.

Benefits of technology

Effectively inhibit PKMYT1 kinase, reduce the drug resistance of tumor cells, enhance the effect of chemotherapy, and provide a new method to treat tumor proliferation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005049864310000021
    Figure BDA0005049864310000021
  • Figure BDA0005049864310000041
    Figure BDA0005049864310000041
  • Figure BDA0005049864310000042
    Figure BDA0005049864310000042
Patent Text Reader

Abstract

Described herein are inhibitors of PKMYT1 (Myt1) and pharmaceutical compositions comprising the inhibitors. The compounds and compositions of the invention are useful for the treatment of diseases or conditions associated with PKMYT1.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-references

[0002] This patent application claims the benefit of international application PCT / CN2022 / 076941 filed on February 18, 2022; the entire text of which is incorporated herein by reference. Background Art

[0003] PKMYT1 (or Myt1) is a member of the Wee family and was first reported as a kinase that can effectively phosphorylate Cdc2 on both threonine-14 and tyrosine-15 in the African clawed frog. PKMYT1 inhibits cell cycle progression by inhibiting the activity of cell cycle-related proteins such as cyclin A, CDK1 and CDK2. PKMYT1 also drives the progression of a variety of tumors.

[0004] Inhibitory phosphorylation of cdc2 is important for the timing of entry into mitosis. Entry into mitosis is initiated by the M phase promoting factor (MPF), a complex containing the cdc2 protein kinase and cyclin B. Proper regulation of MPF ensures that mitosis occurs only after the early stages of the cell cycle are completed. Phosphorylation of cdc2 at Tyr-15 and Thr-14 inhibits this activity during interphase (Gl, S, and G2). At the G2-M transition, cdc2 is dephosphorylated at Tyr-15 and Thr-14, allowing MPF to phosphorylate its mitotic substrates.

[0005] Studies have shown that premature activation of cdc2 leads to mitotic catastrophe and cell death. Inhibition of Myt1 is predicted to lead to premature activation of cdc2, killing rapidly proliferating cells. Furthermore, Myt1 inhibition is predicted to reduce resistance to conventional DNA-damaging chemotherapeutic agents, as the mechanism by which cells avoid death involves arrest in the G2 phase of the cell cycle, and repair or DNA damage prior to division. This arrest should be prevented by blocking Myt1 inhibitory phosphorylation of cdc2, thereby forcing cells to enter mitosis prematurely. Myt1 kinase is an important cell cycle regulator, particularly during the G2 / M phase. This is due to cell cycle regulation and subsequent repair of damage to DNA or the mitotic apparatus, which is the target of the most effective chemotherapeutic agents. Myt1 kinase provides an intervention point downstream of these mechanisms by which tumor cells develop resistance. Inhibition of Myt1 may have therapeutic benefits in itself in reducing tumor proliferation, and moreover, could be used in combination with conventional chemotherapy to overcome resistance.

[0006] Based on the foregoing, there is a need to identify effective PKMYT1 (Myt1) kinase inhibitors for the treatment of cancer. Summary of the invention

[0007] Disclosed herein is a compound of formula (I) or a pharmaceutically acceptable salt thereof:

[0008]

[0009] in:

[0010] Ring A is cycloalkyl, heterocycloalkyl, aryl or heteroaryl;

[0011] Each R 1 are independently halogen, -CN, -NO2, -OH, -OR a 、-OC(=O)R a 、-OC(=O)OR b 、-OC(=O)NR c R d , -SH, -SR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR c R d 、-NR c R d 、-NR b C(=O)NR c R d 、-NR b C(=O)R a 、-NR b C(=O)OR b 、-NR b S(=O)2R a 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are independently and optionally replaced by one or more R 1a replace;

[0012] or two R on the same atom 1 Together they form an oxo group;

[0013] Each R 1a are independently halogen, -CN, -NO2, -OH, -OR a 、-OC(=O)R a 、-OC(=O)OR b 、-OC(=O)NRc R d , -SH, -SR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR c R d 、-NR c R d 、-NR b C(=O)NR c R d 、-NR b C(=O)R a 、-NR b C(=O)OR b 、-NR b S(=O)2R a 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently optionally substituted with one or more R;

[0014] or two R on the same atom 1a Together they form an oxo group;

[0015] n is 0-6;

[0016] R 2 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl or heterocycloalkyl;

[0017] W is N or CR W ;

[0018] R W It is hydrogen, halogen, -CN, -OH, -OR a , -SH, -SR a 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally replaced by one or more R Wa replace;

[0019] Each R Wa are independently halogen, -CN, -NO2, -OH, -OR a , -SH, -SR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR c R d 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently optionally substituted with one or more R;

[0020] or two R on the same atom Wa Together they form an oxo group;

[0021] X is N or CR X ;

[0022] R X It is hydrogen, halogen, -CN, -OH, -OR a 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted with one or more R;

[0023] Y is N or CR Y ;

[0024] R Y It is hydrogen, halogen, -CN, -OH, -OR a 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted with one or more R;

[0025] Z is N or CR Z ;

[0026] R Z It is hydrogen, halogen, -CN, -OH, -OR a 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted with one or more R;

[0027] R 3 is halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl or C1-C6 heteroalkyl, cycloalkyl or heterocycloalkyl;

[0028] R 4 is halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl or C1-C6 heteroalkyl, cycloalkyl or heterocycloalkyl;

[0029] R 5 It is hydrogen, halogen, -CN, -NO2, -OH, -OR a 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NRc R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl or heterocycloalkyl;

[0030] R 6 It is hydrogen, halogen, -CN, -NO2, -OH, -OR a 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl or heterocycloalkyl;

[0031] Each R a is independently C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl), wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are independently optionally substituted with one or more R;

[0032] Or two R a taken together with the atoms to which they are attached form heterocycloalkyl optionally substituted with one or more R;

[0033] Each R b is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene(cycloalkyl), C1-C6 alkylene(heterocycloalkyl), C1-C6 alkylene(aryl) or C1-C6 alkylene(heteroaryl), wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently optionally substituted with one or more R;

[0034] Or two R b taken together with the atoms to which they are attached form heterocycloalkyl optionally substituted with one or more R;

[0035] R c and Rd each independently is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene(cycloalkyl), C1-C6 alkylene(heterocycloalkyl), C1-C6 alkylene(aryl) or C1-C6 alkylene(heteroaryl), wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently optionally substituted with one or more R;

[0036] or R c and R d taken together with the atoms to which they are attached form heterocycloalkyl optionally substituted with one or more R; and

[0037] each R is independently halogen, -CN, -OH, -S(=O)CH3, -S(=O)2CH3, -S(=O)2NH2, -S(=O)2NHCH3, -S(=O)2N(CH3)2, -NH2, -NHCH3, -N(CH3)2, -C(=O)CH3, -C(=O)OH, -C(=O)OCH3, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl or C3-C6 cycloalkyl;

[0038] Alternatively, two R's on the same atom form an oxo group.

[0039] In some embodiments of the compound of Formula (I), the compound has Formula (Ia):

[0040]

[0041] In some embodiments of the compound of Formula (I), the compound has Formula (Ib):

[0042]

[0043] In some embodiments of the compound of Formula (I), the compound has Formula (Ic):

[0044]

[0045] Also disclosed herein is a pharmaceutical composition comprising a compound disclosed herein or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0046] Also disclosed herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a compound disclosed herein or a pharmaceutically acceptable salt thereof.

[0047] Also disclosed herein is a method of modulating PKMYT1 in a subject, the method comprising administering to the subject a compound disclosed herein or a pharmaceutically acceptable salt thereof.

[0048] Also disclosed herein is a method of inhibiting PKMYT1 in a subject, the method comprising administering to the subject a compound disclosed herein or a pharmaceutically acceptable salt thereof.

[0049] Also disclosed herein is a method of inhibiting PKMYT1 and WEE1 in a subject, the method comprising administering to the subject a compound disclosed herein or a pharmaceutically acceptable salt thereof.

[0050] In some embodiments, the subject has cancer. In some embodiments, the cancer depends on the activity of PKMYT1. In some embodiments, the cancer overexpresses CCNE1. In some embodiments, the cancer has an inactivating mutation in the FBXW7 gene. In some embodiments, the cancer is a solid tumor. In some embodiments, the cancer is breast cancer, colorectal cancer, endometrial cancer, esophageal cancer, glioblastoma, hepatocellular carcinoma, lung cancer, neuroblastoma, ovarian cancer, prostate cancer, gastric cancer, or uterine cancer.

[0051] Incorporated by Reference

[0052] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. DETAILED DESCRIPTION

[0053] definition

[0054] In the following description, certain specific details are set forth in order to provide a thorough understanding of the various embodiments. However, those skilled in the art will appreciate that the present invention may be practiced without these details. In other cases, well-known structures are not shown or described in detail to avoid unnecessarily obscuring the description of the embodiments. Unless the context requires otherwise, throughout the specification and the claims that follow, the word "comprise" and variations thereof, such as "comprises" and "comprising" should be interpreted in an open, inclusive sense, i.e., "including, but not limited to". In addition, the headings provided herein are for convenience only and do not interpret the scope or meaning of the claimed invention.

[0055] References throughout this specification to "some embodiments" or "embodiments" mean that a particular feature, structure, or characteristic described in conjunction with the embodiment is included in at least one embodiment. Therefore, the appearance of the phrase "in one embodiment" or "in an embodiment" throughout this specification does not necessarily refer to the same embodiment. In addition, in one or more embodiments, the particular features, structures, or characteristics may be combined in any suitable manner. In addition, as used in this specification and the appended claims, unless the content clearly provides otherwise, the singular forms "a / an" and "the" include multiple referents. It should also be noted that unless the content clearly provides otherwise, the term "or" is generally used in its meaning that includes "and / or".

[0056] Unless otherwise indicated, the following terms as used herein have the following meanings:

[0057] "Oxo" refers to =0.

[0058] "Carboxyl" refers to -COOH.

[0059] "Cyano" refers to -CN.

[0060] "Alkyl" refers to a straight or branched saturated hydrocarbon monovalent radical having one to about ten carbon atoms, more preferably one to six carbon atoms. Examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl and hexyl, as well as longer alkyl groups such as heptyl, octyl, etc. Whenever a numerical range appears herein, such as "C1-C6 alkyl" or "C 1-6 The term "alkyl" means that the alkyl group can be composed of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, but the definition also covers the occurrence of the term "alkyl" without specifying a numerical range. In some embodiments, the alkyl group is C 1-10 In some embodiments, the alkyl group is C 1-6 In some embodiments, the alkyl group is C 1-5 In some embodiments, the alkyl group is C 1-4 In some embodiments, the alkyl group is C 1-3Alkyl. Unless otherwise specifically stated in the specification, alkyl can be optionally substituted, for example, by oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, alkyl is optionally substituted by oxo, halogen, -CN, -COOH, -COOMe, -OH, -OMe, -NH or -NO. In some embodiments, alkyl is optionally substituted by halogen, -CN, -OH or -OMe. In some embodiments, alkyl is optionally substituted by halogen.

[0061] "Alkenyl" refers to a straight or branched hydrocarbon monovalent radical having one or more carbon-carbon double bonds and having two to about ten carbon atoms, more preferably two to about six carbon atoms. The group can be in cis or trans conformation about the double bond and is understood to include both isomers. Examples include, but are not limited to, vinyl (-CH=CH2), 1-propenyl (-CH2CH=CH2), isopropenyl [-C(CH3)=CH2], butenyl, 1,3-butadienyl, etc. Whenever it appears in this document, a numerical range such as "C2-C6 alkenyl" or "C 2-6 "Alkenyl" means that the alkenyl group can be composed of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, but the present definition also covers the occurrence of the term "alkenyl" without specifying a numerical range. Unless otherwise specifically stated in the specification, the alkenyl group can be optionally substituted, for example, by oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, the alkenyl group is optionally substituted by oxo, halogen, -CN, -COOH, -COOMe, -OH, -OMe, -NH2 or -NO2. In some embodiments, the alkenyl group is optionally substituted by halogen, -CN, -OH or -OMe. In some embodiments, the alkenyl group is optionally substituted by halogen.

[0062] "Alkynyl" refers to a straight or branched hydrocarbon monovalent radical having one or more carbon-carbon triple bonds and having two to about ten carbon atoms, more preferably two to about six carbon atoms. Examples include, but are not limited to, ethynyl, 2-propynyl, 2-butynyl, 1,3-butadiynyl, and the like. Whenever a numerical range such as "C2-C6 alkynyl" or "C 2-6"Alkynyl" means that the alkynyl group can be composed of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, but the present definition also covers the occurrence of the term "alkynyl" without specifying a numerical range. Unless otherwise specifically stated in the specification, the alkynyl group can be optionally substituted, for example, by oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, the alkynyl group is optionally substituted by oxo, halogen, -CN, -COOH, COOMe, -OH, -OMe, -NH2 or -NO2. In some embodiments, the alkynyl group is optionally substituted by halogen, -CN, -OH or -OMe. In some embodiments, the alkynyl group is optionally substituted by halogen.

[0063] "Alkylene" refers to a straight or branched divalent hydrocarbon chain. Unless otherwise specifically stated in the specification, alkylene can be optionally substituted, for example, by oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, alkylene is optionally substituted by oxo, halogen, -CN, -COOH, COOMe, -OH, -OMe, -NH or -NO. In some embodiments, alkylene is optionally substituted by halogen, -CN, -OH or -OMe. In some embodiments, alkylene is optionally substituted by halogen.

[0064] "Alkoxy" refers to a group of the formula -OR a A group in which R a It is an alkyl group as defined. Unless specifically stated otherwise in the specification, alkoxy can be optionally substituted, for example, by oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, alkoxy is optionally substituted by halogen, -CN, -COOH, COOMe, -OH, -OMe, -NH or -NO. In some embodiments, alkoxy is optionally substituted by halogen, -CN, -OH or -OMe. In some embodiments, alkoxy is optionally substituted by halogen.

[0065] "Aryl" refers to a group derived from a hydrocarbon ring system comprising 6 to 30 carbon atoms and at least one aromatic ring. Aryl can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include a fused (when fused with a cycloalkyl or heterocycloalkyl ring, the aryl is bonded by an aromatic ring atom) or a bridged ring system. In some embodiments, aryl is a 6- to 10-membered aryl. In some embodiments, aryl is a 6-membered aryl (phenyl). Aryl includes but is not limited to aryl derived from anthracene, naphthyl, phenanthrenyl, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, asymmetric indacene, symmetric indacene, indane, indene, naphthalene, phenanthene, phenanthren, pyrene and triphenylene hydrocarbon ring system. Unless otherwise specifically stated in the specification, aryl can be optionally substituted by halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl etc. In some embodiments, aryl is optionally substituted by halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF , -OH, -OMe, -NH or -NO . In some embodiments, aryl is optionally substituted by halogen, methyl, ethyl, -CN, -CF , -OH or -OMe. In some embodiments, aryl is optionally substituted by halogen.

[0066] "Cycloalkyl" refers to a partially or fully saturated monocyclic or polycyclic carbocyclic ring, which may include fused (when fused to an aryl or heteroaryl ring, the cycloalkyl is bonded through a non-aromatic ring atom), spirocyclic, or bridged ring systems. In some embodiments, the cycloalkyl is fully saturated. Representative cycloalkyls include, but are not limited to, cycloalkyls having three to fifteen carbon atoms (C3-C 15 Cycloalkyl or C3-C 15 cycloalkenyl), three to ten carbon atoms (C3-C 10 Cycloalkyl or C3-C 10In some embodiments, the cycloalkyl group is a 3- to 10-membered cycloalkyl group or a 3- to 10-membered cycloalkenyl group. In some embodiments, the cycloalkyl group is a 3- to 6-membered cycloalkyl group or a 3- to 6-membered cycloalkenyl group. In some embodiments, the cycloalkyl group is a 5- to 6-membered cycloalkyl group or a 5- to 6-membered cycloalkenyl group. Monocyclic cycloalkyl groups include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic cycloalkyl includes, for example, adamantyl, norbornyl, decalinyl, bicyclo[3.3.0]octane, bicyclo[4.3.0]nonane, cis-decalin, trans-decalin, bicyclo[2.1.1]hexane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane and bicyclo[3.3.2]decane, and 7,7-dimethyl-bicyclo[2.2.1]heptane. Partially saturated cycloalkyl includes, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl. Unless otherwise specifically stated in the specification, cycloalkyl is optionally substituted, for example, by oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, cycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF3, -OH, -OMe, -NH2 or -NO2. In some embodiments, cycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH or -OMe. In some embodiments, cycloalkyl is optionally substituted with halogen.

[0067] "Halo" or "halogen" refers to bromo, chloro, fluoro, or iodo. In some embodiments, halogen is fluoro or chloro. In some embodiments, halogen is fluoro.

[0068] "Haloalkyl" refers to an alkyl group as defined above substituted with one or more halo groups as defined above, for example, trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, and the like.

[0069] "Hydroxyalkyl" refers to an alkyl group as defined above that is substituted with one or more hydroxyl groups. In some embodiments, the alkyl group is substituted with one hydroxyl group. In some embodiments, the alkyl group is substituted with one, two, or three hydroxyl groups. Hydroxyalkyl groups include, for example, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, or hydroxypentyl. In some embodiments, the hydroxyalkyl group is hydroxymethyl.

[0070] "Aminoalkyl" refers to an alkyl group as defined above that is substituted with one or more amines. In some embodiments, the alkyl group is substituted with one amine. In some embodiments, the alkyl group is substituted with one, two, or three amines. Aminoalkyl groups include, for example, aminomethyl, aminoethyl, aminopropyl, aminobutyl, or aminopentyl. In some embodiments, the aminoalkyl group is aminomethyl.

[0071] "Heteroalkyl" refers to an alkyl group in which one or more of the backbone atoms of the alkyl group are selected from atoms other than carbon (e.g., oxygen, nitrogen (e.g., -NH-, -N(alkyl)-), sulfur, phosphorus, or a combination thereof). The heteroalkyl group is attached to the rest of the molecule at a carbon atom of the heteroalkyl group. In one aspect, the heteroalkyl group is a C1-C6 heteroalkyl group, wherein the heteroalkyl group is composed of 1 to 6 carbon atoms and one or more atoms other than carbon (e.g., oxygen, nitrogen (e.g., -NH-, -N(alkyl)-), sulfur, phosphorus, or a combination thereof), wherein the heteroalkyl group is attached to the rest of the molecule at a carbon atom of the heteroalkyl group. Examples of such heteroalkyl groups are, for example, -CH2OCH3, -CH2CH2OCH3, -CH2CH2OCH2CH2OCH3, -CH(CH3)OCH3, -CH2NHCH3, -CH2N(CH3)2, -CH2CH2NHCH3, or -CH2CH2N(CH3)2. Unless otherwise specifically stated in the specification, heteroalkyl is optionally substituted by, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, heteroalkyl is optionally substituted by oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2 or -NO2. In some embodiments, heteroalkyl is optionally substituted by oxo, halogen, methyl, ethyl, -CN, -CF3, -OH or -OMe. In some embodiments, heteroalkyl is optionally substituted by halogen.

[0072] "Heterocycloalkyl" refers to a 3- to 24-membered partially or fully saturated ring group containing 2 to 23 carbon atoms and 1 to 8 heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorus, silicon and sulfur. In some embodiments, heterocycloalkyl is fully saturated. In some embodiments, heterocycloalkyl contains one to three heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. In some embodiments, heterocycloalkyl contains one to three heteroatoms selected from the group consisting of nitrogen and oxygen. In some embodiments, heterocycloalkyl contains one to three nitrogen. In some embodiments, heterocycloalkyl contains one or two nitrogen. In some embodiments, heterocycloalkyl contains one nitrogen. In some embodiments, heterocycloalkyl contains one nitrogen and one oxygen. Unless otherwise specifically stated in the specification, the heterocycloalkyl group may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include a fused (when fused to an aryl or heteroaryl ring, the heterocycloalkyl group is bonded through a non-aromatic ring atom), a spirocyclic or a bridged ring system; and the nitrogen, carbon or sulfur atoms in the heterocycloalkyl group may be optionally oxidized; the nitrogen atom may be optionally quaternized. Representative heterocycloalkyl groups include, but are not limited to, groups having two to fifteen carbon atoms (C2-C 15 Heterocycloalkyl or C2-C 15 Heterocycloalkenyl), two to ten carbon atoms (C2-C 10 Heterocycloalkyl or C2-C 10C2-C8 heterocycloalkyl or C2-C8 heterocycloalkenyl), C2-C7 heterocycloalkyl or C2-C7 heterocycloalkenyl), C2-C6 heterocycloalkyl or C2-C7 heterocycloalkenyl), C2-C5 heterocycloalkyl or C2-C5 heterocycloalkenyl), or C2-C4 heterocycloalkyl or C2-C4 heterocycloalkenyl. Examples of such heterocycloalkyl groups include, but are not limited to, aziridinyl, azetidinyl, oxetanyl, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolinyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, Pyrazolidinyl, quinuclidine, thiazolidinyl, tetrahydrofuranyl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiomorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, 1,3-dihydroisobenzofuran-1-yl, 3-oxo-1,3-dihydroisobenzofuran-1-yl, methyl-2-oxo-1,3-dioxol-4-yl and 2-oxo-1,3-dioxol-4-yl. The term heterocycloalkyl also includes all ring forms of carbohydrates, including but not limited to monosaccharides, disaccharides and oligosaccharides. In some embodiments, heterocycloalkyl has 2 to 10 carbons in the ring. It should be understood that when referring to the number of carbon atoms in heterocycloalkyl, the number of carbon atoms in heterocycloalkyl is different from the total number of atoms (including heteroatoms) (i.e., the skeleton atoms of heterocycloalkyl ring) constituting heterocycloalkyl. In some embodiments, heterocycloalkyl is a 3- to 8-membered heterocycloalkyl. In some embodiments, heterocycloalkyl is a 3- to 7-membered heterocycloalkyl. In some embodiments, heterocycloalkyl is a 3- to 6-membered heterocycloalkyl. In some embodiments, heterocycloalkyl is a 4- to 6-membered heterocycloalkyl. In some embodiments, heterocycloalkyl is a 5- to 6-membered heterocycloalkyl. In some embodiments, heterocycloalkyl is a 3- to 8-membered heterocycloalkenyl. In some embodiments, heterocycloalkyl is a 3- to 7-membered heterocycloalkenyl. In some embodiments, heterocycloalkyl is a 3- to 6-membered heterocycloalkenyl. In some embodiments, heterocycloalkyl is a 4- to 6-membered heterocycloalkenyl. In some embodiments, heterocycloalkyl is a 5- to 6-membered heterocycloalkenyl. Unless otherwise specifically stated in the specification, heterocycloalkyl can be optionally substituted as described below, for example, by oxo, halogen, amino, nitrile, nitro, hydroxy, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, heterocycloalkyl is optionally substituted by oxo, halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF3, -OH, -OMe, -NH2 or -NO2.In some embodiments, heterocycloalkyl is optionally substituted by halogen, methyl, ethyl, -CN, -CF3, -OH or -OMe. In some embodiments, heterocycloalkyl is optionally substituted by halogen.

[0073] "Heteroaryl" refers to a 5- to 14-membered ring system group containing one to thirteen carbon atoms, one to six heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorus and sulfur, and at least one aromatic ring. In some embodiments, the heteroaryl group contains one to three heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. In some embodiments, the heteroaryl group contains one to three heteroatoms selected from the group consisting of nitrogen and oxygen. In some embodiments, the heteroaryl group contains one to three nitrogens. In some embodiments, the heteroaryl group contains one or two nitrogens. In some embodiments, the heteroaryl group contains one nitrogen. The heteroaryl group can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include a fused (when fused with a cycloalkyl or heterocycloalkyl ring, the heteroaryl group is bonded by an aromatic ring atom) or a bridged ring system; and the nitrogen, carbon or sulfur atoms in the heteroaryl group can be optionally oxidized; the nitrogen atom can be optionally quaternized. In some embodiments, the heteroaryl group is a 5- to 10-membered heteroaryl group. In some embodiments, the heteroaryl group is a 5- to 6-membered heteroaryl group. In some embodiments, the heteroaryl group is a 6-membered heteroaryl group. In some embodiments, the heteroaryl group is a 5-membered heteroaryl group. Examples include, but are not limited to, azepine, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxinyl, benzopyranyl, benzopyrone, benzofuranyl, benzofuranone, benzothiophenyl (benzophenylthio), benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzophenylthio, furanyl, furanone, isothiazolyl, imidazolyl, indazolyl, indolyl, isoindolyl, indolinyl, isoindolyl, isoquinolinyl, indolizinyl, isoxazolyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinetrienyl, oxazolyl, oxiranyl, 1-oxidopyridinyl, 1-oxidopyrimidinyl, 1-oxidopyrazinyl, 1-oxidopyridazinyl, 1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and thiophenyl (i.e., thienyl). Unless otherwise specifically stated in the specification, heteroaryl groups may be optionally substituted, for example, by halogen, amino, nitrile, nitro, hydroxy, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, heteroaryl groups are optionally substituted by halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF3, -OH, -OMe, -NH2, or -NO2.In some embodiments, heteroaryl is optionally substituted by halogen, methyl, ethyl, -CN, -CF3, -OH or -OMe. In some embodiments, heteroaryl is optionally substituted by halogen.

[0074] The term "optional" or "optionally" means that the event or situation described subsequently may or may not occur, and the description includes both situations where the event or situation occurs and situations where it does not occur. For example, "optionally substituted alkyl" means "alkyl" or "substituted alkyl" as defined above. In addition, the optionally substituted group can be unsubstituted (e.g., -CH2CH3), fully substituted (e.g., -CF2CF3), monosubstituted (e.g., -CH2CH2F) or substituted at any level between fully substituted and monosubstituted (e.g., -CH2CHF2, -CH2CF3, -CF2CH3, -CFHCHF2, etc.). It will be understood by those skilled in the art that, with respect to any group containing one or more substituents, such groups are not intended to introduce any sterically impractical and / or synthetically infeasible substitution or substitution pattern (e.g., substituted alkyl includes optionally substituted cycloalkyl, which is in turn defined to include optionally substituted alkyl, possibly indefinitely). Thus, any substituents described will generally be understood to have a maximum molecular weight of about 1,000 Daltons, and more typically, up to about 500 Daltons.

[0075] When referring to optional substituents, the term "one or more" means that the main group is optionally substituted by one, two, three or four substituents. In some embodiments, the main group is optionally substituted by one, two or three substituents. In some embodiments, the main group is optionally substituted by one or two substituents. In some embodiments, the main group is optionally substituted by one substituent. In some embodiments, the main group is optionally substituted by two substituents.

[0076] "Effective amount" or "therapeutically effective amount" refers to that amount of a compound administered to a mammalian subject, either in a single dose or as part of a series of doses, which is effective to produce the desired therapeutic effect.

[0077] As used herein, the terms "treat," "treating," or "treatment" include alleviating, reducing, or ameliorating at least one symptom of a disease or condition, preventing additional symptoms, inhibiting a disease or condition, such as arresting the development of a disease or condition, relieving a disease or condition, causing regression of a disease or condition, relieving a condition caused by a disease or condition, or halting symptoms of a disease or condition.

[0078] As used herein, a "disease or condition associated with PKMYT1" or alternatively a "PKMYT1-mediated disease or condition" means any disease or other deleterious condition in which PKMYT1 or a mutant thereof is known or suspected to play a role.

[0079] As used herein, a "disease or disorder associated with Myt1" or alternatively a "Myt1-mediated disease or disorder" means any disease or other deleterious condition in which Myt1 or a mutant thereof is known or suspected to play a role.

[0080] Compound

[0081] Described herein are compounds or pharmaceutically acceptable salts thereof for use in treating a disease or condition associated with PKMYT1.

[0082] Disclosed herein is a compound of formula (I) or a pharmaceutically acceptable salt thereof:

[0083]

[0084] in:

[0085] Ring A is cycloalkyl, heterocycloalkyl, aryl or heteroaryl;

[0086] Each R 1 are independently halogen, -CN, -NO2, -OH, -OR a 、-OC(=O)R a 、-OC(=O)OR b 、-OC(=O)NR c R d , -SH, -SR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR c R d 、-NR c R d 、-NR b C(=O)NR c R d 、-NR b C(=O)R a 、-NR b C(=O)OR b 、-NR b S(=O)2R a 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are independently and optionally replaced by one or more R 1a replace;

[0087] or two R on the same atom 1 Together they form an oxo group;

[0088] Each R 1a are independently halogen, -CN, -NO2, -OH, -OR a 、-OC(=O)R a 、-OC(=O)OR b 、-OC(=O)NR c R d , -SH, -SR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR c R d 、-NR c R d 、-NR b C(=O)NR c R d 、-NR b C(=O)R a 、-NR b C(=O)OR b 、-NR b S(=O)2R a 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently optionally substituted with one or more R;

[0089] or two R on the same atom 1a Together they form an oxo group;

[0090] n is 0-6;

[0091] R 2is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl or heterocycloalkyl;

[0092] W is N or CR W ;

[0093] R W It is hydrogen, halogen, -CN, -OH, -OR a , -SH, -SR a 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally replaced by one or more R Wa replace;

[0094] Each R Wa are independently halogen, -CN, -NO2, -OH, -OR a , -SH, -SR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR c R d 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently optionally substituted with one or more R;

[0095] or two R on the same atom Wa Together they form an oxo group;

[0096] X is N or CR X ;

[0097] R XIt is hydrogen, halogen, -CN, -OH, -OR a 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted with one or more R;

[0098] Y is N or CR Y ;

[0099] R Y It is hydrogen, halogen, -CN, -OH, -OR a 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted with one or more R;

[0100] Z is N or CR Z ;

[0101] R Z It is hydrogen, halogen, -CN, -OH, -OR a 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted with one or more R;

[0102] R 3is halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl or C1-C6 heteroalkyl, cycloalkyl or heterocycloalkyl;

[0103] R 4 is halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl or C1-C6 heteroalkyl, cycloalkyl or heterocycloalkyl;

[0104] R 5 It is hydrogen, halogen, -CN, -NO2, -OH, -OR a 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl or heterocycloalkyl;

[0105] R 6 It is hydrogen, halogen, -CN, -NO2, -OH, -OR a 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl or heterocycloalkyl;

[0106] Each R a is independently C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl), wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are independently optionally substituted with one or more R;

[0107] Or two R a taken together with the atoms to which they are attached form heterocycloalkyl optionally substituted with one or more R;

[0108] Each R b is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene(cycloalkyl), C1-C6 alkylene(heterocycloalkyl), C1-C6 alkylene(aryl) or C1-C6 alkylene(heteroaryl), wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently optionally substituted with one or more R;

[0109] Or two R b taken together with the atoms to which they are attached form heterocycloalkyl optionally substituted with one or more R;

[0110] R c and R d each independently is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene(cycloalkyl), C1-C6 alkylene(heterocycloalkyl), C1-C6 alkylene(aryl) or C1-C6 alkylene(heteroaryl), wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently optionally substituted with one or more R;

[0111] or R c and R d taken together with the atoms to which they are attached form heterocycloalkyl optionally substituted with one or more R; and

[0112] each R is independently halogen, -CN, -OH, -S(=O)CH3, -S(=O)2CH3, -S(=O)2NH2, -S(=O)2NHCH3, -S(=O)2N(CH3)2, -NH2, -NHCH3, -N(CH3)2, -C(=O)CH3, -C(=O)OH, -C(=O)OCH3, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl or C3-C6 cycloalkyl;

[0113] Alternatively, two R's on the same atom form an oxo group.

[0114] Disclosed herein is a compound of formula (I) or a pharmaceutically acceptable salt thereof:

[0115]

[0116] in:

[0117] Ring A is cycloalkyl, heterocycloalkyl, aryl or heteroaryl;

[0118] Each R 1 are independently halogen, -CN, -NO2, -OH, -OR a 、-OC(=O)R a 、-OC(=O)OR b 、-OC(=O)NR c R d , -SH, -SR a 、-S(=O)R a 、-S(=O)2R a 、-S(=O)2NR c R d 、-NR c R d 、-NR b C(=O)NR c R d 、-NR b C(=O)R a 、-NR b C(=O)OR b 、-NR b S(=O)2R a 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are independently and optionally replaced by one or more R 1a replace;

[0119] or two R on the same atom 1 Together they form an oxo group;

[0120] Each R 1a are independently halogen, -CN, -NO2, -OH, -OR a 、-OC(=O)R a 、-OC(=O)OR b 、-OC(=O)NR c R d , -SH, -SR a 、-S(=O)R a 、-S(=O)2R a、-S(=O)2NR c R d 、-NR c R d 、-NR b C(=O)NR c R d 、-NR b C(=O)R a 、-NR b C(=O)OR b 、-NR b S(=O)2R a 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently optionally substituted with one or more R;

[0121] or two R on the same atom 1a Together they form an oxo group;

[0122] n is 0-6;

[0123] R 2 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl or heterocycloalkyl;

[0124] W is N or CR W ;

[0125] R W It is hydrogen, halogen, -CN, -OH, -OR a 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted with one or more R;

[0126] X is N or CRX ;

[0127] R X It is hydrogen, halogen, -CN, -OH, -OR a 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted with one or more R;

[0128] Y is N or CR Y ;

[0129] R Y It is hydrogen, halogen, -CN, -OH, -OR a 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted with one or more R;

[0130] Z is N or CR Z ;

[0131] R Z It is hydrogen, halogen, -CN, -OH, -OR a 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted with one or more R;

[0132] R 3 is halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl or C1-C6 heteroalkyl, cycloalkyl or heterocycloalkyl;

[0133] R 4 is halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl or C1-C6 heteroalkyl, cycloalkyl or heterocycloalkyl;

[0134] R 5 It is hydrogen, halogen, -CN, -NO2, -OH, -OR a 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl or heterocycloalkyl;

[0135] R 6 It is hydrogen, halogen, -CN, -NO2, -OH, -OR a 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl or heterocycloalkyl;

[0136] Each R ais independently C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl), wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are independently optionally substituted with one or more R;

[0137] Or two R a taken together with the atoms to which they are attached form heterocycloalkyl optionally substituted with one or more R;

[0138] Each R b is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene(cycloalkyl), C1-C6 alkylene(heterocycloalkyl), C1-C6 alkylene(aryl) or C1-C6 alkylene(heteroaryl), wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently optionally substituted with one or more R;

[0139] Or two R b taken together with the atoms to which they are attached form heterocycloalkyl optionally substituted with one or more R;

[0140] R c and R d each independently is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene(cycloalkyl), C1-C6 alkylene(heterocycloalkyl), C1-C6 alkylene(aryl) or C1-C6 alkylene(heteroaryl), wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently optionally substituted with one or more R;

[0141] or R c and R d taken together with the atoms to which they are attached form heterocycloalkyl optionally substituted with one or more R; and

[0142] each R is independently halogen, -CN, -OH, -S(=O)CH3, -S(=O)2CH3, -S(=O)2NH2, -S(=O)2NHCH3, -S(=O)2N(CH3)2, -NH2, -NHCH3, -N(CH3)2, -C(=O)CH3, -C(=O)OH, -C(=O)OCH3, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl or C3-C6 cycloalkyl;

[0143] Alternatively, two R's on the same atom form an oxo group.

[0144] In some embodiments of the compound of Formula (I), X is N. In some embodiments of the compound of Formula (I), X is CR X .

[0145] In some embodiments of the compound of Formula (I), Y is N. In some embodiments of the compound of Formula (I), Y is CR Y .

[0146] In some embodiments of the compound of Formula (I), W is N. In some embodiments of the compound of Formula (I), W is CR W .

[0147] In some embodiments of the compound of Formula (I), Z is N. In some embodiments of the compound of Formula (I), Z is CR Z .

[0148] In some embodiments of the compound of Formula (I), the compound has Formula (Ia):

[0149]

[0150] In some embodiments of the compound of Formula (I), the compound has Formula (Ib):

[0151]

[0152] In some embodiments of the compound of Formula (I), the compound has Formula (Ic):

[0153]

[0154] In some embodiments of the compound of Formula (I) or (Ia)-(Ic), R 3 is halogen, C1-C6 alkyl or C1-C6 haloalkyl. In some embodiments of the compounds of Formula (I) or (Ia)-(Ic), R 3is halogen or C1-C6 alkyl. In some embodiments of the compounds of Formula (I) or (Ia)-(Ic), R 3 is C1-C6 alkyl. In some embodiments of the compounds of Formula (I) or (Ia)-(Ic), R 3 is C1-C3 alkyl. In some embodiments of the compounds of Formula (I) or (Ia)-(Ic), R 3 In some embodiments of the compounds of Formula (I) or (Ia)-(Ic), R 3 In some embodiments of the compounds of Formula (I) or (Ia)-(Ic), R 3 It's methyl.

[0155] In some embodiments of the compound of Formula (I) or (Ia)-(Ic), R 4 is halogen, C1-C6 alkyl or C1-C6 haloalkyl. In some embodiments of the compounds of Formula (I) or (Ia)-(Ic), R 4 is halogen or C1-C6 alkyl. In some embodiments of the compounds of Formula (I) or (Ia)-(Ic), R 4 is C1-C6 alkyl. In some embodiments of the compounds of Formula (I) or (Ia)-(Ic), R 4 is C1-C3 alkyl. In some embodiments of the compounds of Formula (I) or (Ia)-(Ic), R 4 In some embodiments of the compounds of Formula (I) or (Ia)-(Ic), R 4 In some embodiments of the compounds of Formula (I) or (Ia)-(Ic), R 4 It's methyl.

[0156] In some embodiments of the compound of Formula (I) or (Ia)-(Ic), R 5 is hydrogen, halogen, C1-C6 alkyl or C1-C6 haloalkyl. In some embodiments of the compounds of Formula (I) or (Ia)-(Ic), R 5 is hydrogen, halogen, C1-C3 alkyl or C1-C3 haloalkyl. In some embodiments of the compounds of Formula (I) or (Ia)-(Ic), R 5 It's hydrogen.

[0157] In some embodiments of the compound of Formula (I) or (Ia)-(Ic), R 6 is hydrogen, halogen, C1-C6 alkyl or C1-C6 haloalkyl. In some embodiments of the compounds of Formula (I) or (Ia)-(Ic), R 6is hydrogen, halogen, C1-C3 alkyl or C1-C3 haloalkyl. In some embodiments of the compounds of Formula (I) or (Ia)-(Ic), R 6 It's hydrogen.

[0158] In some embodiments of the compound of Formula (I) or (Ia)-(Ic), R 2 is hydrogen or C1-C6 alkyl. In some embodiments of the compounds of Formula (I) or (Ia)-(Ic), R 2 It's hydrogen.

[0159] In some embodiments of the compounds of Formula (I) or (Ia)-(Ib), R X It is hydrogen, halogen, -CN, -OH, -OR a 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl or C1-C6 haloalkyl.

[0160] In some embodiments of the compounds of Formula (I) or (Ia)-(Ib), R X is hydrogen, halogen, -CN, -C(=O)NR c R d , C1-C6 alkyl or C1-C6 haloalkyl.

[0161] In some embodiments of the compounds of Formula (I) or (Ia)-(Ib), R X It is hydrogen, halogen, -CN, C1-C6 alkyl or C1-C6 haloalkyl.

[0162] In some embodiments of the compounds of Formula (I) or (Ia)-(Ib), R X is hydrogen, halogen or -CN.

[0163] In some embodiments of the compounds of Formula (I) or (Ia)-(Ib), R X It is hydrogen, halogen, C1-C6 alkyl or C1-C6 haloalkyl.

[0164] In some embodiments of the compounds of Formula (I) or (Ia)-(Ib), R X is hydrogen, halogen or C1-C6 alkyl. In some embodiments of the compounds of Formula (I) or (Ia)-(Ib), R X is hydrogen or halogen. In some embodiments of the compounds of Formula (I) or (Ia)-(Ib), R XIn some embodiments of the compounds of Formula (I) or (Ia)-(Ib), R X In some embodiments of the compounds of Formula (I) or (Ia)-(Ib), R X is C1-C6 alkyl. In some embodiments of the compounds of Formula (I) or (Ia)-(Ib), R X is C1-C3 alkyl. In some embodiments of the compounds of Formula (I) or (Ia)-(Ib), R X Yes-CN.

[0165] In some embodiments of the compound of Formula (I) or (Ia)-(Ic), R Y is hydrogen, halogen, C1-C6 alkyl or C1-C6 haloalkyl. In some embodiments of the compounds of Formula (I) or (Ia)-(Ic), R Y is hydrogen, halogen, C1-C3 alkyl or C1-C3 haloalkyl. In some embodiments of the compounds of Formula (I) or (Ia)-(Ic), R Y It's hydrogen.

[0166] In some embodiments of the compound of Formula (I), R Z is hydrogen, halogen or C1-C6 alkyl. In some embodiments of the compound of formula (I), R Z is hydrogen or halogen. In some embodiments of the compound of Formula (I), R Z It's hydrogen.

[0167] In some embodiments of the compound of Formula (I) or (Ib)-(Ic), R W It is hydrogen, halogen, -CN, -OH, -OR a , -SH, -SR a 、-NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkynyl, cycloalkyl or heterocycloalkyl; wherein alkyl, alkynyl, cycloalkyl and heterocycloalkyl are optionally replaced by one or more R Wa replace.

[0168] In some embodiments of the compound of Formula (I) or (Ib)-(Ic), R W It is hydrogen, halogen, -CN, -OH, -OR a 、-SR a , C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkynyl, cycloalkyl or heterocycloalkyl; wherein alkyl, alkynyl, cycloalkyl and heterocycloalkyl are optionally replaced by one or more R Wa replace.

[0169] In some embodiments of the compound of Formula (I) or (Ib)-(Ic), R W is hydrogen, halogen, -OR a 、-SR a , C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkynyl, cycloalkyl or heterocycloalkyl; wherein alkyl, alkynyl, cycloalkyl and heterocycloalkyl are optionally replaced by one or more R Wa replace.

[0170] In some embodiments of the compound of Formula (I) or (Ib)-(Ic), R W is optionally replaced by one or more R Wa Substituted C2-C6 alkynyl.

[0171] In some embodiments of the compound of Formula (I) or (Ib)-(Ic), R W It is hydrogen, halogen, -OH, -OR a 、-NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted by one or more R.

[0172] In some embodiments of the compound of Formula (I) or (Ib)-(Ic), R W is hydrogen, halogen, -OR a , C1-C6 alkyl, C1-C6 haloalkyl, cycloalkyl or heterocycloalkyl; wherein alkyl, cycloalkyl and heterocycloalkyl are optionally substituted with one or more R. In some embodiments of the compounds of formula (I) or (Ib)-(Ic), R W is hydrogen, -OR a , C1-C6 alkyl or heterocycloalkyl; wherein alkyl and heterocycloalkyl are optionally substituted with one or more R. In some embodiments of the compounds of formula (I) or (Ib)-(Ic), R W is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each of which is optionally substituted with one or more R. In some embodiments of the compound of Formula (I) or (Ib)-(Ic), R W is cycloalkyl or heterocycloalkyl, each of which is optionally substituted with one or more R. In some embodiments, R W is a 5-membered ring. In some embodiments, R W is a 6-membered ring. In some embodiments, R W yes In some embodiments, R W yes In some embodiments, R W yes In some embodiments of the compound of Formula (I) or (Ib)-(Ic), R W In some embodiments of the compounds of Formula (I) or (Ib)-(Ic), R W In some embodiments of the compounds of Formula (I) or (Ib)-(Ic), R W In some embodiments of the compounds of Formula (I) or (Ib)-(Ic), R W is heterocycloalkyl optionally substituted with one or more R. In some embodiments of the compound of Formula (I) or (Ib)-(Ic), R W Yes-OR a In some embodiments of the compounds of Formula (I) or (Ib)-(Ic), R W Yes-OR a , and R a is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each of which is optionally substituted with one or more R. In some embodiments, R a is a 5-membered ring. In some embodiments, R a is a 5-membered or 6-membered cycloalkyl or heterocycloalkyl. a is a 6-membered ring. In some embodiments, R a is a 5-membered or 6-membered aryl or heteroaryl. In some embodiments of the compounds of Formula (I) or (Ib)-(Ic), R W yes In some embodiments of the compound of Formula (I) or (Ib)-(Ic), R W yes In some embodiments of the compound of Formula (I) or (Ib)-(Ic), R W is C1-C6 alkyl. In some embodiments of the compound of Formula (I) or (Ib)-(Ic), R W is C1-C3 alkyl. In some embodiments of the compound of Formula (I) or (Ib)-(Ic), R W is C1-C6 haloalkyl. In some embodiments of the compound of Formula (I) or (Ib)-(Ic), R W It is a C1-C3 haloalkyl group.

[0173] In some embodiments of the compounds of Formula (I) or (Ib)-(Ic), each R Wa are independently halogen, -CN, -OH, -OR a 、-NR c R d, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl or heterocycloalkyl; wherein each alkyl, cycloalkyl and heterocycloalkyl is independently optionally substituted by one or more R.

[0174] In some embodiments of the compounds of Formula (I) or (Ib)-(Ic), each R Wa are independently halogen, -CN, -OH, -OR a 、-NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, cycloalkyl or heterocycloalkyl; wherein each alkyl, cycloalkyl and heterocycloalkyl is independently optionally substituted by one or more R.

[0175] In some embodiments of the compounds of Formula (I) or (Ib)-(Ic), each R Wa is independently halogen, C1-C6 alkyl, C1-C6 haloalkyl, cycloalkyl or heterocycloalkyl; wherein each alkyl, cycloalkyl and heterocycloalkyl is independently optionally substituted by one or more R.

[0176] In some embodiments of compounds of Formula (I) or (Ia)-(Ic), Ring A is cycloalkyl or heterocycloalkyl. In some embodiments of compounds of Formula (I) or (Ia)-(Ic), Ring A is heterocycloalkyl. In some embodiments of compounds of Formula (I) or (Ia)-(Ic), Ring A is 5-membered or 6-membered heterocycloalkyl. In some embodiments of compounds of Formula (I) or (Ia)-(Ic), Ring A is 5-membered heterocycloalkyl. In some embodiments of compounds of Formula (I) or (Ia)-(Ic), Ring A is 6-membered heterocycloalkyl. In some embodiments of compounds of Formula (I) or (Ia)-(Ic), Ring A is tetrahydropyridinyl.

[0177] In some embodiments of compounds of Formula (I) or (Ia)-(Ic), Ring A is aryl or heteroaryl. In some embodiments of compounds of Formula (I) or (Ia)-(Ic), Ring A is heteroaryl.

[0178] In some embodiments of compounds of Formula (I) or (Ia)-(Ic), Ring A is a 5-membered or 6-membered heteroaryl. In some embodiments of compounds of Formula (I) or (Ia)-(Ic), Ring A is a 5-membered heteroaryl. In some embodiments of compounds of Formula (I) or (Ia)-(Ic), Ring A is a 6-membered heteroaryl. In some embodiments of compounds of Formula (I) or (Ia)-(Ic), Ring A is a monocyclic heteroaryl. In some embodiments of compounds of Formula (I) or (Ia)-(Ic), Ring A is a bicyclic heteroaryl. In some embodiments of compounds of Formula (I) or (Ia)-(Ic), Ring A is a 5-6, 6-5, 5-5, or 6-6 fused bicyclic heteroaryl. In some embodiments of compounds of Formula (I) or (Ia)-(Ic), Ring A is a fused bicyclic heteroaryl. In some embodiments of compounds of Formula (I) or (Ia)-(Ic), Ring A is pyridinyl. In some embodiments of compounds of Formula (I) or (Ia)-(Ic), Ring A is pyrimidinyl. In some embodiments of compounds of Formula (I) or (Ia)-(Ic), Ring A is pyrazinyl. In some embodiments of compounds of Formula (I) or (Ia)-(Ic), Ring A is

[0179] In some embodiments of the compounds of Formula (I) or (Ia)-(Ic), Ring A is

[0180] In some embodiments of the compounds of Formula (I) or (Ia)-(Ic), Ring A is

[0181] In some embodiments of the compounds of Formula (I) or (Ia)-(Ic), each R 1 are independently halogen, -CN, -OH, -OR a 、-S(=O)2R a 、-S(=O)2NR c R d 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are independently and optionally replaced by one or more R 1asubstitution; or two R on the same atom 1 Together they form an oxo group.

[0182] In some embodiments of the compounds of Formula (I) or (Ia)-(Ic), each R 1 are independently halogen, -CN, -OH, -OR a 、-S(=O)2R a 、-NR c R d 、-C(=O)R a , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein each alkyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently optionally replaced by one or more R 1a substitution; or two R on the same atom 1 Together they form an oxo group.

[0183] In some embodiments of the compound of Formula (I) or (Ia)-(Ic), each R 1 are independently halogen, -CN, -OH, -OR a 、-S(=O)2R a 、-NR c R d 、-C(=O)R a , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 heteroalkyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl or heteroaryl; wherein each alkyl, alkynyl, cycloalkyl, heterocycloalkyl and heteroaryl is independently optionally replaced by one or more R 1a substitution; or two R on the same atom 1 Together they form an oxo group.

[0184] In some embodiments of the compound of Formula (I) or (Ia)-(Ic), each R 1 are independently halogen, -CN, -OH, -OR a 、-S(=O)2R a 、-NR c R d 、-C(=O)R a , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 heteroalkyl or C2-C6 alkynyl; wherein each alkyl and alkynyl is independently optionally replaced by one or more R 1a substitution; or two R on the same atom 1 Together they form an oxo group.

[0185] In some embodiments of the compound of Formula (I) or (Ia)-(Ic), each R 1 is independently cycloalkyl, heterocycloalkyl or heteroaryl; wherein each cycloalkyl, heterocycloalkyl and heteroaryl is independently optionally replaced by one or more R 1a substitution; or two R on the same atom 1 Together they form an oxo group.

[0186] In some embodiments of the compound of Formula (I) or (Ia)-(Ic), each R 1 are independently halogen, -CN, -OH, -OR a 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently optionally replaced by one or more R 1a In some embodiments, one or more R 1 Yes-OR a In some embodiments, one or more R 1 Yes - NR c R d In some embodiments, one or more R 1 Yes-C(=O)R a In some embodiments, one or more R 1 is an optionally substituted C1-C6 alkyl. In some embodiments, one or more R 1 is an optionally substituted C1-C6 haloalkyl. 1 is an optionally substituted C1-C6 hydroxyalkyl. 1 is an optionally substituted cycloalkyl. 1 is an optionally substituted heterocycloalkyl. 1 is an optionally substituted 6-membered heterocycloalkyl group containing 1-2 nitrogen atoms.

[0187] In some embodiments of the compound of Formula (I) or (Ia)-(Ic), each R 1 are independently halogen, -OR a 、-NR c Rd 、-C(=O)R a , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, cycloalkyl or heterocycloalkyl; wherein each alkyl, cycloalkyl and heterocycloalkyl is independently optionally replaced by one or more R 1a replace.

[0188] In some embodiments of the compounds of Formula (I) or (Ia)-(Ic), each R 1 are independently halogen, -OR a 、-NR c R d 、-C(=O)R a , C1-C6 alkyl, C1-C6 hydroxyalkyl or heterocycloalkyl; wherein each alkyl and heterocycloalkyl is independently optionally replaced by one or more R 1a replace.

[0189] In some embodiments of the compounds of Formula (I) or (Ia)-(Ic), each R 1a are independently halogen, -CN, -OH, -OR a 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl or heterocycloalkyl; wherein each alkyl, cycloalkyl or heterocycloalkyl is independently optionally substituted by one or more R.

[0190] In some embodiments of the compounds of Formula (I) or (Ia)-(Ic), each R 1a are independently halogen, -OH, -C(=O)OR b 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, cycloalkyl or heterocycloalkyl; wherein each alkyl, cycloalkyl or heterocycloalkyl is independently optionally substituted by one or more R.

[0191] In some embodiments of the compounds of Formula (I) or (Ia)-(Ic), each R 1a are independently halogen, -CN, -OH, -OR a 、-NR c R d 、-C(=O)R a 、-C(=O)ORb 、-C(=O)NR c R d , C1-C6 alkyl, C1-C6 haloalkyl, cycloalkyl or heterocycloalkyl; wherein each alkyl, cycloalkyl, heterocycloalkyl is independently optionally substituted with one or more R. In some embodiments of the compounds of formula (I) or (Ia)-(Ic), each R 1a is independently halogen, C1-C6 alkyl or C1-C6 haloalkyl; wherein each alkyl is independently optionally substituted with one or more R. In some embodiments of the compounds of Formula (I) or (Ia)-(Ic), each R 1a are independently halogen, C1-C6 alkyl or C1-C6 haloalkyl.

[0192] In some embodiments of compounds of Formula (I) or (Ia)-(Ic), n is 0-2. In some embodiments of compounds of Formula (I) or (Ia)-(Ic), n is 1 or 2. In some embodiments of compounds of Formula (I) or (Ia)-(Ic), n is 0. In some embodiments of compounds of Formula (I) or (Ia)-(Ic), n is 1. In some embodiments of compounds of Formula (I) or (Ia)-(Ic), n is 2.

[0193] In some embodiments of the compound of Formula (I) or (Ia)-(Ic), n is 0.

[0194] In some embodiments of the compound of Formula (I) or (Ia)-(Ic), yes

[0195]

[0196] In some embodiments of the compound of Formula (I) or (Ia)-(Ic), yes

[0197]

[0198]

[0199] In some embodiments of the compound of Formula (I) or (Ia)-(Ic), yes

[0200]

[0201] In some embodiments of the compound of Formula (I) or (Ia)-(Ic), yes

[0202]

[0203]

[0204] In some embodiments of the compound of Formula (I) or (Ia)-(Ic), yes

[0205]

[0206] In some embodiments of the compound of Formula (I) or (Ia)-(Ic), yes

[0207]

[0208]

[0209] In some embodiments of the compound of Formula (I) or (Ia)-(Ic), yes

[0210] In some embodiments of the compound of Formula (I) or (Ia)-(Ic), yes

[0211] In some embodiments of the compound of Formula (I) or (Ia)-(Ic), yes In some embodiments of the compound of Formula (I) or (Ia)-(Ic), yes In some embodiments of the compound of Formula (I) or (Ia)-(Ic), yes In some embodiments of the compound of Formula (I) or (Ia)-(Ic), yes In some embodiments of the compound of Formula (I) or (Ia)-(Ic), yes In some embodiments of the compound of Formula (I) or (Ia)-(Ic), yes In some embodiments of the compound of Formula (I) or (Ia)-(Ic), yes In some embodiments of the compound of Formula (I) or (Ia)-(Ic), yes In some embodiments of the compound of Formula (I) or (Ia)-(Ic), yes In some embodiments of the compound of Formula (I) or (Ia)-(Ic), yes

[0212] In some embodiments of the compound of Formula (I) or (Ia)-(Ic), yes In some embodiments of the compound of Formula (I) or (Ia)-(Ic), yes In some embodiments of the compound of Formula (I) or (Ia)-(Ic), In some embodiments of the compound of Formula (I) or (Ia)-(Ic), In some embodiments of the compound of Formula (I) or (Ia)-(Ic), In some embodiments of the compound of Formula (I) or (Ia)-(Ic),

[0213] In some embodiments of the compound of Formula (I) or (Ia)-(Ic), yes

[0214]

[0215] In some embodiments of the compounds disclosed herein, each R a is independently C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently optionally substituted with one or more R. In some embodiments of the compounds disclosed herein, each R a is independently C1-C6 alkyl, C1-C6 haloalkyl or cycloalkyl, heterocycloalkyl; wherein each alkyl, cycloalkyl and heterocycloalkyl is independently optionally substituted by one or more R. In some embodiments of the compounds disclosed herein, each R a R is independently C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl). In some embodiments of the compounds disclosed herein, each R aR is independently C1-C6 alkyl, C1-C6 haloalkyl or cycloalkyl, heterocycloalkyl. In some embodiments of the compounds disclosed herein, each R a is independently C1-C6 alkyl or C1-C6 haloalkyl. In some embodiments of the compounds disclosed herein, each R a are independently C1-C6 alkyl.

[0216] In some embodiments of the compounds disclosed herein, each R b R is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently optionally substituted with one or more R. In some embodiments of the compounds disclosed herein, each R b is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl or cycloalkyl, heterocycloalkyl; wherein each alkyl, cycloalkyl and heterocycloalkyl is independently optionally substituted with one or more R. In some embodiments of the compounds disclosed herein, each R b R is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl). In some embodiments of the compounds disclosed herein, each R b R is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl or cycloalkyl, heterocycloalkyl. In some embodiments of the compounds disclosed herein, each R b R is independently hydrogen, C1-C6 alkyl or C1-C6 haloalkyl. b is independently hydrogen or C1-C6 alkyl. In some embodiments of the compounds disclosed herein, each R b is hydrogen. In some embodiments of the compounds disclosed herein, each R b are independently C1-C6 alkyl.

[0217] In some embodiments of the compounds disclosed herein, each R c and R dR is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently optionally substituted with one or more R. In some embodiments of the compounds disclosed herein, each R c and R d is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl or cycloalkyl, heterocycloalkyl; wherein each alkyl, cycloalkyl and heterocycloalkyl is independently optionally substituted with one or more R. In some embodiments of the compounds disclosed herein, each R c and R d R is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl). In some embodiments of the compounds disclosed herein, each R c and R d R is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl or cycloalkyl, heterocycloalkyl. In some embodiments of the compounds disclosed herein, each R c and R d R is independently hydrogen, C1-C6 alkyl or C1-C6 haloalkyl. c and R d is independently hydrogen or C1-C6 alkyl. In some embodiments of the compounds disclosed herein, each R c and R d is hydrogen. In some embodiments of the compounds disclosed herein, each R c and R d are independently C1-C6 alkyl.

[0218] In some embodiments of the compounds disclosed herein, R c and R d Taken together with the atoms to which they are attached form a heterocycloalkyl group optionally substituted with one or more R.

[0219] In some embodiments of the compounds disclosed herein, each R is independently halogen, -CN, -OH, -NH2, -NHCH3, -N(CH3)2, -C(=O)CH3, -C(=O)OH, -C(=O)OCH3, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, or C3-C6 cycloalkyl; or two R on the same atom form an oxo. In some embodiments of the compounds disclosed herein, each R is independently halogen, -CN, -OH, -NH2, -NHCH3, -N(CH3)2, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, or C3-C6 cycloalkyl; or two R on the same atom form an oxo. In some embodiments of the compounds disclosed herein, each R is independently halogen, -CN, -OH, C1-C6 alkyl, C1-C6 alkoxy or C1-C6 haloalkyl; or two R on the same atom form an oxo. In some embodiments of the compounds disclosed herein, each R is independently halogen, -CN, -OH or C1-C6 alkyl; or two R on the same atom form an oxo. In some embodiments of the compounds disclosed herein, each R is independently halogen, -OH or C1-C6 alkyl. In some embodiments of the compounds disclosed herein, each R is independently halogen or C1-C6 alkyl. In some embodiments of the compounds disclosed herein, each R is independently halogen.

[0220] In some embodiments of the compounds disclosed herein, R 1 , R 1a , R 2 , R 3 , R 4 , R 5 , R 6 , R X , R Y , R Z , R W , R a , R b , R c and R d One or more of the groups comprises a percentage of deuterium above the natural abundance of deuterium.

[0221] In some embodiments of the compounds disclosed herein, in the following groups R, R 1 , R 1a , R 2 , R 3 , R 4 , R 5 , R 6, R X , R Y , R Z , R W , R a , R b , R c and R d One or more of 1 H is replaced by one or more deuteriums.

[0222] In some embodiments of the compounds disclosed herein, R, R 1 , R 1a , R 2 , R 3 , R 4 , R 5 , R 6 , R X , R Y , R Z , R W , R a , R b , R c and R d The deuterium abundance of each of is independently at least 1 mol%, at least 10 mol%, at least 20 mol%, at least 30 mol%, at least 40 mol%, at least 50 mol%, at least 60 mol%, at least 70 mol%, at least 80 mol%, at least 90 mol%, or 100 mol%.

[0223] In some embodiments of the compounds disclosed herein, one or more hydrogens of Ring A are replaced with one or more deuteriums.

[0224] Any combination of the above groups for the various variables is contemplated herein. Throughout the specification, groups and substituents are selected by one skilled in the art to provide stable moieties and compounds.

[0225] In some embodiments, the compound disclosed herein, or a pharmaceutically acceptable salt thereof, is one of the compounds in Table 1.

[0226] Table 1

[0227]

[0228]

[0229]

[0230]

[0231]

[0232]

[0233]

[0234]

[0235]

[0236]

[0237]

[0238]

[0239]

[0240]

[0241]

[0242]

[0243]

[0244] In some embodiments, the compound disclosed herein, or a pharmaceutically acceptable salt thereof, is one of the compounds in Table 2.

[0245] Table 2

[0246]

[0247]

[0248] Other forms of the compounds disclosed herein

[0249] Isomers / stereoisomers

[0250] In some embodiments, the compounds described herein exist in the form of geometric isomers. In some embodiments, the compounds described herein have one or more double bonds. The compounds described herein include all cis, trans, same side, opposite side, trans (entgegen) (E) and cis (zusammen) (Z) isomers and their corresponding mixtures. In some cases, the compounds described herein have one or more chiral centers, and each center exists in R configuration or S configuration. The compounds described herein include all diastereomers, enantiomers and diastereoisomers and their corresponding mixtures. In other embodiments of the compounds and methods provided herein, the mixture of enantiomers and / or diastereomers produced by a single preparation step, combination or interconversion can be used for the applications described herein. In some embodiments, the racemic mixture of the compound is reacted with an optically active resolving agent to form a pair of diastereomeric compounds, the diastereomers are separated and the optically pure enantiomers are recovered, and the compounds described herein are prepared as their individual stereoisomers. In some embodiments, dissociable complexes are preferred. In some embodiments, diastereomers have different physical properties (e.g., melting points, boiling points, solubility, reactivity, etc.) and are separated by utilizing these differences. In some embodiments, diastereomers are separated by chiral chromatography, or preferably by separation / resolution techniques based on solubility differences. In some embodiments, optically pure enantiomers and resolving agents are then recovered by any practical method that does not result in racemization.

[0251] In some embodiments, the compounds described herein contain bonds with hindered rotation, allowing separation of two individual rotational isomers or atropisomers. In some embodiments, atropisomers are In some embodiments, these atropisomers are separated and found to have different biological activities, which may be advantageous. In some embodiments, the atropisomers are In some embodiments, the atropisomer is In some embodiments, the compounds disclosed herein are racemic mixtures:

[0252]

[0253] Labeled compounds

[0254] In some embodiments, the compounds described herein exist in their isotopically labeled form. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such isotopically labeled compounds. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such isotopically labeled compounds as pharmaceutical compositions. Therefore, in some embodiments, the compounds disclosed herein include isotopically labeled compounds that are identical to those described herein, but in fact one or more atoms are replaced by atoms having an atomic mass or mass number different from the atomic mass or mass number typically found in nature. Examples of isotopes that can be incorporated into the compounds disclosed herein include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chlorine, such as, respectively. 2 H(D), 3 H. 13 C. 14 C. l5 N. 18 O. 17 O. 31 P. 32 P. 35 S. 18 F and 36 Cl. The compounds described herein and pharmaceutically acceptable salts thereof containing the aforementioned isotopes and / or other isotopes of other atoms are within the scope of the invention. Certain isotopically labeled compounds, for example, compounds incorporating radioactive isotopes such as 3 H and 14 C, can be used in drug and / or substrate tissue distribution assays. 3 H) and carbon-14 (i.e., 14 C) Isotopes are particularly preferred because they are easy to prepare and detect.

[0255] In some embodiments, the abundance of deuterium in each substituent disclosed herein is independently at least 1%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or 100% of the total amount of hydrogen and deuterium. In some embodiments, the percentage of deuterium included in one or more substituents disclosed herein is higher than the natural abundance of deuterium. In some embodiments, in one or more substituents disclosed herein, one or more hydrogens are replaced by one or more deuteriums.

[0256] In some embodiments, the compounds described herein are labeled by other means, including but not limited to the use of chromophores or fluorescent moieties, bioluminescent labels, or chemiluminescent labels.

[0257] Pharmaceutically acceptable salts

[0258] In some embodiments, the compounds described herein exist in the form of pharmaceutically acceptable salts thereof. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts as pharmaceutical compositions.

[0259] In some embodiments, the compounds described herein have acidic or basic groups and therefore react with any of a number of inorganic or organic bases and inorganic and organic acids to form pharmaceutically acceptable salts. In some embodiments, these salts are prepared in situ during the final isolation and purification of the compounds disclosed herein, or by reacting the purified free form of the compound with a suitable acid or base separately and isolating the salt thus formed.

[0260] Examples of pharmaceutically acceptable salts include those prepared by reacting the compounds described herein with an inorganic substance, an organic acid or an inorganic base, such salts include acetate, acrylate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, bisulfite, bromide, butyrate, butyne-1,4-dioate, camphorate, camphorsulfonate, hexanoate, octanoate, chlorobenzoate, chloride, citrate, cyclopentanepropionate, decanoate, digluconate, dihydrogen phosphate, dinitrobenzoate, dodecyl sulfate, ethanesulfonate, formate, fumarate, gluconate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hexyne-1,6-dioate, hydroxybenzoate, gamma-hydroxybutyrate , hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isobutyrate, lactate, maleate, malonate, methanesulfonate, mandelate, metaphosphate, methanesulfonate, methoxybenzoate, methylbenzoate, monohydrogenphosphate, 1-naphthalenesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, palmitate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, pyrosulfate, pyrophosphate, propiolate, phthalate, phenylacetate, phenylbutyrate, propanesulfonate, salicylate, succinate, sulfate, sulfite, succinate, suberate, sebacate, sulfonate, tartrate, thiocyanate, toluenesulfonate, undecanoate, and xylenesulfonate.

[0261] In addition, the compounds described herein can be prepared as pharmaceutically acceptable salts by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid, including but not limited to inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, metaphosphoric acid, and the like; and organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, p-toluenesulfonic acid, tartaric acid, trifluoroacetic acid, citric acid, benzoic acid, , 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, arylsulfonic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid, 4-methylbicyclo-[2.2.2]oct-2-ene-1-carboxylic acid, glucoheptonic acid, 4,4'-methylenebis-(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, dodecylsulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid and muconic acid. In some embodiments, other acids that are not pharmaceutically acceptable themselves, such as oxalic acid, are used to prepare salts that can be used as intermediates to obtain the compounds disclosed herein and their pharmaceutically acceptable acid addition salts.

[0262] In some embodiments, those compounds described herein that contain free acid groups are reacted with a suitable base (such as a pharmaceutically acceptable metal cation hydroxide, carbonate, bicarbonate, sulfate), with ammonia, or with a pharmaceutically acceptable organic primary, secondary, tertiary or quaternary amine. Representative salts include alkali metal or alkaline earth metal salts, such as lithium, sodium, potassium, calcium and magnesium, and aluminum salts, etc. Illustrative examples of bases include sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate, N + (C 1-4 Alkyl)4, etc.

[0263] Representative organic amines for forming base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, and the like. It should be understood that the compounds described herein also include the quaternization of any basic nitrogen-containing groups they contain. In some embodiments, water-soluble or oil-soluble or dispersible products are obtained by such quaternization.

[0264] Tautomer

[0265] In some cases, compounds exist as tautomers. The compounds described herein include all possible tautomers in the chemical formulas described herein. Tautomers are compounds that convert to each other through the migration of hydrogen atoms, accompanied by the conversion of single bonds and adjacent double bonds. In the bonding arrangement where tautomerization may occur, there will be a chemical equilibrium of tautomers. All tautomeric forms of the compounds disclosed herein are contemplated. The exact ratio of tautomers depends on several factors, including temperature, solvent, and pH.

[0266] Treatment

[0267] Disclosed herein are methods of treating a disease regulated at least in part by PKMYT1 in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof.

[0268] Disclosed herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound disclosed herein or a pharmaceutically acceptable salt thereof.

[0269] In some embodiments, the cancer is dependent on the activity of PKMYT1.

[0270] In some embodiments, the cancer overexpresses CCNE1. In some embodiments, cancers with a high incidence of CCNE1 overexpression include, for example, breast cancer, endometrial cancer, esophageal cancer, lung cancer, ovarian cancer, gastric cancer, and uterine cancer.

[0271] In some embodiments, the cancer has an inactivating mutation in the FBXW7 gene. In some embodiments, cancers lacking FBXW7 include, for example, breast cancer, colorectal cancer, esophageal cancer, lung cancer, and uterine cancer.

[0272] In some embodiments, the cancer is a solid tumor.

[0273] In some embodiments, the cancer is breast cancer, colorectal cancer, endometrial cancer, esophageal cancer, glioblastoma, hepatocellular carcinoma, lung cancer, neuroblastoma, ovarian cancer, prostate cancer, gastric cancer, or uterine cancer.

[0274] Disclosed herein is a method for regulating PKMYT1 of a subject, the method comprising administering a compound disclosed herein or a pharmaceutically acceptable salt thereof to the subject.Disclosed herein is a method for inhibiting PKMYT1 of a subject, the method comprising administering a compound disclosed herein or a pharmaceutically acceptable salt thereof to the subject. Further disclosed herein is a method for selectively inhibiting PKMYT1 of a subject (e.g., selectively over WEE1), the method comprising administering a compound disclosed herein or a pharmaceutically acceptable salt thereof to the subject.

[0275] WEE1 is widely present in human tissues and plays an important role in all stages of the cell cycle. In the methods of treatment described herein, it may be beneficial to use compounds that selectively inhibit PKMYT1 rather than WEE1. In some embodiments, the compounds disclosed herein do not inhibit WEE1. In some embodiments, the compounds disclosed herein have a WEE1 IC50 value of at least about 100nM, at least about 500nM, at least about 1000nM or at least about 10,000nM determined in the WEE1ADP-Glo ​​assay. For example, the WEE1 IC50 value can be determined according to Example B.

[0276] Drug administration

[0277] In certain embodiments, a composition containing a compound as described herein is administered for therapeutic treatment. In certain therapeutic applications, the composition is administered to a patient already suffering from a disease or condition in an amount sufficient to cure or at least partially inhibit at least one symptom of the disease or condition. The effective amount for this use depends on the severity and course of the disease or condition, previous treatment, the patient's health, body weight, response to the drug, and the judgment of the attending physician. The therapeutically effective amount is optionally determined by methods including, but not limited to, dose escalation and / or dose range clinical trials.

[0278] In certain embodiments where the patient's condition does not improve, the compound is administered chronically (i.e., over an extended period of time), including throughout the patient's life span, at the physician's discretion, in order to ameliorate or otherwise control or limit the symptoms of the patient's disease or condition.

[0279] Once the patient's condition improves, a maintenance dose is administered as necessary. Subsequently, in a specific embodiment, the dose or the frequency of administration, or both, is reduced according to the symptoms.

[0280] The amount of a given agent corresponding to such amounts varies depending on factors such as the specific compound, the disease condition and its severity, the identity of the subject or host in need of treatment (e.g., weight, sex), etc., but will still be determined by the particular circumstances surrounding the case, including, for example, the specific agent administered, the route of administration, the condition being treated, and the subject or host being treated.

[0281] In some embodiments, the dosage for adult treatment is generally within the range of 0.01 mg-5000 mg per day. In some embodiments, the daily dosage suitable for the compounds described herein or their pharmaceutically acceptable salts is from about 0.01 to about 50 mg / kg / body weight. In various embodiments, the daily dosage and unit dosage vary according to many variables, including but not limited to the activity of the compound used, the disease or condition to be treated, the mode of administration, the needs of the individual subject, the severity of the disease or condition to be treated, and the judgment of the physician.

[0282] Route of administration

[0283] Suitable routes of administration include, but are not limited to, oral, intravenous, rectal, aerosol, parenteral, ocular, pulmonary, transmucosal, transdermal, vaginal, ear, nasal, and topical administration. In addition, parenteral delivery includes, by way of example only, intramuscular, subcutaneous, intravenous, intramedullary injection, as well as intrathecal, direct intraventricular, intraperitoneal, intralymphatic, and intranasal injection.

[0284] In certain embodiments, the compound as described herein is applied in a local rather than systemic manner, for example, via direct injection of the compound into an organ, usually in the form of a long-acting preparation or a sustained release preparation. In a specific embodiment, the long-acting preparation is applied by implantation (e.g., subcutaneous or intramuscular) or intramuscular injection. In addition, in other embodiments, the drug is delivered in a targeted drug delivery system, for example, in a liposome coated with an organ-specific antibody. In such embodiments, the liposome is targeted to an organ and selectively absorbed by the organ. In other embodiments, the compound as described herein is provided in the form of a rapid release preparation, in the form of an extended release preparation, or in the form of an immediate release preparation.

[0285] Pharmaceutical compositions / preparations

[0286] According to standard pharmaceutical practice, the compounds described herein are administered to a subject in need thereof, alone or in combination with a pharmaceutically acceptable carrier, excipient or diluent, as a pharmaceutical composition. In some embodiments, the compounds described herein are administered to animals.

[0287] On the other hand, provided herein is a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient. The pharmaceutical composition is formulated in a conventional manner using one or more pharmaceutically acceptable excipients, which aid in processing the active compound into a pharmaceutically usable preparation. The appropriate formulation depends on the selected route of administration. An overview of the pharmaceutical compositions described herein can be found, for example, in Remington: The Science and Practice of Pharmacy, 19th Edition (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, HA and Lachman, L., eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, NY, 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th Edition (Lippincott Williams & Wilkins 1999), such disclosures are incorporated herein by reference.

[0288] In some embodiments, the pharmaceutically acceptable excipient is selected from a carrier, a binder, a filler, a suspending agent, a flavoring agent, a sweetener, a disintegrant, a dispersant, a surfactant, a lubricant, a colorant, a diluent, a solubilizer, a humectant, a plasticizer, a stabilizer, a penetration enhancer, a wetting agent, a defoaming agent, an antioxidant, a preservative, and any combination thereof.

[0289] The pharmaceutical formulations described herein include, but are not limited to, aqueous liquid dispersions, liquids, gels, syrups, elixirs, slurries, suspensions, self-emulsifying dispersions, solid solutions, liposomal dispersions, aerosols, solid oral dosage forms, powders, immediate release formulations, controlled release formulations, fast melt formulations, tablets, capsules, pills, powders, dragees, effervescent formulations, lyophilized formulations, delayed release formulations, extended release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate and controlled release formulations.

[0290] combination

[0291] Disclosed herein are methods of treating a disease or condition associated with PKMYT1 using a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with an additional therapeutic agent.

[0292] In some embodiments, the additional therapeutic agent is administered simultaneously with the compounds disclosed herein. In some embodiments, the additional therapeutic agent and the compounds disclosed herein are administered sequentially. In some embodiments, the additional therapeutic agent is administered less frequently than the compounds disclosed herein. In some embodiments, the additional therapeutic agent is administered more frequently than the compounds disclosed herein. In some embodiments, the additional therapeutic agent is administered before the compounds disclosed herein are administered. In some embodiments, the additional therapeutic agent is administered after the compounds disclosed herein are administered.

[0293] In some embodiments, the additional therapeutic agent is an anti-cancer agent.

[0294] Example

[0295] Example 1: Preparation of 2,4-dimethyl-3-(2-(2-methyl-6-(4-methylpiperazin-1-yl)pyridin-3-yl)-3H-imidazo[4,5-b]pyridin-6-yl)phenol

[0296] The title compound was prepared according to the following synthetic procedure.

[0297]

[0298] Step 1: Preparation of compound 1-2

[0299] Pin2B2 (245 mg, 0.97 mmol), KOAc (142 mg, 1.45 mmol) and Pd(dppf)Cl2 (73 mg, 0.1 mmol) were added to a solution of compound 1-1 (250 mg, 0.48 mmol) in dioxane (2 mL). The mixture was stirred at 90 ° C for 6 hours under N2. The reaction mixture was cooled to room temperature, diluted with water (10 mL), extracted with EA (20 mL×3), washed with brine (80 mL), dried over Na2SO4, filtered, and concentrated to dryness. The crude compound 1-2 was used in the next step. LCMS: 483.4 [M+H] + .

[0300] Step 2: Preparation of compound 1-4

[0301] Compound 1-3 (33 mg, 0.18 mmol), K2CO3 (49 mg, 0.36 mmol) and Pd(PPh3)4 (55 mg, 0.048 mmol) were added to a solution of compound 1-2 (60 mg, 0.12 mmol) in dioxane (2 mL) and H2O (0.2 mL). The mixture was stirred at 90 ° C for 3 hours under N2. The reaction mixture was filtered. The filtrate was concentrated to dryness. The residue was purified by preparative TLC to obtain compound 1-4. LCMS: 559.3 [M+H]+ .

[0302] Step 3: Preparation of Example 1

[0303] To a solution of compound 1-4 (73 mg, 0.12 mmol) in dioxane (2 mL) was added TFA (1.0 mL). The mixture was stirred at 20 °C under N2 for 1 hour. The reaction mixture was concentrated and purified by preparative HPLC to give Example 1. LCMS: 429.3 [M+H] + ; 1 H NMR: (400MHz, CD3OD) δ8.10(s,1H),7.97(d,J=8.6Hz,1H),7.73(s,1H),6.93(dd,J=29.8,8.5Hz,2H),6.76 (d,J=8.3Hz,1H),3.94(s,4H),3.24(s,4H),2.83(d,J=14.8Hz,3H),2.73(s,3H),1.94(s,3H),1.90(s,3H).

[0304] Example 2: Preparation of 2,4-dimethyl-3-(7-methyl-2-(2-methyl-6-(4-methylpiperazin-1-yl)pyridin-3-yl)-3H-imidazo[4,5-b]pyridin-6-yl)phenol

[0305] The title compound was prepared according to the following synthetic procedure.

[0306]

[0307] Step 1: Preparation of compound 2-2

[0308] Compound 1-3 (20 mg, 0.104 mmol), pd(dtbpf)Cl2 (67 mg, 0.104 mmol), Na2CO3 (10 mg, 0.104 mmol) and H2O (0.2 mL) were added to a solution of compound 2-1 (60 mg, 0.104 mmol) in dioxane (2 mL). The reactants were stirred at 90 ° C for 2 hours under N2. The reaction mixture was quenched with water (20 mL) and extracted with EA (3×20 mL). The organic layers were combined, washed with brine (50 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography to give compound 2-2. LCMS: 573.3 [M+H] + .

[0309] Step 2: Preparation of Example 2

[0310] To a stirred solution of compound 2-2 (50 mg, 0.087 mmol) in DCM (2 mL) was added TFA (0.5 mL). The reactant was stirred at 25 ° C for 1 hour under N2. The reaction mixture was carefully added to ice water (20 mL) and adjusted to pH about 8 with NaHCO3. The mixture was extracted with DCM (30 mL×3). The organic layers were combined and concentrated to dryness. The residue was purified by preparative HPLC to give Example 2. LCMS: 443.0 [M+H] + ; 1 H NMR: (400MHz, DMSO-d6) δ12.86(d,J=188.9Hz,1H),9.18(s,1H),8.18–8.03(m,1H),7.88(d,J=28.6Hz,1H),6.96 (d,J=8.1Hz,2H),6.78(d,J=8.2Hz,1H),3.31–3.00(m,8H),2.80(s,6H),2.20(s,3H),1.79(s,3H),1.73(s,3H).

[0311] Example 3: Preparation of 2,4-dimethyl-3-(3-methyl-2-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)phenol

[0312] The title compound was prepared according to the following synthetic procedure.

[0313]

[0314] Step 1: Preparation of compound 3-2

[0315] At 0°C, NaH (0.38 g 9.476 mmol) was added to a solution of compound 3-1 (1.0 g, 4.738 mmol) in THF (20 mL). The mixture was stirred at 0°C for 0.5 hours under N2. TsCl (1.08 g, 1.780 mmol) was then added. The mixture was stirred at 20°C for 1 hour under N2. The reactant was quenched by NH4Cl (50 ml, saturated aqueous solution), extracted with EA (100 mL×3), washed with (100 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give compound 3-2 as a white solid. LCMS: 366.8 [M+H] + .

[0316] Step 2: Preparation of compound 3-3

[0317] To a solution of compound 3-2 (500 mg, 1.369 mmol) in THF (10 mL) was added LDA (1.03 mL) under N2 at -78 °C. The mixture was stirred at -78 °C for 0.5 h under N2. I2 (451 mg, 1.780 mmol) was then added. The mixture was stirred at -78 °C for 1 h under N2. The reactant was quenched by NH4Cl (50 ml, saturated aqueous solution), extracted with EA (100 mL×3), washed with brine (100 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give compound 3-3 as a white solid. LCMS: 492.6 [M+H] + .

[0318] Step 3: Preparation of compound 3-5

[0319] Compound 3-4 (135 mg, 0.448 mmol), Pd(dppf)Cl2 (30 mg, 0.041 mmol) and CsF (186 mg, 1.221 mmol) were added to a solution of compound 3-3 (200 mg, 0.407 mmol) in dioxane (6 mL) and H2O (1 mL). The mixture was stirred at 90 °C for 1.5 hours under N2. The mixture was diluted with EA (100 mL), washed with brine (100 mL×3), dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography to give compound 3-5. LCMS: 542.2 [M+H] + .

[0320] Step 4: Preparation of Compound 3-6

[0321] Pin2B2 (72 mg, 0.285 mmol), KOAc (42 mg, 0.428 mmol) and Pd(dppf)Cl2 (11 mg, 0.014 mmol) were added to a solution of compound 3-5 (77 mg, 0.143 mmol) in dioxane (2 mL). The mixture was reacted at 90 ° C for 1.5 hours under N2, cooled to room temperature, diluted with water (10 mL), extracted with EA (20 mL×3), washed with brine (60 mL), dried over Na2SO4, filtered, and concentrated to dryness. The crude product 3-6 was used directly in the next step. LCMS: 588.3 [M+H] + .

[0322] Step 5: Preparation of compound 3-7

[0323] Compound 1-3 (43 mg, 0.214 mmol), K2CO3 (59 mg, 0.429 mmol) and Pd(dtbpf)Cl2 (9.5 mg, 0.014 mmol) were added to a solution of compound 3-6 (54 mg, 0.009 mmol) in dioxane (2 mL) and H2O (0.3 mL). The mixture was stirred at 90 ° C for 1.5 hours under N2, cooled to room temperature, and filtered. The filtrate was concentrated and purified by silica gel column chromatography to obtain compound 3-7. LCMS: 582.3 [M+H] + .

[0324] Step 6: Preparation of Example 3

[0325] To a solution of compound 3-7 (55 mg, 0.095 mmol) in EtOH (2 mL) was added NaOH (0.5 mL, 1 M aqueous solution). The mixture was stirred at 60 ° C under N2 for 5 hours. The reaction mixture was concentrated to dryness. The residue was purified by preparative HPLC to give Example 3. LCMS: 428.0 [M+H] + . 1 H NMR: (400MHz, DMSO-d6) δ11.69(s,1H),9.12(s,1H),8.49(s,1H),7.88(d,J=9.3Hz,2H),7.62(s,1H),7.00(d,J=12.0Hz,1H),6.93(d ,J=8.0Hz,1H),6.74(d,J=8.1Hz,1H),3.61(s,4H),2.48–2.45(m,3H),2.36(s,3H),2.30(d,J=8.6Hz,4H),1.88(s,3H),1.81(s,3H).

[0326] Example 4: Preparation of 2,4-dimethyl-3-(2-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)phenol

[0327] The title compound was prepared according to the following synthetic procedure.

[0328]

[0329] Step 1: Preparation of compound 4-2

[0330] To a solution of compound 4-1 (3 g, 15.23 mmol) in THF (60 mL) was added NaH (0.73 g, 30.45 mmol) at 0°C. The mixture was stirred at 0°C for 0.5 h under N2. TsCl (3.48 g, 18.27 mmol) was then added. The mixture was stirred at 20°C under N2 for 1 h. The reactant was quenched by NH4Cl (50 mL, saturated), extracted with EA (100 mL×3), washed with brine (100 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give compound 4-2 as a white solid. LCMS: 352.7 [M+H] + .

[0331] Step 2: Preparation of compound 4-3

[0332] To a solution of compound 4-2 (1 g, 2.390 mmol) in THF (10 mL) was added LDA (0.46 g, 4.271 mmol) at -78 °C. The mixture was stirred at -78 °C under N2 for 0.5 h. I2 (1.64 g, 3.701 mmol) was then added. The mixture was stirred at -78 °C under N2 for 1 h. The reactant was quenched by NH4Cl (50 ml, saturated), extracted with EA (100 mL×3), washed with brine (100 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give compound 4-3 as a white solid. LCMS: 476.9 [M+H] + .

[0333] Step 3: Preparation of compound 4-4

[0334] Compound 3-4 (629 mg, 2.075 mmol), CsF (860 mg, 5.659 mmol) and Pd(dppf)Cl2 (69 mg, 0.094 mmol) were added to a solution of compound 4-3 (900 mg, 1.886 mmol) in dioxane (6 mL) and H2O (1 mL). The mixture was stirred at 90 ° C for 1.5 hours under N2. The mixture was filtered. The filtrate was concentrated and purified by silica gel column chromatography to obtain compound 4-4. LCMS: 528.1 [M+H] + .

[0335] Step 4: Preparation of compound 4-5

[0336] Pin2B2 (49 mg, 0.190 mmol), KOAc (27.97 mg, 0.285 mmol) and Pd(dppf)Cl2 (6.20 mg, 0.009 mmol) were added to a solution of compound 4-4 (50 mg, 0.095 mmol) in dioxane (2 mL). The mixture was stirred at 90 ° C for 1.5 hours under N2. The reaction mixture was cooled to room temperature, diluted with water (10 mL), extracted with EA (20 mL×3), washed with brine (80 mL), dried over Na2SO4, filtered, and concentrated to dryness. The crude product 4-5 was used directly in the next step. LCMS: 574.0 [M+H] + .

[0337] Step 5: Preparation of Compound 4-6

[0338] Compound 1-3 (28 mg, 0.141 mmol), K2CO3 (39 mg, 0.282 mmol) and Pd(dtbpf)Cl2 (6.14 mg, 0.009 mmol) were added to a solution of compound 4-5 (54 mg, 0.009 mmol) in dioxane (2 mL) and H2O (0.3 mL). The mixture was stirred at 90 °C under N2 for 1.5 hours. The mixture was filtered. The filtrate was concentrated to give crude compound 4-6, which was used without further purification. LCMS: 568.0 [M+H] + .

[0339] Step 5: Preparation of Example 4

[0340] To a solution of compound 4-6 (80 mg, 0.141 mmol) in EtOH (2 mL) was added NaOH (1.4 mL, 1 M aqueous solution). The mixture was stirred at 60 °C under N2 for 5 hours. The reaction mixture was concentrated to dryness. The residue was purified by preparative HPLC to give Example 4. LCMS: 414.2 [M+H] + . 1 H NMR: (400MHz, DMSO-d6) δ12.04(s,1H),9.12(s,1H),8.71(d,J=2.4Hz,1H),8.16(s,1H),8.06(dd,J=8.9,2.5Hz,1H),7.85(d,J=2.0Hz,1H),7.58(d,J =1.9Hz,1H),6.94(dd,J=11.2,8.7Hz,2H),6.76(dd,J=11.2,5.1Hz,2H),3. 60–3.53(m,4H),2.40–2.45(m,4H),2.23(s,3H),1.88(s,3H),1.81(s,3H).

[0341] Example 5: Preparation of 2,4-dimethyl-3-(2-(6-methylpyridin-3-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)phenol

[0342] The title compound was prepared according to the following synthetic procedure.

[0343]

[0344] Step 1: Preparation of compound 5-2

[0345] To a solution of compound 5-1 (150 mg, 0.339 mmol) in dioxane (6 mL) was added 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolan (172 mg, 0.678 mmol), Pd(dppf)Cl2 (25 mg, 0.034 mmol) and potassium acetate (100 mg, 1.017 mmol). The reaction mixture was stirred at 100 °C for 2 hours. The mixture was cooled to room temperature, diluted with water (20 mL), extracted with EA (30 mL×3), washed with brine (100 mL), dried over Na2SO4, filtered, and concentrated to dryness. The crude compound 5-2 was used directly in the next step. LCMS: 408.2 [M+H] + .

[0346] Step 2: Preparation of compound 5-3

[0347] Compound 1-3 (62 mg, 0.306 mmol), K2CO3 (127 mg, 0.919 mmol) and Pd(dtbpf)Cl2 (20 mg, 0.031 mmol) were added to a solution of compound 5-2 (150 mg, 0.306 mmol) in dioxane (6 mL) and H2O (1 mL). The reaction mixture was stirred at 90 °C for 2 hours. The reactants were diluted with DCM and water. The organic layer was separated and concentrated in vacuo. The crude material was purified by silica gel column to give compound 5-3. LCMS: 484.2 [M+H] + .

[0348] Step 3: Preparation of Example 5

[0349] To a solution of compound 5-3 (120 mg, 0.248 mmol) in EtOH (4 mL) and H2O (2 mL) was added NaOH (99 mg, 2.481 mmol). The reaction mixture was stirred at 80 °C for 1 hour. The reactant was diluted with DCM and water. The organic layer was separated and concentrated in vacuo. The organic layer was collected and concentrated in vacuo. The crude product was purified by preparative HPLC to give Example 5. LCMS: 330.1 [M+H] + . 1 H NMR: (400MHz, DMSO-d6) δ12.27(s,1H),9.16(s,1H),9.05–9.04(m,1H),8.22–8.19(m,1H),7.94(d,J=2.0Hz,1H),7.68(d,J=1.9Hz,1 H),7.37(d,J=8.1Hz,1H),7.00(d,J=4.0Hz,1H),6.93(d,J=8.0Hz,1H),6.76(d,J=8.2Hz,1H),2.51(s,3H),1.89(s,3H),1.82(s,3H).

[0350] Example 6: Preparation of 1-(4-(5-(3-hydroxy-2,6-dimethylphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-3,6-dihydropyridin-1(2H)-yl)ethan-1-one

[0351] The title compound was prepared according to the following synthetic procedure.

[0352]

[0353] Step 1: Preparation of compound 6-1

[0354] Pd(dppf)Cl2 (153 mg, 0.209 mmol) and cesium fluoride (957 mg, 6.300 mmol) were added to a solution of compound 4-3 and 1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridin-1-yl]ethan-1-one (579 mg, 2.306 mmol) in dioxane (10 mL) and H2O (2 mL). The mixture was stirred at 100 ° C. for 1 hour under N2. The reaction mixture was cooled to room temperature and extracted with EA (20 mL×2). The organic layers were combined, dried over Na2SO4, and filtered. The filtrate was concentrated and purified by silica gel column chromatography to give compound 6-1.LCMS: 448.9 [M+H] + .

[0355] Step 3: Preparation of compound 6-2

[0356] To a solution of compound 6-1 (350 mg, 0.738 mmol) and 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)-1,3,2-dioxaborolane (224 mg, 0.885 mmol) in dioxane (3 mL) was added KOAc (217 mg, 2.213 mmol) and Pd(dppf)Cl2 (54 mg, 0.074 mmol). The mixture was stirred at 100°C for 1 hour. The mixture was cooled to room temperature, diluted with water (10 mL), extracted with EA (20 mL×3), washed with brine (80 mL), dried over Na2SO4, filtered, and concentrated to dryness. The crude compound 6-2 was used directly in the next step. LCMS: 522.3 [M+H] + .

[0357] Step 4: Preparation of compound 6-3

[0358] Pd(dtbpf)Cl2 (44 mg, 0.067 mmol) and K2CO3 (278 mg, 2.014 mmol) were added to a solution of compound 6-2 (350 mg, 0.671 mmol) and compound 1-3 (135 mg, 0.671 mmol) in dioxane (5 mL) and H2O (1 mL). The mixture was stirred at 90 °C for 2 hours. The mixture was extracted with EA (10 mL). The organic layer was dried over Na2SO4, filtered, concentrated, and purified by silica gel column chromatography to give compound 6-3. LCMS: 516.3 [M+H] + .

[0359] Step 5: Preparation of Example 6

[0360] To a solution of compound 6-3 (100 mg, 0.194 mmol) in EtOH (2 mL) and H2O (1 mL) was added sodium hydroxide (8.0 mg, 0.194 mmol). The mixture was stirred at 80 °C for 1 hour. The reaction mixture was cooled to room temperature, diluted with EA (30 mL), and washed with brine (30 mL). The organic layer was dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by preparative HPLC to give Example 6. LCMS: 362.4 [M+H] + . 1H NMR: (400MHz, DMSO-d6) δ11.81(d,J=12.8Hz,1H),9.12(s,1H),7.88(s,1H),7.60(s,1H),6.91(d,J=8.2Hz,1H),6.74(d,J=8.2Hz,1H),6 .52(s,1H),6.47(d,J=5.1Hz,1H),4.21(s,1H),4.15(s,1H),3.65(s,2H),2.60(s,2H),2.07(d,J=12.6Hz,3H),1.86(s,3H),1.79(s,3H).

[0361] Example 7: Preparation of 2,4-dimethyl-3-(2-(2-methylpyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)phenol

[0362] The title compound was prepared according to the following synthetic procedure.

[0363]

[0364] Step 1: Preparation of compound 7-2

[0365] A solution of compound 4-3 (170 mg, 0.36 mmol), compound 7-1 (49 mg, 0.36 mmol), K2CO3 (123 mg, 0.89 mmol) and Pd(dppf)Cl2 (26 mg, 0.036 mmol) in dioxane (1.0 mL) and water (0.2 mL) was stirred at 100 °C for 2.5 hours. The mixture was concentrated. The residue was purified by silica gel column chromatography to give compound 7-2 as a yellow solid. LCMS: 445.0 [M+H] + .

[0366] Step 2: Preparation of compound 7-3

[0367] A solution of compound 7-2 (100 mg, 0.23 mmol), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)-1,3,2-dioxaborolane (115 mg, 0.45 mmol), KOAc (67 mg, 0.68 mmol) and Pd(dppf)Cl2 (17 mg, 0.023 mmol) in dioxane (2 mL) was stirred at 100 ° C for 16 hours. The mixture was cooled to room temperature, diluted with water (10 mL), extracted with EA (20 mL×3), washed with brine (80 mL), dried over Na2SO4, filtered, and concentrated to dryness. The crude compound 7-3 was used in the next step without further purification. LCMS: 409.1 [M+H]+ .

[0368] Step 3: Preparation of compound 7-4

[0369] A solution of compound 7-3, compound 1-3 (50 mg, 0.25 mmol), K2CO3 (78 mg, 0.57 mmol) and Pd(dtbpf)Cl2 (15 mg, 0.023 mmol) in dioxane / water (2 mL / 0.2 mL) was stirred at 100°C for 4 hours. The mixture was concentrated. The residue was purified by silica gel column chromatography to obtain compound 7-4. LCMS: 485.2 [M+H] + .

[0370] Step 4: Preparation of Example 7

[0371] To a solution of compound 7-4 (122 mg, 0.25 mmol) in EtOH (5 mL) was added NaOH (2 M, 1.26 mL, 2.52 mmol). The mixture was stirred at 70 °C for 16 hours. The mixture was concentrated, diluted with water (2 mL), neutralized with HCl (2 M) solution to pH about 5 and concentrated. The crude product was purified by preparative HPLC to give Example 7. LCMS: 331.2 [M+H] + . 1 HNMR: (400MHz, DMSO-d6) δ12.39(s,1H),9.25(s,2H),9.15(s,1H),7.98(d,J=1.9Hz,1H),7.72(d,J=1.9H z,1H),7.12(s,1H),6.93(d,J=8.2Hz,1H),6.76(d,J=8.1Hz,1H),2.67(s,3H),1.88(s,3H),1.81(s,3H).

[0372] Example 8: Preparation of 3-(2-(5-methoxypyridin-3-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-2,4-dimethylphenol

[0373] The title compound was prepared according to the following synthetic procedure.

[0374]

[0375] Step 1: Preparation of compound 8-2

[0376] Pd(dppf)Cl2 (24.54 mg, 0.034 mmol), compound 8-1 (61.55 mg, 0.402 mmol), potassium carbonate (139.04 mg, 1.006 mmol) and H2O (0.8 mL) were added to a stirred solution of compound 4-3 (160 mg, 0.335 mmol) in dioxane (4 mL). The reactants were stirred at 100 ° C. for 2 hours by microwave under argon and quenched with water (25 mL). The resulting mixture was extracted with EA (3×20 mL). The EA layers were combined, washed with brine (2×30 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography to give compound 8-2. LCMS: 457.9 [M+H] + .

[0377] Step 2: Preparation of compound 8-3

[0378] To a stirred solution of compound 8-2 (80 mg, 0.175 mmol) in dioxane (2 mL) was added 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolan (66.49 mg, 0.262 mmol), Pd(dppf)Cl2 (127.72 mg, 0.175 mmol) and KOAC (51.32 mg, 0.524 mmol). The reactants were stirred at 90 °C for 3 hours and quenched with H2O (10 mL). The resulting mixture was extracted with EA (3×15 mL). The EA layers were combined, washed with brine (2×20 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography to give compound 8-3. LCMS: 506.2 [M+H] + .

[0379] Step 4: Preparation of compound 8-4

[0380] Compound 1-3 (27.85 mg, 0.139 mmol), Cs2CO3 (173.19 mg, 0.532 mmol), Pd(dtbpf)Cl2 (9.14 mg, 0.014 mmol) and H2O (0.4 mL) were added to a stirred solution of compound 8-3 (70 mg, 0.139 mmol) in dioxane (2 mL). The reactants were stirred at 90 ° C for 2 hours under argon. The reaction mixture was quenched with water (15 mL). The resulting mixture was extracted with EA (3×15 mL). The EA layers were combined, washed with brine (2×20 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography to give compound 8-4. LCMS: 500.2 [M+H] +.

[0381] Step 5: Preparation of Example 8

[0382] To a stirred solution of compound 8-4 (60 mg, 0.120 mmol) in EtOH (4 mL) was added sodium hydroxide (4.80 mg, 0.120 mmol). The reactant was stirred at 70 ° C for 2 hours by microwave. The reaction mixture was quenched with HCl aqueous solution (1 M) to pH about 7. The mixture was concentrated to dryness. The residue was purified by preparative HPLC to give Example 8. LCMS: 346.3 [M + H] + ; 1 H NMR: (400MHz, DMSO-d6) δ12.33(s,1H),9.16(s,1H),8.79(d,J=1.6Hz,1H),8.27(d,J=2.7Hz,1H),8.16(s,1H),7.97(d,J=2.0Hz,1H),7.96–7 .91(m,1H),7.71(d,J=1.9Hz,1H),7.12(d,J=1.9Hz,1H),6.94(d,J=8.2Hz,1H),6.76(d,J=8.2Hz,1H),3.93(s,3H),1.89(s,3H),1.82(s,3H).

[0383] Example 9: Preparation of 4-(5-(3-hydroxy-2,6-dimethylphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-1-methylpyridin-2(1H)-one

[0384] The title compound was prepared according to the following synthetic procedure.

[0385]

[0386] Step 1: Preparation of compound 9-2

[0387] Compound 9-1 (187.24 mg, 0.796 mmol), cesium fluoride (362.95 mg, 2.389 mmol) and Pd(dppf)Cl2 (58.28 mg, 0.080 mmol) were added to a solution of compound 4-3 (380 mg, 0.796 mmol) in dioxane (6 mL) and H2O (1 mL). The resulting mixture was stirred at 90 ° C for 2 hours under N2. The reaction mixture was quenched with water (20 mL) and extracted with EA (30 mL×3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by silica gel column chromatography to give compound 9-2. LCMS: 460.0 [M+H] + .

[0388] Step 2: Preparation of compound 9-3

[0389] To a solution of compound 9-2 (200 mg, 0.436 mmol) in dioxane (6 mL) was added 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolan (132.97 mg, 0.524 mmol), KOAc (128.48 mg, 1.309 mmol) and Pd(dppf)Cl2 (31.93 mg, 0.044 mmol). The reactants were stirred at 100 °C for 3 hours under N2. The reaction mixture was diluted with water (20 mL) and extracted with EA (30 mL×3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by silica gel column chromatography to give compound 9-3. LCMS: 506.1 [M+H] + .

[0390] Step 3: Preparation of compound 9-4

[0391] Compound 1-3 (79.25 mg, 0.394 mmol), Pd(dtbpf)Cl2 (25.77 mg, 0.039 mmol) and K2CO3 (163.42 mg, 1.182 mmol) were added to a solution of compound 9-3 (200 mg, 0.394 mmol) in dioxane (6 mL) and H2O (1 mL). The reactants were stirred at 90 °C for 2 hours under N2. The reaction mixture was diluted with water (20 mL) and extracted with EA (30 mL×3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by silica gel column chromatography to give compound 9-4. LCMS: 500.2 [M+H] + .

[0392] Step 4: Preparation of Example 9

[0393] To a solution of compound 9-4 (100 mg, 0.200 mmol) in EtOH (3 mL) and H2O (3 mL) was added NaOH (80.07 mg, 2.002 mmol). The reactants were stirred at room temperature for 3 hours. The reactants were diluted with DCM and ice water and adjusted to pH about 7 with HCl (0.5 M aqueous solution). The reaction mixture was diluted with water (20 mL) and extracted with EA (30 mL×3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated to dryness. The crude product was purified by preparative HPLC to give Example 9. LCMS: 346.1 [M+H] + . 1 H NMR: (400MHz, DMSO-d6) δ12.27(s,1H),9.17(s,1H),8.01(d,J=1.8Hz,1H),7.84–7.64(m,2H),7.17–7.08(m, 1H),7.02(d,J=1.4Hz,1H),6.94(d,J=8.2Hz,1H),6.82–6.73(m,2H),3.45(s,3H),1.88(s,3H),1.81(s,3H).

[0394] Example 10: Preparation of 3-(4-chloro-2-(6-methylpyridin-3-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-2,4-dimethylphenol

[0395] The title compound was prepared according to the following synthetic procedure.

[0396]

[0397] Step 1: Preparation of compound 10-2

[0398] At 0°C, NaH (328.3 mg, 60% dispersion in mineral oil, 8.208 mmol) was added to a solution of compound 10-1 (950 mg, 4.104 mmol) in THF (20 mL). The mixture was stirred at 0°C for 0.5 hours. TsCl (935.72 mg, 4.925 mmol) was then added. The mixture was stirred at room temperature for 1 hour. The reaction mixture was quenched by saturated NH4Cl (aqueous solution, 20 mL) and extracted with EA (150 mL). The organic layers were combined and dried over Na2SO4. After filtration, the filtrate was concentrated and purified by silica gel column chromatography to give compound 10-2. LCMS: 387.0 [M+H] + .

[0399] Step 2: Preparation of compound 10-3

[0400] At -78 ° C, LDA (1.09 mL, 2.182 mmol) was added to a solution of compound 10-2 (700 mg, 1.818 mmol) in THF (10 mL). The mixture was stirred at this temperature for 1 hour. I2 (692.18 mg, 2.727 mmol) was then added, and the resulting mixture was stirred at -78 ° C for 1 hour. The mixture was quenched with saturated NH4Cl (aqueous solution, 20 mL) and extracted with EA (100 mL). The organic layer was washed with saturated Na2SO3 (aqueous solution, 30 mL). The organic layer was dried over Na2SO4 and concentrated to dryness. The residue was purified by silica gel column chromatography to obtain compound 10-3. LCMS: 512.9 [M + H] + .

[0401] Step 3: Preparation of compound 10-5

[0402] Compound 10-4 (100.38 mg, 0.733 mmol), CsF (222.85 mg, 1.466 mmol) and Pd(dppf)Cl2 (35.72 mg, 0.049 mmol) were added to a solution of compound 10-3 (250 mg, 0.489 mmol) in dioxane (5 mL) and H2O (1 mL). The mixture was stirred at 90 ° C for 6 hours under N2. The reaction mixture was filtered. The filtrate was concentrated to dryness. The residue was purified by silica gel column chromatography to obtain compound 10-5. LCMS: 477.8 [M+H] + .

[0403] Step 4: Preparation of compound 10-7

[0404] Compound 10-6 (61.35 mg, 0.234 mmol), Pd(dtbpf)Cl2 (14.25 mg, 0.020 mmol) and K2CO3 (80.85 mg, 0.585 mmol) were added to a solution of compound 10-5 (93 mg, 0.195 mmol) in dioxane (5 mL) and H2O (1 mL). The mixture was stirred at 90°C for 2 hours. The reaction mixture was filtered. The filtrate was concentrated to dryness. The residue was purified by preparative TLC to give compound 10-7. LCMS: 532.2 [M+H] + .

[0405] Step 5: Preparation of compound 10-8

[0406] To a solution of compound 10-7 (60 mg, 0.113 mmol) in DCM (3 mL) was added BBr3 (0.1 mL) at 0°C. The mixture was stirred for 0.5 hours. The reaction was quenched with MeOH (1 mL). The mixture was concentrated to dryness. The residue was purified by silica gel column chromatography to give compound 10-8. LCMS: 518.2 [M+H] + .

[0407] Step 6: Preparation of Example 10

[0408] To a solution of compound 10-8 (40 mg, 0.077 mmol) in EtOH (5 mL) was added NaOH (1.5 mL, 1 M aqueous solution). The mixture was stirred at 65 °C for 3 hours. The mixture was concentrated to dryness. The residue was purified by preparative HPLC to give Example 10. LCMS: 364.2 [M+H] + . 1 H NMR: (400MHz, DMSO-d6) δ12.75(s,1H),9.21(s,1H),8.48(d,J=7.9Hz,1H),8.04(s,1H),7.59(d,J=7.9Hz,1H),7.54(d,J= 7.7Hz,1H),7.25(s,1H),7.03(d,J=7.9Hz,1H),6.86(d,J=8.1Hz,1H),2.64(s,3H),2.35(s,1H),1.90(s,3H),1.83(s,3H).

[0409] Example 11: Preparation of 2,4-dimethyl-3-(6-(6-methylpyridin-3-yl)-5H-pyrrolo[2,3-b]pyrazin-2-yl)phenol

[0410] The title compound was prepared according to the following synthetic procedure.

[0411]

[0412] Step 1: Preparation of compound 11-2

[0413] At 0°C, NaH (260.48 mg, 60% dispersion in mineral oil, 6.512 mmol) was added to a solution of compound 11-1 (500 mg, 3.256 mmol) in THF (10 mL). The mixture was stirred at this temperature for 0.5 hours. TsCl (744.87 mg, 3.907 mmol) was then added. The reaction mixture was stirred at room temperature for 1 hour. The mixture was quenched with saturated NH4Cl (aqueous solution, 20 mL) and extracted with EA (100 mL). The organic layer was dried over Na2SO4 and concentrated to dryness. The residue was purified by silica gel column chromatography to give compound 11-2. LCMS: 307.9 [M+H] + .

[0414] Step 2: Preparation of compound 11-3

[0415] To a solution of compound 11-2 (1.1 g, 3.574 mmol) in THF (20 mL) was added LDA (2.32 mL, 4.647 mmol) at -78 °C. The mixture was stirred at this temperature for 1 hour. I2 (1.36 g, 5.361 mmol) was then added and stirred at -78 °C for 1 hour. The mixture was quenched with saturated NH4Cl (aqueous solution, 20 mL) and extracted with EA (100 mL). The organic layer was washed with Na2SO3 (saturated aqueous solution, 30 mL), dried over Na2SO4 and concentrated to dryness. The residue was purified by silica gel column chromatography to give compound 11-3. LCMS: 434.0 [M+H] + .

[0416] Step 3: Preparation of compound 11-4

[0417] Compound 10-4 (236.84 mg, 1.730 mmol), CsF (525.77 mg, 1.730 mmol) and Pd(dppf)Cl2 (84.28 mg, 0.115 mmol) were added to a solution of compound 11-3 (500 mg, 1.153 mmol) in dioxane (10 mL) and H2O (2 mL). The mixture was stirred at 90 ° C overnight under N2. The reaction mixture was filtered. The filtrate was concentrated to dryness. The residue was purified by silica gel column chromatography to obtain compound 11-4. LCMS: 399.0 [M+H] + .

[0418] Step 4: Preparation of compound 11-5

[0419] Compound 10-6 (157.74 mg, 0.60 mmol), Pd(dtbpf)Cl2 (32.7 mg, 0.05 mmol) and K2CO3 (207.89 mg, 1.504 mmol) were added to a mixture of compound 11-4 (200 mg, 0.50 mmol) in dioxane (5 mL) and H2O (1 mL). The mixture was stirred at 90 ° C for 2 hours. The reaction mixture was filtered. The filtrate was concentrated to dryness. The residue was purified by silica gel column chromatography to obtain compound 11-5. LCMS: 499.2 [M+H] + .

[0420] Step 5: Preparation of compound 11-6

[0421] To a solution of compound 11-5 (200 mg, 0.011 mmol) in DCM (10 mL) was added BBr3 (0.2 mL) at 0°C. The mixture was stirred for 0.5 hours. The reaction was quenched with MeOH (1 mL). The mixture was concentrated to dryness. The residue was purified by silica gel column chromatography to give compound 11-6. LCMS: 485.2 [M+H] + .

[0422] Step 6: Preparation of Example 11

[0423] To a solution of compound 7 (120 mg, 0.248 mmol) in EtOH (10 mL) was added NaOH (2.5 mL, 1 M aqueous solution). The mixture was stirred at 65 °C for 3 hours. The mixture was concentrated to dryness. The residue was purified by preparative HPLC to Example 11. LCMS: 331.2 [M+H] + . 1 H NMR: (400MHz, CD3OD) δ9.00(d,J=1.9Hz,1H),8.27(dd,J=8.1,2.2Hz,1H),8.15(s,1H),7.47(d,J=8.2Hz ,1H),7.09(s,1H),6.98(d,J=8.2Hz,1H),6.80(d,J=8.2Hz,1H),2.62(s,3H),1.94(s,3H),1.89(s,3H).

[0424] Example 12: Preparation of 3-(7-fluoro-6-(2-methylpyrimidin-5-yl)-5H-pyrrolo[2,3-b]pyrazin-2-yl)-2,4-dimethylphenol

[0425] The title compound was prepared according to the following synthetic procedure.

[0426]

[0427] Step 1: Preparation of compound 12-2

[0428] To a solution of compound 12-1 (500 mg, 2.525 mmol) in HOAc (2 mL) and CH3CN (10 mL) was added a selective fluorine reagent (1341.8 mg, 3.787 mmol). The solution was heated to 90 ° C under N2 for 16 hours. The solution was quenched by saturated NaHCO3 aqueous solution (50 mL) and extracted with EA (50 mL×3). The combined organic layer was washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography to give compound 12-2 (100 mg, 0.463 mmol, 18.33%). LCMS: 215.9 [M+H] + .

[0429] Step 2: Preparation of compound 12-3

[0430] At 0°C, NaH (27.8 mg, 0.694 mmol) was added in batches to a solution of compound 12-2 (100 mg, 0.463 mmol) in DMF (2 mL). The mixture was stirred at 0°C for 30 minutes. TsCl (132.4 mg, 0.694 mmol) was then added. The reaction mixture was stirred at 0°C for 1 hour and quenched by H2O (10 mL). The suspension was filtered and the solid was dried to give compound 12-3 (150 mg, 0.405 mmol, 87.52%). LCMS: 370.1 [M+H] + .

[0431] Step 3: Preparation of compound 12-4

[0432] Under N2, a mixture of compound 12-3 (150 mg, 0.405 mmol), compound 10-6 (138.1 mg, 0.527 mmol), K2CO3 (168.0 mg, 1.216 mmol) and Pd(dtbpf)Cl2 (26.2 mg, 0.041 mmol) in dioxane-water (5:1) (5 mL) was heated to 90 ° C for 2 hours. The mixture was diluted with H2O (10 mL) and extracted with EA (10 mL×3). The combined organic layer was washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography to give compound 12-4 (100 mg, 0.235 mmol, 58.00%). LCMS: 426.0 [M+H] + .

[0433] Step 4: Preparation of compound 12-6

[0434] At -78 ° C, LDA (0.22 mL, 0.447 mmol) was added dropwise to a solution of compound 12-4 (95 mg, 0.223 mmol) in THF (4 mL). The solution was stirred at -78 ° C for 30 minutes. Then a solution of compound 12-5 (145.4 mg, 0.447 mmol) in THF (0.4 ml) was added. The reaction mixture was stirred at -78 ° C for 1 hour under N2. The mixture was quenched by saturated NH4Cl aqueous solution (20 mL), diluted with H2O (20 mL), and extracted with EA (30 mL×3). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography to give compound 12-6 (90 mg, 0.178 mmol, 79.92%). LCMS: 505.6 [M+H] + .

[0435] Step 5: Preparation of compound 12-7

[0436] A solution of compound 12-6 (200 mg, 0.397 mmol) and NaOH (4.0 mL, 3.965 mmol) in EtOH (4 mL) was heated to 50 ° C for 1 hour. The mixture was cooled to 0 ° C, the pH was adjusted to 6 by 1N HCl, diluted with H2O (10 mL), and extracted with EA (10 mL×3). The combined organic layer was washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography to give compound 12-7. LCMS: 351.7 [M+H] + .

[0437] Step 6: Preparation of compound 12-9

[0438] Under N2 atmosphere, a mixture of compound 12-7 (100 mg, 0.286 mmol), compound 12-8 (81.7 mg, 0.371 mmol), K2CO3 (118.4 mg, 0.857 mmol) and Pd(dtbpf)Cl2 (18.7 mg, 0.029 mmol) in dioxane-water (5:1) (2 mL) was heated to 90 ° C for 3 hours. The mixture was concentrated, and the residue was diluted with H2O (10 mL) and extracted with EA (10 mL×3). The combined organic layer was washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography to obtain compound 12-9.

[0439] LCMS: 364.1 [M+H] + .

[0440] Step 7: Preparation of Example 12

[0441] To a solution of compound 12-9 (50 mg, 0.138 mmol) in DCM (4 mL) was added BBr3 (344.7 mg, 1.376 mmol) dropwise at 0°C. The mixture was stirred at room temperature for 1 hour. The mixture was quenched by MeOH (2 mL) and concentrated. The residue was purified by preparative HPLC to give Example 12. LCMS: 350.0 [M+H] + . 1 H NMR: (400MHz, DMSO-d6) δ12.76(s,1H),9.26(s,1H),9.23(s,2H),8.27(s,1H),6. 96(d,J=8.2Hz,1H),6.82(d,J=8.2Hz,1H),2.72(s,3H),1.88(s,3H),1.80(s,3H).

[0442] Example 13: Preparation of 2,4-dimethyl-3-(7-methyl-6-(2-methylpyrimidin-5-yl)-5H-pyrrolo[2,3-b]pyrazin-2-yl)phenol

[0443] Example 13 was synthesized from compound 13-1, which was prepared according to the method described in Example 12 using similar starting materials.

[0444]

[0445] Step 1: Preparation of compound 13-2

[0446] To a solution of compound 13-1 (200.0 mg, 0.579 mmol) in CH3CN (10.0 mL) at 0°C, NBS (103.1 mg, 0.579 mmol) was added. The mixture was stirred at room temperature for 2 hours. The reaction mixture was purified by reverse phase column chromatography to give compound 13-2. LCMS: 426.0 [M+H] + .

[0447] Step 2: Preparation of compound 13-4

[0448] A mixture of compound 13-2 (243.0 mg, 0.573 mmol), compound 13-3 (151.0 mg, 1.203 mmol), K2CO3 (336.4 mg, 2.434 mmol) and Pd(dtbpf)Cl2 (37.4 mg, 0.057 mmol) in dioxane-water (6 mL, 5:1) was stirred at 100 ° C for 16 hours under N2. The reaction mixture was cooled to room temperature and diluted with water (20 mL), which was extracted with EA (30 mL×3). The combined organic layer was washed with brine (30 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography to give compound 13-4. LCMS: 360.2 [M+H] + .

[0449] Step 3: Preparation of Example 13

[0450] At 0°C, BBr3 (1.69 mg, 6.733 mmol) was added to a solution of compound 13-4 (242.0 mg, 0.673 mmol) in DCM (10.0 mL). The mixture was stirred at 0°C for 1 hour. The reaction mixture was carefully added to MeOH (5 mL) while stirring and diluted with water (20 mL), which was adjusted to pH = 8 with NaHCO3 and extracted with EA (30 mL×3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by preparative HPLC to give Example 13. LCMS: 346.1 [M+H] + ; 1 H NMR: (400MHz, DMSO-d6) δ12.41(s,1H),9.23(s,1H),9.11(d,J=2.8Hz,2H),8.15(d,J=2.8Hz,1H),6. 95(d,J=8.0Hz,1H),6.84-6.74(m,1H),2.72(s,3H),2.47(d,J=2.8Hz,3H),1.88(s,3H),1.80(s,3H).

[0451] Example 14: Preparation of 3-(6-(2-aminopyrimidin-5-yl)-7-(3-hydroxy-3-methylbut-1-yn-1-yl)-5H-pyrrolo[2,3-b]pyrazin-2-yl)-2,4-dimethylphenol

[0452] Example 14 was synthesized from compound 14-1, which was prepared according to the method described in Example 12 using similar starting materials.

[0453]

[0454] Step 1: Preparation of compound 14-2

[0455] To a solution of compound 14-1 (320 mg, 0.963 mmol) in DMF (2 mL) was added Boc2O (0.2 mL, 1.059 mmol) and TEA (0.2 mL, 1.444 mmol) and DMAP (6 mg, 0.048 mmol). The mixture was stirred at 60 ° C for 2 hours. The reaction mixture was diluted with EA (10 mL), which was washed with brine (10 mL×3). The organic layer was dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by silica gel column chromatography to give compound 14-2 (255 mg, 0.590 mmol, 61.2%). LCMS: 433.4 [M+H] + .

[0456] Step 2: Preparation of compound 14-3

[0457] To a solution of compound 14-2 (260 mg, 0.509 mmol) in CAN (10 mL) was added NIS (103 mg, 0.458 mmol). The mixture was stirred at 25 °C for 2 hours. The reaction mixture was diluted with water (10 mL) and extracted with EA (10 mL×3). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel column chromatography to give compound 14-3. LCMS: 559.3 [M+H] + .

[0458] Step 3: Preparation of compound 14-5

[0459] Compound 14-4 (51 mg, 0.518 mmol), CuI (40 mg, 0.207 mmol) and PdCl2(PPh3)2 (81 mg, 0.104 mmol) were added to a solution of compound 14-3 (250 mg, 0.518 mmol) in TEA (0.9 mL) and DMF (0.3 mL). The mixture was stirred at 40 ° C for 2 hours under N2. The solution was purified by preparative HPLC to give compound 14-5. LCMS: 515.4 [M+H] + .

[0460] Step 4: Preparation of Example 14

[0461] To a solution of compound 14-5 (35 mg, 0.068 mmol) in MeOH (2 mL) was added K2CO3 (28 mg, 0.204 mmol). The mixture was stirred at 70 ° C for 2 hours under N2. The reaction mixture was diluted with water (5 mL), which was extracted with EA (5 mL×3). The combined organic layers were washed with brine (10 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by preparative TLC to give Example 14. LCMS: 415.1 [M+H] + ; 1 H NMR: (400MHz, DMSO-d6) δ12.68(s,1H),9.24(s,1H),9.07(s,2H),8.11(s,1H),7.27(s,1H),6. 95(d,J=8.4Hz,1H),6.81(d,J=8.4Hz,1H),5.48(s,1H),1.86(s,3H),1.78(s,3H),1.48(s,6H).

[0462] The following Examples 15-27 were prepared according to the methods described in Examples 12-14 using similar starting materials.

[0463]

[0464]

[0465]

[0466]

[0467] Example 29: Preparation of 2,4-dimethyl-3-(2-(5-methylpyrazin-2-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)phenol

[0468] Example 29 was synthesized from compound 29-1, which was prepared according to the method described in Example 12 using similar starting materials.

[0469]

[0470] Step 1: Preparation of compound 29-2

[0471] To a solution of compound 29-1 (585 mg, 1.439 mmol) in THF (10 mL) was added LDA (1.1 mL, 2.159 mmol) at -78 ° C. The mixture was stirred at this temperature for 0.5 hours. I2 (766.05 mg, 5.361 mmol) was then added and stirred at -78 ° C for 1 hour. The mixture was quenched with NH4Cl (saturated aqueous solution, 20 mL) and extracted with EA (100 mL). The organic layer was washed with Na2SO3 (saturated aqueous solution, 30 mL). The organic layer was dried over Na2SO4 and concentrated to dryness. The residue was purified by silica gel column chromatography to give compound 29-2 (550 mg, 1.03 mmol, 71.78%). LCMS: 533.4 [M + H] + .

[0472] Step 2: Preparation of compound 29-4

[0473] Compound 29-3 (97.88 mg, 0.281 mmol), Pd(PPh3)4 (29.47 mg, 0.026 mmol), CuI (9.71 mg, 0.051 mmol) and LiCl (32.43 mg, 0.765 mmol) were added to a solution of compound 29-2 (136 mg, 0.255 mmol) in DMF (2 mL). The mixture was stirred at 120 ° C for 2 hours. The reaction mixture was filtered. The filtrate was concentrated to dryness. The residue was purified by preparative TLC to obtain compound 29-4. LCMS: 499.7 [M + H] + .

[0474] Step 3: Preparation of compound 29-5

[0475] To a solution of compound 29-4 (48 mg, 0.096 mmol) in DCM (5 mL) was added BBr3 (0.241 mL, 2.0 M in DCM). The mixture was stirred at room temperature under N2 for 1 hour. The reaction was quenched with MeOH (5 mL). The mixture was concentrated to dryness. The residue was purified by preparative TLC to give compound 29-5. LCMS: 485.2 [M+H] + .

[0476] Step 4: Preparation of Example 29

[0477] To a solution of compound 29-5 (28 mg, 0.058 mmol) in EtOH (3 mL) was added NaOH (0.6 mL, 1.0 M). The mixture was stirred at 60 °C for 2 hours. The mixture was concentrated to dryness. The residue was purified by preparative HPLC to give Example 29. LCMS: 331.0 [M+H]+ ; 1 H NMR: (400MHz, CD3OD) δ9.10(s,1H),8.61(s,1H),8.03(s,1H),7.89(s,1H),7 .29(s,1H),6.95(s,1H),6.75(s,1H),2.61(s,3H),1.94(s,3H),1.90(s,3H).

[0478] Example 30: Preparation of 3-(4-amino-2-(2-methylpyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-2,4-dimethylphenol

[0479] Example 30 was synthesized from compound 30-1, which was prepared according to the method described in Example 12 using similar starting materials.

[0480]

[0481] Step 1: Preparation of compound 30-2

[0482] To a solution of compound 30-1 (300.0 mg, 0.563 mmol) in DMSO (6.0 mL) was added CuI (750.6 mg, 3.940 mmol), L-proline (453.6 mg, 3.940 mmol) and NaN3 (512.2 mg, 7.880 mmol). The reaction mixture was stirred at 140 ° C for 18 hours under N2. The reaction mixture was diluted with water (20 mL) and extracted with EA (20 mL×3). The combined organic layer was washed with brine (20 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by preparative TLC to give compound 30-2. LCMS: 360.2 [M+H] + .

[0483] Step 2: Preparation of Example 30

[0484] To a solution of compound 30-2 (40 mg, 0.111 mmol) in DCM (1.5 mL) was added BBr3 (0.1 mL, 0.111 mmol). The mixture was stirred at room temperature for 2 hours. The reaction mixture was carefully added to MeOH (5 mL) while stirring, and the pH was adjusted to 7-8 with NH3 / MeOH. After filtration, the filtrate was concentrated to dryness. The residue was purified by silica gel column chromatography to give Example 30. LCMS: 346.2 [M+H] + ; 1H NMR: (400MHz, CD3OD) δ9.12(s,2H),7.46-7.21(m,3H),7.01(d,J=8.0Hz,1H),6.77(d,J=8.0Hz,1H),2.74(s,3H),1.96(s,3H),1.92(s,3H).

[0485] Example 31: Preparation of (R)-2,4-dimethyl-3-(2-(2-methylpyrimidin-5-yl)-4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)phenol

[0486] Example 31 was prepared according to the following synthetic procedure.

[0487]

[0488] Step 1: Preparation of compound 31-1

[0489] To a solution of compound 10-2 (4 g, 10.372 mmol) in CH3CN (60 mL) was added NaI (7.77 g, 51.859 mmol) and acetyl chloride (2.212 mL, 31.115 mmol). The mixture was stirred at 80 ° C overnight under N2. The reaction mixture was diluted with water (50 mL) and extracted with EA (100 mL×3). The combined organic layer was washed with brine (300 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by silica gel column chromatography to give compound 31-1 (3.2 g, 6.707 mmol, 64.67%). LCMS: 476.8 [M+H] + .

[0490] Step 2: Preparation of compound 31-2

[0491] At 80 ° C, CuI (239.50 mg, 1.258 mmol) and methyl 2,2-difluoro-2-fluoro-sulfonyl acetate (965.82 mg, 5.030 mmol) were added to a solution of compound 31-1 (600 mg, 1.258 mmol) in DMF (20 mL). The mixture was stirred at this temperature for 12 hours. The mixture was quenched with H2O (20 mL) and extracted with EA (100 mL). The organic layer was dried over Na2SO4 and concentrated to dryness. The residue was purified by silica gel column chromatography to give compound 31-2 (450 mg, 1.073 mmol, 85.36%). LCMS: 418.9 [M + H] + .

[0492] Step 3: Preparation of Example 31

[0493] Example 31 was prepared from compound 31-2 according to the method described in Example 12. Spectral data of Example 31: LCMS: 399.1 [M+H] + ; 1 H NMR: (400MHz, DMSO-d6) δ12.97(s,1H),9.35(s,2H),9.22(s,1H),8.03(s,1H),7.34(s,1 H),6.94(d,J=8.0Hz,1H),6.78(d,J=8.0Hz,1H),2.69(s,3H),1.78(s,3H),1.71(s,3H).

[0494] Example 32: Preparation of (S)-5-(3-hydroxy-2,6-dimethylphenyl)-2-(2-methylpyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile

[0495] Example 32 was prepared according to the following synthetic procedure.

[0496]

[0497] Step 1: Preparation of compound 32-1

[0498] To a solution of compound 31-1 (23.5 g, 49.255 mmol) in DMF (235 mL) was added Zn(CN)2 (2.891 g, 24.627 mmol) and Pd(PPh3)4 (5.692 g, 4.925 mmol). The mixture was stirred at 110 °C for 16 hours. The mixture was quenched by water (100 mL) and extracted with EtOAc (500 mL×3). The organic layer was washed with brine, concentrated, and purified by silica gel column chromatography to give compound 32-1 (25 g, 35.983 mmol, 73.1%). LCMS: 378.1 [M+H] + .

[0499] Step 2: Preparation of compound 32-2

[0500] Pd(dtbpf)Cl2 (1.7 g, 2.658 mmol) and K2CO3 (11.0 g, 79.745 mmol) were added to a solution of compound 32-1 (10 g, 26.582 mmol) and compound 10-6 (10.5 g, 39.872 mmol) in dioxane (100 mL) and H2O (20 mL). The mixture was stirred at 90 ° C for 16 hours under N2. The mixture was concentrated. The residue was purified by silica gel column chromatography to give compound 32-2 (8.32 g, 19.299 mmol, 72.6%). LCMS: 432.3 [M+H]+ .

[0501] Step 3: Preparation of compound 32-3

[0502] To a solution of compound 32-2 (27 g, 62.571 mmol) in THF (500 mL) was added dropwise LDA (62.57 mL, 125.142 mmol) at -78 °C. The mixture was stirred at -78 °C for 30 minutes. A solution of compound 12-5 (40.7 g, 125.142 mmol) in THF (5 mL) was then added. The mixture was stirred at -78 °C for 1 hour, then warmed to room temperature and continued for 16 hours. The mixture was quenched by saturated NH4Cl aqueous solution (100 mL) and extracted with EA (50 mL×3). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography to give compound 32-3 (18 g, 35.266 mmol, 56.4%). LCMS: 511.8 [M+H] + .

[0503] Step 4: Preparation of compound 32-4

[0504] A mixture of compound 32-3 (7 g, 13.715 mmol) and NaOH (1 M, 137.15 mL, 137.147 mmol) in EtOH (150 mL) and MeOH (150 mL) was heated to 60 ° C for 2 hours. The mixture was cooled to 0 ° C, adjusted to pH = 6 by 1N HCl, and extracted with EA (200 mL x3). The combined organic layer was washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography and further purified by SFC to obtain compound 32-4. LCMS: 357.9 [M + H] + . 1 H NMR: (400MHz, DMSO-d6) δ13.32 (s, 1H), 8.30-8.02 (m, 1H), 7.18 (d, J = 7.6Hz, 1H),7.06-6.92(m,1H),6.85(s,1H),3.83(s,3H),1.88(s,3H),1.80(s,3H).

[0505] Step 5: Preparation of Example 32

[0506] Example 32 was prepared from compound 32-4 according to the method described in Example 12. Spectral data of Example 32: LCMS: 356.2 [M+H] + ; 1H NMR: (400MHz, DMSO-d6) δ13.09(s,1H),9.37(s,3H),8.21(s,1H),7.43(s,1H),7. 01(d,J=8.2Hz,1H),6.85(d,J=8.2Hz,1H),2.70(s,3H),1.87(s,3H),1.79(s,3H).

[0507] Example 33: Preparation of (S)-3-chloro-5-(3-hydroxy-2,6-dimethylphenyl)-2-(2-methylpyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile

[0508] The title compound was synthesized from compound 33-1, which was prepared according to the method described in Example 32 using similar starting materials.

[0509]

[0510] Step 1: Preparation of compound 33-2

[0511] To a solution of compound 33-1 (40 mg, 0.108 mmol) in CH3CN (2 mL) was added NCS (14.4 mg, 0.108 mmol). The mixture was stirred at 40 °C for 16 hours. The mixture was diluted with H2O (15 mL) and extracted with DCM (10 mL×3). The combined organic layers were washed with brine (10 mL×3), dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography to give compound 33-2. LCMS: 404.1 [M+H] + .

[0512] Step 2: Preparation of Example 33

[0513] To a solution of compound 33-2 (30 mg, 0.0743 mmol) in DCM (3 mL) was added BBr3 (186.2 mg, 0.743 mmol). The mixture was stirred at room temperature under N2 for 1 hour. The reaction was quenched with MeOH (5 mL). The mixture was concentrated to dryness. The residue was purified by preparative HPLC to give Example 33. LCMS: 390.1 [M+H] + ; 1 H NMR: (400MHz, DMSO-d6) δ13.42(s,1H),9.40(s,1H),9.23(s,2H),8.33(s,1H),7. 02(d,J=8.4Hz,1H),6.86(d,J=8.4Hz,1H),2.74(s,3H),1.87(s,3H),1.79(s,3H).

[0514] Example 34: Preparation of 5-(3-hydroxy-2,6-dimethylphenyl)-2-(2-methylpyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-4-carboxamide

[0515] The title compound was synthesized from compound 33-1, which was prepared according to the method described in Example 32 using similar starting materials.

[0516]

[0517] Step 1: Preparation of compound 34-1

[0518] To a solution of compound 33-1 (50 mg, 0.135 mmol) in MeOH (1 mL) and H2O (0.5 mL) was added H2O2 (85.72 mg, 0.677 mmol) and NaOH (16.24 mg, 0.406 mmol). The mixture was stirred at 40 °C for 16 hours. The mixture was filtered and concentrated to dryness. The residue was purified by silica gel column chromatography to give compound 34-1. LCMS: 388.4 [M+H] + .

[0519] Step 2: Preparation of Example 34

[0520] To a solution of compound 34-1 (22 mg, 0.057 mmol) in DCM (5 mL) was added BBr3 (0.142 mL, 0.284 mmol). The mixture was stirred at room temperature under N2 for 0.5 h. The reaction was quenched with MeOH (5 mL). The mixture was concentrated to dryness. The residue was purified by preparative HPLC to give Example 34. LCMS: 374.3 [M+H] + ; 1 H NMR: (400MHz, DMSO-d6) δ12.51(s,1H),9.29(s,2H),9.05(s,1H),7.90(s,1H),7.48(s,1H),7.42(s,1 H),7.16(s,1H),6.86(d,J=8.0Hz,1H),6.71(d,J=8.0Hz,1H),2.68(s,3H),1.87(s,3H),1.79(s,3H).

[0521] The following Examples 35-81 were prepared according to the methods described in Examples 32-34 using similar starting materials.

[0522]

[0523]

[0524]

[0525]

[0526]

[0527]

[0528]

[0529]

[0530]

[0531]

[0532]

[0533]

[0534]

[0535]

[0536]

[0537] Example 82: Preparation of (R)-3-chloro-5-(3-hydroxy-2,6-dimethylphenyl)-2-(2-(2-oxooxazolidin-3-yl)pyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile

[0538] The title compound was prepared according to the following synthetic procedure.

[0539]

[0540] Step 1: Preparation of compound 82-3

[0541] Compound 82-2 (449.14 mg, 5.158 mmol) was added to a solution of compound 82-1 (1.1 g, 5.687 mmol) in NMP (20 mL), and the reactants were stirred at 80 ° C for 18 hours under N2. The reaction mixture was diluted with water (100 mL) and extracted with EA (100 mL×3). The combined organic layers were washed with brine (100 mL), dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography to give compound 82-3 (500 mg, 2.049 mmol, 37.74%). LCMS: 244.0 [M+H] + .

[0542] Step 2: Preparation of compound 82-4

[0543] To a solution of compound 82-3 (500 mg, 2.049 mmol) in dioxane (3 mL) was added 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolan (1.30 g, 5.122 mmol), KOAc (603.20 mg, 6.146 mmol) and Pd(dppf)Cl2 (224.86 mg, 0.307 mmol), and the reactants were stirred at 90 ° C. under N2 for 3 hours. The reaction mixture was filtered and concentrated to dryness. The residue was purified by reverse phase chromatography to give compound 82-4 (300 mg, 1.436 mmol, 70.07%). LCMS: 209.9 [M+H] + .

[0544] Step 3: Preparation of Example 82

[0545] Example 82 was prepared from compound 82-4 according to the method described in Example 32-33. Spectral data of Example 82: LCMS: 461.0 [M+H] + ; 1 H NMR: (400MHz, DMSO-d6) δ13.40(s,1H),10.48(s,1H),9.42(d,J=12.0Hz,1H),9.29(d,J=8.8Hz,1H),9.26-9.20(m,1H),8.33(d,J =4.8Hz,1H),7.03(d,J=8.2Hz,1H),6.87(d,J=8.2Hz,1H),4.78(t,J=9.6Hz,2H),4.02(t,J=9.6Hz,2H),1.87(s,3H),1.79(s,3H).

[0546] Example 83: Preparation of (5R)-2-(2-(2,3-dihydroxypropoxy)pyrimidin-5-yl)-5-(3-hydroxy-2,6-dimethylphenyl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile

[0547] The title compound was prepared according to the following synthetic procedure.

[0548]

[0549] Step 1: Preparation of compound 83-2

[0550] To a solution of compound 83-1 (512.43 mg, 3.877 mmol) in THF (10 mL) was added NaH (124.08 mg, 3.102 mmol) and then compound 82-1 (500 mg, 2.585 mmol) at 0°C over 0.5 hours. The mixture was stirred at room temperature for 4 hours. The reaction mixture was diluted with water (20 mL) and extracted with EA (30 mL×3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by silica gel column chromatography to give compound 83-2 (550 mg, 1.902 mmol, 73.6%). LCMS: 291.1 [M+H] + .

[0551] Step 2: Preparation of compound 83-3

[0552] To a solution of compound 83-2 (300 mg, 1.038 mmol) and 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)-1,3,2-dioxaborolane (790.4 mg, 3.113 mmol) in dioxane (5 mL) was added KOAc (305.4 mg, 3.113 mmol) and Pd(dppf)Cl2 (75.9 mg, 0.104 mmol). The reaction mixture was purged of gas three times. The reaction mixture was stirred at 90 ° C. under N2 overnight. The reaction mixture was diluted with water (30 mL) and extracted with EA (30 mL×3). The combined organic layers were washed with brine (50 mL×2), dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography to obtain compound 83-3 (130 mg, 1.200 mmol, 26.0%). LCMS: 255.2 [M+H] + .

[0553] Step 3: Preparation of Example 83

[0554] Example 83 was prepared from compound 83-3 according to the method described in Examples 32-33. Spectral data of Example 83: LCMS: 432.2 [M+H] + ; 1H NMR: (400MHz, DMSO-d6) δ12.88(s,1H),9.37(s,1H),9.26(d,J=9.2Hz,2H),8 .17(s,1H),7.32(d,J=5.2Hz,1H),7.01(d,J=8.4Hz,1H),6.85(d,J=8.4Hz,1 H),4.98-4.94(m,1H),4.72(s,1H),4.43(dd,J=11.0,4.0Hz,1H),4.30(dd,J =11.0,6.4Hz,1H),3.81-3.76(m,1H),3.48(s,2H),1.87(s,3H),1.80(s,3H).

[0555] Example 84: Preparation of (R)-3-chloro-2-(2-(1,1-dioxothiomorpholinyl)pyrimidin-5-yl)-5-(3-hydroxy-2,6-dimethylphenyl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile

[0556] The title compound was prepared according to the following synthetic procedure.

[0557]

[0558] Step 1: Preparation of compound 84-3

[0559] Compound 84-2 (843.1 mg, 6.237 mmol) and TEA (0.87 mL, 6.237 mmol) were added to a solution of compound 84-1 (500 mg, 2.079 mmol) in ethanol (10 mL), and the reactants were stirred at 80 ° C for 4 hours under N2. The reaction mixture was diluted with water (20 mL) and extracted with EA (30 mL×3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography to give compound 84-3 (500 mg, 1.945 mmol, 93.55%). LCMS: 258.0 [M+H] + .

[0560] Step 2: Preparation of Example 84

[0561] The title compound was prepared from compound 84-3 according to the method described in Examples 32-33. Spectral data of Example 84: LCMS: 509.1 [M+H] + ; 1H NMR: (400MHz, DMSO-d6) δ9.38(s,1H),9.00(s,2H),8.23(s,1H),7.02(d,J=8.4Hz ,1H),6.85(d,J=8.4Hz,1H),4.33(s,4H),3.26(s,4H),1.87(s,3H),1.78(s,3H).

[0562] Example 85: Preparation of 2-(2-(difluoromethoxy)pyrimidin-5-yl)-5-(3-hydroxy-2,6-dimethylphenyl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile

[0563] The title compound was prepared according to the following synthetic procedure.

[0564]

[0565] Step 1: Preparation of compound 85-2

[0566] A solution of compound 85-1 (5 g, 18.860 mmol) in TFA (20 mL, 18.860 mmol) was stirred at 40 °C for 16 hours. The mixture was diluted with EA (100 mL) and water (100 mL) and stirred for 10 minutes. The mixture was filtered. The filtrate was dried under reduced pressure to obtain compound 85-2 (2 g, 11.429 mmol, 60.60%).

[0567] Step 2: Preparation of compound 85-4

[0568] To a solution of compound 85-2 (3 g, 17.144 mmol) and K2CO3 (7.11 g, 51.432 mmol) in DMF (40 mL) was added compound 85-3 (7.84 g, 51.432 mmol) at 80°C. The mixture was stirred at 100°C for 2 hours. The mixture was filtered. The filtrate was diluted with EA (50 mL), which was washed with brine (50 mL×3). The organic layer was dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography to give compound 85-4 (300 mg, 1.333 mmol, 7.78%).

[0569] Step 3: Preparation of compound 85-5

[0570] To a solution of compound 85-4 (65 mg, 0.289 mmol) in dioxane (2 mL) was added KOAc (85.06 mg, 0.867 mmol) and Pd(dppf)Cl2 (21.14 mg, 0.029 mmol). The mixture was stirred at 100°C for 1 hour. The reaction mixture was used directly in the next step. LCMS: 190.9 [M+H] + .

[0571] Step 4: Preparation of Example 85

[0572] Example 85 was prepared from compound 85-5 according to the method described in Examples 32-33. Spectral data of Example 85: LCMS: 408.0 [M+H] + ; 1 H NMR: (400MHz, CD3OD) δ9.26 (s, 2H), 8.19 (s, 1H), 7.69 (t, J = 72.0Hz, 1H), 7.28 ( s,1H),7.04(d,J=8.2Hz,1H),6.84(d,J=8.2Hz,1H),1.95(s,3H),1.90(s,3H).

[0573] Example 86: Preparation of 5-(3-hydroxy-2,6-dimethylphenyl)-2-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile

[0574] The title compound was prepared according to the following synthetic procedure.

[0575]

[0576] Step 1: Preparation of compound 86-2

[0577] To a solution of compound 86-1 (1 g, 4.608 mmol) in THF (10 mL) was added magnesium monobromide methanide (18.431 mL, 18.431 mmol). The mixture was stirred at 0°C for 2 hours. The reaction mixture was diluted with water (20 mL) and extracted with EA (10 mL×3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography to give compound 86-2 (400 mg, 1.843 mmol, 39.99%). LCMS: 219.0 [M+H] + .

[0578] Step 2: Preparation of compound 86-3

[0579] To a solution of compound 86-2 (100 mg, 0.461 mmol) and 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolan (175.48 mg, 0.691 mmol) in dioxane (4 mL) was added KOAc (45.21 mg, 0.461 mmol) and Pd(dppf)Cl2 (337.08 mg, 0.461 mmol). The mixture was stirred at 100° C. for 2 hours. The mixture was used directly in the next step.

[0580] Step 3: Preparation of Example 86

[0581] The title compound was prepared from compound 86-3 according to the method described in Examples 32-33. Spectral data of Example 86: LCMS: 400.1 [M+H] + ; 1 H NMR: (400MHz, DMSO-d6) δ13.15(s,1H),9.46(s,2H),9.37(s,1H),8.23(s,1H),7.47(s,1H),7. 02(d,J=8.4Hz,1H),6.85(d,J=8.4Hz,1H),5.19(s,1H),1.88(s,3H),1.80(s,3H),1.55(s,6H).

[0582] Example 87: Preparation of (R)-2-(6-amino-5-ethynylpyridin-3-yl)-5-(3-hydroxy-2,6-dimethylphenyl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile

[0583] The title compound was prepared according to the following synthetic procedure.

[0584]

[0585] Step 1: Preparation of compound 87-3

[0586] To a solution of compound 87-1 (1.0 g, 3.346 mmol) and triethylamine (10 mL) in THF (10 mL) was added CuI (12.7 mg, 0.067 mmol), bis(triphenylphosphine)palladium(II) chloride (26.0 mg, 0.033 mmol) and compound 87-2 (361.4 mg, 3.680 mmol). The mixture was stirred at room temperature for 1 hour. The mixture was filtered and concentrated, and the residue was purified by silica gel column chromatography to obtain compound 87-3 (870 mg, 3.232 mmol). LCMS: 310.1 [M+CH3CN+H] + .

[0587] Step 2: Preparation of compound 87-4

[0588] To a solution of compound 87-3 (870 mg, 3.232 mmol) in DCM (25 mL) was added di-tert-butyl dicarbonate (2.23 mL, 9.695 mmol) and DMAP (39.5 mg, 0.323 mmol). The mixture was stirred at room temperature for 3 hours. The mixture was concentrated and purified by silica gel column chromatography to give compound 87-4 (1220 mg, 2.599 mmol). 1 H NMR (400MHz, CDCl3) δ8.47(d,J=1.2Hz,1H),7.93(d,J=1.2Hz,1H),1.40(s,18H),0.22(d,J=0.6Hz,9H).

[0589] Step 3: Preparation of Compound 87-5

[0590] A solution of compound 87-4 (1.35 g, 2.875 mmol), bis(pinacolato)diboron (1.46 g, 5.751 mmol), potassium acetate (846.2 mg, 8.626 mmol), and Pd(dppf)Cl2 (210.4 mg, 0.288 mmol) in dioxane (15 mL) was stirred at 90° C. overnight. The mixture was filtered and concentrated, and the residue was purified by silica gel column chromatography to obtain compound 87-5 (920 mg, 2.118 mmol). LCMS: 435.3 [M+H] + .

[0591] Step 4: Preparation of Example 87

[0592] Example 87 was prepared from compound 87-5 according to the method described in Examples 32-33. Spectral data of Example 87: LCMS: 380.2 [M+H] + ; 1 H NMR: (400MHz, DMSO-d6) δ12.62(s,1H),9.61(s,1H),8.59(s,1H),8.34(s,1H),8.20(s,1H),7.97(s,1 H),7.00(d,J=7.4Hz,2H),6.81(d,J=8.2Hz,1H),6.50(s,2H),4.29(s,1H),1.81(s,3H),1.74(s,3H).

[0593] Example 88: Preparation of 3-(2-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-2,4-dimethylphenol

[0594] The title compound was prepared according to the following synthetic procedure.

[0595]

[0596] Step 1: Preparation of compound 88-3

[0597] To a solution of compound 88-1 (2 g, 4.192 mmol) and compound 88-2 (0.9 g, 4.192 mmol) in dioxane (20 mL) and water (4 mL) was added CsF (1.91 g, 12.576 mmol), Pd (dppf) Cl2 (0.31 g, 0.419 mmol). The reactants were stirred at 90 ° C for 16 hours under N2. The reactants were diluted with EA (60 mL) and water (50 mL). The organic layer was separated, washed with brine, and concentrated in vacuo. The residue was purified by silica gel column chromatography to give compound 88-3 (360 mg, 0.739 mmol, 17.62%). LCMS: 489.0 [M + H] + .

[0598] Step 2: Preparation of compound 88-4

[0599] At 0°C, MeMgBr (3.7 mL, 0.739 mmol, 1 M) was added to a solution of compound 88-3 (360 mg, 0.739 mmol) in THF (5 mL), and the reactant was stirred at 0°C for 3 hours. The reaction mixture was carefully added to water (30 mL) under an ice bath and extracted with EA (30 mL×3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated to dryness. The organic layer was separated and concentrated in vacuo. The residue was purified using silica gel column chromatography to give compound 88-4 (200 mg, 0.410 mmol, 55.55%). LCMS: 488.8 [M+H] + .

[0600] Step 3: Preparation of Example 88

[0601] Example 88 was prepared from compound 88-4 according to the method described in Examples 32-33. Spectral data of Example 88: LCMS: 375.1 [M+H] + ; 1H NMR: (400MHz, DMSO-d6) δ12.45(s,1H),9.35(s,2H),9.15(s,1H),8.00(s,1H),7.75(s,1H),7.16(s,1 H),6.94(d,J=8.0Hz,1H),6.76(d,J=8.0Hz,1H),5.12(s,1H),1.89(s,3H),1.82(s,3H),1.54(s,6H).

[0602] Example 89: Preparation of 5-(3-hydroxy-2,6-dimethylphenyl)-2-(5-(4-hydroxypiperidin-1-yl)pyridin-3-yl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile

[0603] The title compound was prepared according to the following synthetic procedure.

[0604]

[0605] Step 1: Preparation of compound 89-3

[0606] To a solution of compound 89-1 (500 mg, 2.11 mmol) in DMF (10 mL) was added compound 89-2 (485 mg, 4.219 mmol) and K2CO3 (874 mg, 6.33 mmol) at room temperature. The mixture was stirred at 120°C for 16 hours. The mixture was quenched with H2O (50 mL) and extracted with EA (60 mL×3). The organic layer was dried over Na2SO4 and concentrated to dryness. The residue was purified by silica gel column chromatography to give compound 89-3 (120 mg, 0.443 mmol, 21%). LCMS: 273.1 [M+H] + .

[0607] Step 2: Preparation of compound 89-4

[0608] To a solution of compound 89-3 (50 mg, 0.185 mmol) in dioxane (1 mL) was added 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolan (140 mg, 0.554 mmol), KOAc (54 mg, 0.554 mmol) and Pd(dppf)Cl2 (18 mg, 0.024 mmol). The mixture was stirred at 90 °C under N2 for 1.5 hours. The mixture was used in the next step. LCMS: 237.1 [M+H] + .

[0609] Step 3: Preparation of Example 89

[0610] Example 89 was prepared from compound 89-4 according to the method described in Examples 32-33. Spectral data of Example 89: LCMS: 440.3 [M+H] + ; 1 H NMR: (400MHz, CD3OD) δ8.45(s,1H),8.20(s,1H),8.03(s,1H),7.81(s,1H),7.10(s,1H),6.92(d,J=8.4Hz,1H),6.72(d,J=8 .4Hz,1H),3.78-3.66(m,3H),3.02(t,J=10.0Hz,2H),1.94(d,J=13.1Hz,2H),1.84(s,3H),1.79(s,3H),1.62-1.57(m,2H).

[0611] Example 90: Preparation of 5-(2-ethyl-3-hydroxy-6-methylphenyl)-2-(2-methylpyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile

[0612] The title compound was prepared according to the following synthetic procedure.

[0613]

[0614] Step 1: Preparation of compound 90-2

[0615] To a solution of compound 90-1 (8.0 g, 39.594 mmol) and ethylboronic acid (5.9 g, 79.188 mmol) in dioxane (100 mL) and H2O (20 mL) were added Pd(dppf)Cl2 (2.9 g, 3.959 mmol) and K2CO3 (16.4 g, 118.782 mmol). The mixture was stirred at 100°C for 12 hours. The reaction mixture was diluted with water (100 mL) and extracted with EA (100 mL×3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by silica gel column chromatography to give compound 90-2 (2.4 g, 15.872 mmol, 40.09%). LCMS: 152.2 [M+H] + .

[0616] Step 2: Preparation of compound 90-3

[0617] To a solution of compound 90-2 (7.0 g, 46.293 mmol) in DMF (20 mL) was added NIS (8.0 g, 46.293 mmol). The mixture was stirred at room temperature for 12 hours. The reaction mixture was diluted with EA (30 mL) and washed with brine (20 mL×3). The organic layer was dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by silica gel column chromatography to give compound 90-3 (8 g, 28.869 mmol, 62.36%). LCMS: 278.2 [M+H] + .

[0618] Step 3: Preparation of compound 90-4

[0619] To a solution of compound 90-3 (850 mg, 3.067 mmol) and 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane (770 mg, 6.135 mmol) in dioxane (20 mL) and H2O (4 mL) were added K2CO3 (1271 mg, 9.202 mmol) and Pd(dtbpf)Cl2 (201 mg, 0.307 mmol). The mixture was stirred at 100°C for 12 hours. The reaction mixture was diluted with water (20 mL) and extracted with EA (20 mL×3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel column chromatography to give compound 90-4 (400 mg, 2.421 mmol, 78.92%). LCMS: 166.3 [M+H] + .

[0620] Step 4: Preparation of Compound 90-5

[0621] At 0°C, a solution of compound 90-4 (700 mg, 4.236 mmol) in AcOH (8 mL) and HBr (1 mL) was added dropwise with a solution of NaNO2 (292 mg, 4.236 mmol) in H2O (1 mL), and the mixture was stirred at 0°C for 2 hours. Then a solution of CuBr (608 mg, 4.236 mmol) in HBr (1 mL) was added. The resulting mixture was stirred at room temperature for 2 hours. The reaction mixture was quenched by water (10 mL) and extracted with EA (10 mL×3). The combined organic layers were washed with brine (10 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by silica gel column chromatography to give compound 90-5 (300 mg, 1.309 mmol, 30.91%). 1H NMR: (400MHz, DMSO-d6) δ7.17 (t, J = 9.8 Hz, 1H), 6.95-6.86 (m, 1H), 3.82-3.75 (m, 3H), 2.82-2.70 (m, 2H), 2.34-2.25 (m, 3H), 1.11-0.98 (m, 3H).

[0622] Step 5: Preparation of compound 90-6

[0623] Potassium acetate (565 mg, 5.761 mmol) and Pd(dppf)Cl2 (140 mg, 0.192 mmol) were added to a solution of compound 90-5 (440 mg, 1.920 mmol) and 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)-1,3,2-dioxaborolane (732 mg, 2.881 mmol) in DMF (5 mL). The mixture was stirred at 130 ° C for 12 hours. The reaction mixture was diluted with EA (20 mL), which was washed with brine (10 mL×3). The organic layer was dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by preparative TLC to give compound 90-6 (260 mg, 0.941 mmol, 49.02%). 1 H NMR: (400MHz, DMSO-d6) δ6.92(d,J=8.4Hz,1H),6.82(d,J=8.4Hz,1H),3.72(s ,3H),2.56(q,J=7.4Hz,2H),2.22(s,3H),1.32(s,12H),1.04(t,J=7.4Hz,3H).

[0624] Step 6: Preparation of Example 90

[0625] The title compound was prepared from compound 90-6 according to the method described in Examples 32-33.

[0626] Spectral data of Example 90: LCMS: 370.4 [M+H] + .

[0627] Example 91: Preparation of (R)-5-(2-ethyl-3-hydroxy-6-methylphenyl)-2-(2-methylpyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile

[0628] Step 1: Preparation of Example 91

[0629] The title compound was isolated from Example 90 by preparative SFC. LCMS: 411.2 [M+H+CH3CN]+ ; 1 HNMR: (400MHz, DMSO-d6) δ13.08(s,1H),9.37(s,2H),9.33(s,1H),8.22(s,1H),7.43(s,1H),7.01(d,J =8.2Hz,1H),6.85(d,J=8.2Hz,1H),2.70(s,3H),2.51-2.19(m,2H),1.84(s,3H),0.87(t,J=7.4Hz,3H).

[0630] Example 92: Preparation of 2-(4-amino-2-methylpyrimidin-5-yl)-5-(3-hydroxy-2,6-dimethylphenyl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile

[0631] The title compound was prepared according to the following synthetic procedure.

[0632]

[0633] Step 1: Preparation of compound 92-2

[0634] To a solution of compound 92-1 (100 mg, 0.53 mmol) in dioxane (2 mL) was added B2Pin2 (405 mg, 1.60 mmol), KOAc (156 mg, 1.60 mmol), and Pd(dppf)Cl2 (51 mg, 0.07 mmol). The mixture was stirred at 100 °C for 3 hours. The mixture was used directly in the next step. LCMS: 154.2 [M+H] + .

[0635] Step 2: Preparation of compound 92-4

[0636] Compound 92-3 (148 mg, 0.266 mmol), CsF (121 mg, 0.80 mmol), BrettphPdG3 (30 mg, 0.03 mmol) and water (0.4 mL) were added to the reaction mixture of step 1, and the mixture was stirred at 75 ° C for 2 hours. The mixture was extracted with DCM (30 mL×3). The combined organic phase was washed with brine (40 mL), dried over Na2SO4, filtered, concentrated, and purified by preparative TLC to give compound 92-4 (20 mg, 0.037 mmol). LCMS: 539.3 [M+H] + .

[0637] Step 3: Preparation of Example 92

[0638] Example 92 was prepared from compound 92-4 according to the method described in Examples 32-33. Spectral data of Example 92: LCMS: 371.2 [M+H] + ; 1 H NMR: (400MHz, DMSO-d6) δ9.33(s,1H),8.45-8.39(m,3H),8.09(s,1H),7.17-7.03(m,1H),7.0 0(d,J=8.0Hz,1H),6.88(s,1H),6.83(d,J=8.2Hz,1H),2.40(s,3H),1.87(s,3H),1.79(s,3H).

[0639] Example 93: Preparation of (R)-5-(3-hydroxy-2,6-dimethylphenyl)-2-(2-(pyrrolidin-1-ylmethyl)pyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile

[0640] The title compound was prepared according to the following synthetic procedure.

[0641]

[0642] Step 1: Preparation of compound 93-2

[0643] To a solution of compound 93-1 (650 mg, 2.580 mmol) in CH3CN (10 mL) was added tetrahydropyrrole (0.4 mL, 5.161 mmol) and K2CO3 (1069.8 mg, 7.741 mmol). The mixture was stirred at room temperature for 4 hours. The mixture was concentrated. The residue was purified by silica gel column chromatography to obtain compound 93-2 (520 mg, 2.148 mmol, 83.23%). LCMS: 244.0 [M+H] + .

[0644] Step 2: Preparation of compound 93-3

[0645] To a solution of compound 93-2 (470 mg, 1.941 mmol) in dioxane (8 mL) were added 1,1,1,2,2,2-hexabutylditinane (2252.2 mg, 3.882 mmol), LiCl (164.6 mg, 3.882 mmol) and Pd(PPh3)4 (224.3 mg, 0.194 mmol). The mixture was stirred at 100 ° C. for 4 hours under N2 atmosphere. The mixture was concentrated. The residue was purified by silica gel column chromatography to give compound 93-3 (530 mg, 1.172 mmol, 60.37%). LCMS: 454.4 [M+H] + .

[0646] Step 3: Preparation of compound 93-4

[0647] Compound 93-3 (253.9 mg, 0.561 mmol), LiCl (11.9 mg, 0.281 mmol) and Pd(PPh3)4 (32.4 mg, 0.028 mmol) were added to a solution of compound 32-4 (100 mg, 0.281 mmol) in dioxane (5 mL). The mixture was added at 100 ° C for 16 hours under N2 atmosphere. The reaction mixture was diluted with DCM (30 mL) and washed with brine (10 mL×3). The organic layer was dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by silica gel column chromatography to obtain compound 93-4. LCMS: 439.5 [M+H] + .

[0648] Step 4: Preparation of Example 93

[0649] To a solution of compound 93-4 (47 mg, 0.107 mmol) in DCM (4 mL) was added BBr3 (134.3 mg, 0.536 mmol) and the mixture was stirred at room temperature for 1 hour. The reaction was quenched with MeOH (5 mL). The mixture was concentrated to dryness and purified by preparative HPLC to give Example 93. LCMS: 425.4 [M+H] + ; 1 H NMR: (400MHz, DMSO-d6) δ13.14(s,1H),9.44(s,2H),9.37(s,1H),8.22(s,1H),8.18(s,1H),7.47(s,1H),7.02(d,J= 8.4Hz,1H),6.85(d,J=8.4Hz,1H),3.93(s,2H),2.65(t,J=5.6Hz,4H),1.87(s,3H),1.80(s,3H),1.76-1.70(m,4H).

[0650] The following Examples 94-95 were prepared according to the method described in Example 93 using similar starting materials.

[0651]

[0652] Example 96: Preparation of (R)-5-(3-hydroxy-2,6-dimethylphenyl)-2-(2-(methyl(oxetane-3-yl)amino)pyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile

[0653] The title compound was synthesized from 96-1, which was prepared according to the methods described in Examples 32-33 using similar starting materials.

[0654]

[0655] Step 1: Preparation of Example 96

[0656] To a solution of compound 96-1 (40 mg, 0.11 mmol) in DMF (1 ml) was added compound 96-2 (19 mg, 0.21 mmol) and TEA (32 mg, 0.32 mmol), and the reaction was stirred at 50° C. overnight. The mixture was purified using preparative HPLC and dried to give Example 96. LCMS: 427.1 [M+H] + ; 1 H NMR: (400MHz, DMSO-d6) δ12.19(s,1H),9.30(s,1H),8.40(s,1H),7.87(s,1H),7.43(s,1H),6.97(d,J=8.0Hz,1H),6.81(d,J=8.4Hz,1H),6.17( s,1H),4.18(d,J=11.6Hz,1H),4.04(d,J=12.0Hz,1H),3.62(s,1H),3.5 1(s,1H),3.20(d,J=8.8Hz,1H),2.84(s,3H),1.85(s,3H),1.78(s,3H).

[0657] The following Examples 97-103 were prepared according to the method described in Example 96 using similar starting materials.

[0658]

[0659]

[0660]

[0661]

[0662] Example 104: Preparation of (R)-5-(3-hydroxy-2,6-dimethylphenyl)-2-(2-(prop-1-yn-1-yl)pyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile

[0663] The title compound was synthesized from compound 96-1, which was prepared according to the method described in Example 32 using similar starting materials.

[0664]

[0665] Step 1: Preparation of Example 104

[0666] A mixture of compound 96-1 (30 mg, 0.080 mmol), compound 104-1 (0.16 mL, 1 M DMF solution, 0.160 mmol), CuI (2.5 mg, 0.008 mmol), bis(triphenylphosphine)palladium(II) chloride (6.2 mg, 0.008 mmol), TEA (24.2 mg, 0.239 mmol) in THF (3 mL) was stirred at 50° C. for 16 hours. The mixture was concentrated and purified by preparative HPLC to give Example 104. LCMS: 380.2 [M+H] + ; 1 H NMR(400MHz,DMSO-d6)δ13.12(s,1H),9.43(s,2H),9.38(s,1H),8.23(s,1H),7.52(s,1 H),7.02(d,J=8.3Hz,1H),6.85(d,J=8.2Hz,1H),2.16(s,3H),1.87(s,3H),1.80(s,3H).

[0667] Example 105: Preparation of (R)-5-(4-cyano-5-(3-hydroxy-2,6-dimethylphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)pyrimidine-2-carboxamide

[0668] The title compound was synthesized from compound 105-1, which was prepared according to the method described in Example 32 using similar starting materials.

[0669]

[0670] Step 1: Preparation of compound 105-2

[0671] To a solution of compound 105-1 (120.0 mg, 0.308 mmol) in DMSO (1.5 mL) was added 4-azabicyclo[2.2.2]octan-7-ol (7.8 mg, 0.062 mmol) and KCN (40.1 mg, 0.616 mmol). The mixture was stirred at 50 ° C for 1 hour. The reaction mixture was diluted with water (20 mL) and extracted with EA (30 mL×3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel column chromatography to give compound 105-2. LCMS: 381.2 [M+H] + .

[0672] Step 2: Preparation of compound 105-3

[0673] To a solution of compound 105-2 (45.0 mg, 0.118 mmol) in MeOH (3.0 mL) was added NaOH (14.2 mg, 0.355 mmol) and H2O2 (12.1 mg, 0.355 mmol). The mixture was stirred at room temperature overnight. The mixture was concentrated and the residue was washed with water. The residue was purified by preparative TLC to give compound 105-3. LCMS: 399.2 [M+H] + .

[0674] Step 3: Preparation of Example 105

[0675] To a solution of compound 105-3 (22.0 mg, 0.055 mmol) in DCM (3.0 mL) was added BBr3 (0.03 mL, 0.276 mmol) at 0°C. The mixture was stirred at 0°C for 1 hour. MeOH (2 mL) was carefully added to the reaction mixture while stirring and diluted with water (10 mL). The pH of the mixture was then adjusted to 8 with NaHCO3. The mixture was extracted with DCM (20 mL) and EA (20 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by preparative TLC to give Example 105. LCMS: 385.2 [M+H] + ; 1 H NMR: (400MHz, DMSO-d6) δ13.46(s,1H),9.67(s,2H),9.54(s,1H),8.36(s,1H),8.27(s,1H),7. 93(s,1H),7.63(s,1H),7.02(d,J=8.4Hz,1H),6.93(d,J=8.4Hz,1H),1.89(s,3H),1.81(s,3H).

[0676] Example 106: Preparation of (R)-2-(2-aminopyrimidin-5-yl)-5-(3-hydroxy-2,6-dimethylphenyl)-3-methyl-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile

[0677] The title compound was prepared according to the following synthetic procedure.

[0678]

[0679] Step 1: Preparation of compound 106-1

[0680] To a solution of compound 39 (100.0 mg, 0.281 mmol) in CH3CN (5 mL) was added NBS (44.9 mg, 0.252 mmol) at 0°C. The mixture was stirred at room temperature for 16 hours. The reaction mixture was diluted with water (30 mL) and extracted with EA (30 mL×3). The combined organic layers were washed with brine (50 mL), dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel column chromatography to give compound 106-1 (120.0 mg, 0.276 mmol, 98.2%). LCMS: 435.2 [M+H] + .

[0681] Step 2: Preparation of compound 106-2

[0682] To a solution of compound 106-1 (120.0 mg, 0.276 mmol) in DMF (6 mL) was added (Boc)2O (60.2 mg, 0.276 mmol), DMAP (1.7 mg, 0.014 mmol) and TEA (41.8 mg, 0.1414 mmol). The mixture was stirred at room temperature for 2 hours. The reaction mixture was diluted with water (30 mL) and extracted with EA (30 mL×3). The combined organic layers were washed with brine (50 mL×3), dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel column chromatography to give compound 106-2. LCMS: 535.2 [M+H] + .

[0683] Step 3: Preparation of compound 106-3

[0684] Compound 13-3 (32.9 mg, 0.262 mmol), K3PO4 (83.4 mg, 0.393 mmol) and Pd(dtbpf)Cl2 (8.6 mg, 0.0132 mmol) were added to a solution of compound 106-2 (70.0 mg, 0.131 mmol) in H2O (0.5 mL) and dioxane (2.5 mL). The mixture was stirred at 80 °C for 6 hours. The reaction mixture was diluted with water (30 mL) and extracted with EA (30 mL×3). The combined organic layers were washed with brine (50 mL), dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel column chromatography to give compound 106-3. LCMS: 471.4 [M+H] + .

[0685] Step 4: Preparation of Example 106

[0686] A mixture of compound 106-3 (43.0 mg, 0.0914 mmol) in HCl-dioxane (2.5 mL) was stirred at room temperature for 1 hour, and the reaction mixture was concentrated to dryness and purified by preparative HPLC to give Example 106. LCMS: 371.2 [M+H] + ; 1 H NMR(400MHz,DMSO-d6)δ12.42(s,1H),9.33(s,1H),8.59(s,2H),8.06(s,1H),7.09(s,2 H),7.00(d,J=8.4Hz,1H),6.83(d,J=8.4Hz,1H),2.53(s,3H),1.86(s,3H),1.79(s,3H).

[0687] The following Examples 107-108 were prepared according to the method described in Example 106 using similar starting materials.

[0688]

[0689]

[0690] Example 109: Preparation of (S)-3-ethynyl-5-(3-hydroxy-2,6-dimethylphenyl)-2-(2-methylpyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile

[0691] The title compound was prepared according to the following synthetic procedure.

[0692]

[0693] Step 1: Preparation of compound 109-1

[0694] To a solution of compound 33-1 (141 mg, 0.382 mmol) in CAN / DMF (1:1, 5 mL) was added NIS (94.5 mg, 0.420 mmol) at 0°C. The mixture was stirred at room temperature for 2 hours. The reaction mixture was diluted with EA (60 mL), which was washed with brine (30 mL×3). The organic layer was dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by silica gel column chromatography to give compound 109-1. LCMS: 496.4 [M+H] + .

[0695] Step 2: Preparation of compound 109-2

[0696] To a solution of compound 109-1 (85 mg, 0.172 mmol) in DCM (5 mL) was added BBr3 (215.5 mg, 0.860 mmol). The mixture was stirred at room temperature under N2 atmosphere for 1 hour. The mixture was quenched by MeOH (5 mL) and concentrated. The residue was purified by silica gel column chromatography to give compound 109-2. LCMS: 482.1 [M+H] + .

[0697] Step 3: Preparation of compound 109-3

[0698] Compound 87-2 (61.2 mg, 0.623 mmol), CuI (7.9 mg, 0.042 mmol), PdCl2(PPh3)2 (16.2 mg, 0.021 mmol) and TEA (210.3 mg, 2.078 mmol) were added to a solution of compound 109-2 (100.0 mg, 0.208 mmol) in DMF (3 mL). The mixture was stirred at 80 ° C for 2 hours. The mixture was purified by preparative HPLC to give compound 109-3. LCMS: 452.5 [M+H] + .

[0699] Step 4: Preparation of Example 109

[0700] To a solution of compound 109-3 (20.0 mg, 0.0443 mmol) in MeOH (3 mL) was added K2CO3 (18.4 mg, 0.133 mmol). The mixture was stirred at room temperature for 16 hours. The mixture was purified by preparative HPLC to give Example 109. LCMS: 380.1 [M+H] + ; 1 H NMR (400MHz, CD3OD) δ9.44(s,2H),8.24(s,1H),7.02(d,J=8.4Hz,1H),6.83(d,J=8.4Hz,1H),4.00(s,1H),2.80(s,3H),1.94(s,3H),1.89(s,3H).

[0701] The following Examples 110-111 were prepared according to the method described in Example 109 using similar starting materials.

[0702]

[0703] Example 112: Preparation of 5-(3-hydroxy-2,6-dimethylphenyl)-2-(2-methylpyrimidin-5-yl)-3-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile

[0704] The title compound was prepared according to the following synthetic procedure.

[0705]

[0706] Step 1: Preparation of compound 112-1

[0707] Cu (12.84 mg, 0.202 mmol) and diphenyl (trifluoromethyl) sulfonium (204.20 mg, 0.505 mmol) were added to a solution of compound 109-1 (50 mg, 0.101 mmol) in DMF (2 mL) at room temperature. The mixture was stirred at 60 ° C for 24 hours. The mixture was quenched with H2O (5 mL) and extracted with EA (20 mL). The organic layer was dried over Na2SO4 and concentrated to dryness. The residue was purified by silica gel column chromatography to obtain compound 112-1. LCMS: 438.4 [M + H] + .

[0708] Step 2: Preparation of Example 112

[0709] To a solution of compound 112-1 (22 mg, 0.050 mmol) in DCM (5 mL) was added BBr3 (0.12 mL, 0.251 mmol). The mixture was stirred at room temperature under N2 for 0.5 h. The reaction was quenched with MeOH (5 mL). The mixture was concentrated to dryness. The residue was purified by preparative HPLC to give Example 112. LCMS: 424.1 [M+H] + ; 1 H NMR: (400MHz, DMSO-d6) δ9.40(s,1H),9.00(s,2H),8.39(s,1H),7.02(d,J=8.4Hz,1H),6.85(d,J=8.4Hz,1H),2.74(s,3H),1.85(s,3H),1.78(s,3H).

[0710] Example 113: Preparation of 5-(3-hydroxy-2,6-dimethylphenyl)-2-(2-methylpyrimidin-5-yl)-3-(phenylthio)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile

[0711] The title compound was prepared according to the following synthetic procedure.

[0712]

[0713] Step 1: Preparation of compound 113-2

[0714] To a solution of compound 113-1 (200 mg, 0.353 mmol) in DMF (10 mL) were added sodium thiophenolate (69.8 mg, 0.529 mmol), CuI (67.1 mg, 0.353 mmol), ethylene glycol (43.8 mg, 0.706 mmol) and K2CO3 (146.3 mg, 1.059 mmol). The mixture was stirred at 80 ° C for 3 hours. The reaction mixture was filtered. The filtrate was concentrated to dryness. The residue was purified by silica gel column chromatography to give compound 113-2 (170 mg, 0.310 mmol, 87.75%) as a yellow solid. LCMS: 549.1 [M+H] + .

[0715] Step 2: Preparation of Example 113

[0716] Example 113 was prepared from compound 113-2 according to the method described in Examples 32-33. Spectral data of Example 113: LCMS: 464.2 [M+H] + ; 1 H NMR: (400MHz, CD3OD) δ9.15(s,2H),8.26(s,1H),7.21(t,J=7.6Hz,2H),7.11(d,J=7.3Hz,1H),7.03( d,J=7.5Hz,2H),6.97(d,J=8.2Hz,1H),6.78(d,J=8.2Hz,1H),2.75(s,3H),1.86(s,3H),1.81(s,3H).

[0717] Example 114: Preparation of 2,4-dimethyl-3-(2-(2-methylpyrimidin-5-yl)-3H-imidazo[4,5-b]pyridin-6-yl)phenol

[0718] The title compound was prepared according to the following synthetic procedure.

[0719]

[0720] Step 1: Preparation of compound 114-2

[0721] Compound 10-6 (836.5 mg, 3.191 mmol), Pd(dppf)Cl2 (194.6 mg, 0.266 mmol) and K2CO3 (1.102 g, 7.977 mmol) were added to a solution of compound 114-1 (500 mg, 2.659 mmol) in dioxane (5 mL) and water (1 mL). The mixture was stirred at 90 ° C for 2 hours under N2. The reaction mixture was diluted with water (20 mL) and extracted with EA (30 mL×3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by silica gel column chromatography to obtain compound 114-2. LCMS: 244.2 [M+H] + .

[0722] Step 2: Preparation of compound 114-4

[0723] Compound 114-3 (75.29 mg, 0.616 mmol) was added to a solution of compound 114-2 (150 mg, 0.616 mmol) in AcOH (5 mL). The mixture was stirred at 90 ° C for 1 hour under N2. The reaction mixture was diluted with water (20 mL) and extracted with EA (30 mL×3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by silica gel column chromatography to give compound 114-4. LCMS: 346.0 [M+H] + .

[0724] Step 3: Preparation of Example 114

[0725] To a solution of compound 114-4 (160 mg, 0.463 mmol) in DCM (3 mL) was added BBr3 (1.16 g, 4.63 mmol). The mixture was stirred at room temperature under N2 for 2 hours. The reaction mixture was diluted with water (15 mL) and extracted with EA (20 mL×3). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by preparative TLC to give Example 114. LCMS: 332.1 [M+H] + ; 1 H NMR: (400MHz, DMSO-d6) δ9.45(s,2H),8.19(s,1H),7.94(d,J=1.4Hz,1H),6.95(s,1H),6.79(d,J=8.2Hz,1H),2.74(s,3H),1.89(s,3H),1.82(s,3H).

[0726] Example 115: Preparation of 3-(2-(2-(cyclopropylamino)thiazol-5-yl)-3H-imidazo[4,5-b]pyridin-6-yl)-2,4-dimethylphenol

[0727] The title compound was prepared according to the following synthetic procedure.

[0728]

[0729] Step 1: Preparation of compound 115-2

[0730] To a solution of compound 114-2 (100 mg, 0.41 mmol) in AcOH (1.5 mL) was added compound 115-1 (73 mg, 0.49 mmol). The mixture was stirred at 90 ° C for 20 hours under N2. The reactant was diluted with EA (10 ml) and brine (10 ml). The aqueous layer was extracted with EA (10 mL×3). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by preparative TCL to give compound 115-2. LCMS: 371.0 [M+H] + .

[0731] Step 2: Preparation of compound 115-4

[0732] Compound 115-3 (1 mL) was added to a solution of compound 115-2 (40 mg, 0.11 mmol) in CH3CN (1.5 mL). The mixture was stirred at 100°C for 3 hours. The reactant was dried to obtain the title crude compound 115-4. LCMS: 392.1 [M+H] + .

[0733] Step 3: Preparation of Example 115

[0734] To a solution of compound 115-4 (55 mg, 0.14 mmol) in DCM (2 mL) was added BBr3 (0.1 mL), and the reaction was stirred at room temperature under N2 for 0.5 h. The reaction was quenched with MeOH (3 mL) and NH3 / MeOH (3 mL). The residue was purified by preparative HPLC to give Example 115. LCMS: 378.1 [M+H] + ; 1H NMR: (400MHz, DMSO-d6) δ13.33(s,1H),9.18(s,1H),8.57(s,1H),7.98(s,1H),7.92(s,1H),7.61(s,1H),6.93(d,J=8 .2Hz,1H),6.76(d,J=8.2Hz,1H),2.63-2.59(m,1H),1.88(s,3H),1.81(s,3H),0.93-0.76(m,2H),0.62-0.57(m,2H).

[0735] Example 116: Preparation of (S)-2-(2-aminopyrimidin-5-yl)-6-(3-hydroxy-2,6-dimethylphenyl)-3H-imidazo[4,5-b]pyridine-7-carbonitrile

[0736] The title compound was prepared according to the following synthetic procedure.

[0737]

[0738] Step 1: Preparation of compound 116-2

[0739] To a solution of compound 116-1 (5 g, 19.802 mmol) in EtOH (150 mL) were added Fe (11.0 g, 198.020 mmol) and AcOH (22.67 mL, 396.040 mmol). The mixture was stirred at 90 ° C for 2 hours. The reaction mixture was carefully added to ice water (150 mL) while stirring, and its pH was adjusted to 8 with NaOH (4M aqueous solution). The mixture was extracted with DCM (200 mL×3). The combined organic layers were washed with brine (300 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by silica gel column chromatography to give compound 116-2 (3.5 g, 15.730 mmol, 79.4%). LCMS: 221.9 [M+H] + .

[0740] Step 2: Preparation of compound 116-3

[0741] Compound 10-6 (3.182 g, 12.135 mmol), Pd(dtbpf)Cl2 (264.1 mg, 0.404 mmol) and K2CO3 (1.677 g, 12.135 mmol) were added to a solution of compound 116-2 (900 mg, 4.045 mmol) in dioxane (22.5 mL) and H2O (4.5 mL). The mixture was stirred at 100°C for 16 hours. The reaction mixture was diluted with water (50 mL), which was extracted with EA (40 mL×3). The combined organic layers were washed with brine (100 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by silica gel column chromatography to give compound 116-3 (240 mg, 0.864 mmol, 21.4%). LCMS: 278.2 [M+H] + .

[0742] Step 3: Preparation of Compound 116-5

[0743] Compound 116-4 (102.6 mg, 0.720 mmol) and AcOH (2 mL) were added to a solution of compound 116-3 (200 mg, 0.720 mmol) in dioxane (4 mL). The mixture was stirred at 75 ° C for 8 hours. The reaction mixture was carefully added to ice water (20 mL) while stirring, and its pH was adjusted to 8 with NaHCO3 (saturated aqueous solution). The mixture was extracted with EA (20 mL×3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by silica gel column chromatography to give compound 116-5 (67 mg, 0.167 mmol, 23.2%). LCMS: 400.1 [M+H] + .

[0744] Step 4: Preparation of Compound 116-6

[0745] A solution of compound 116-5 (60 mg, 0.150 mmol) in NH3 / EtOH (1.5 mL) was stirred at 70°C for 48 hours. The reaction mixture was diluted with water (10 mL) and extracted with EA (10 mL×3). The combined organic layer was washed with brine (20 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by silica gel column chromatography to obtain compound 116-6. LCMS: 381.2 [M+H] + .

[0746] Step 5: Preparation of Compound 116-7

[0747] To a solution of compound 116-6 (45 mg, 0.118 mmol) in DCM (1 mL) was added BBr3 (0.4 mL). The mixture was stirred at room temperature under N2 for 2 hours. The reaction mixture was carefully added to MeOH (10 mL). The pH of the mixture was then adjusted to 7-8 with TEA. After filtration, the filtrate was concentrated to dryness. The residue was purified by silica gel column chromatography to give compound 116-7. LCMS: 367.1 [M+H] + .

[0748] Step 6: Preparation of Example 116

[0749] To a solution of compound 116-7 (21 mg, 0.057 mmol) in DMA (1 mL) was added Zn (3.7 mg, 0.057 mmol), Zn (CN) 2 (6.7 mg, 0.057 mmol) and Pd (dppf) Cl 2 · CH 2 Cl 2 (46.8 mg, 0.057 mmol), Pd 2 (dba) 3 (52.4 mg, 0.057 mmol). The mixture was stirred at 140 ° C under N 2 for 18 hours. The residue was purified by preparative HPLC and further purified by SFC to give Example 116. LCMS: 358.3 [M + H] + ; 1 H NMR: (400MHz, CD3OD) δ9.09(s,2H),8.19(s,1H),7.02(d,J=8.2Hz,1H),6.83(d,J=8.2Hz,1H),1.94(s,3H),1.89(s,3H).

[0750] Example 117: Preparation of (S)-5-(3-hydroxy-2,6-dimethylphenyl)-2-(1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile

[0751] The title compound was prepared according to the following synthetic procedure.

[0752]

[0753] Step 1: Preparation of compound 117-3

[0754] To a solution of compound 117-1 (1 g, 5.155 mmol) and compound 117-2 (1.2 g, 10.825 mmol) in DMF (10 mL) was added Cs2CO3 (4.2 g, 12.887 mmol). The mixture was stirred at 140 ° C for 2.5 hours by microwave. The reaction mixture was diluted with EA (20 mL), which was washed with brine (20 mL×3). The organic layer was dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by silica gel column chromatography to obtain compound 117-3. LCMS: 266.6 [M+H] + .

[0755] Step 2: Preparation of Example 117

[0756] To a solution of compound 117-3 (40 mg, 0.117 mmol) and compound 117-4 (62 mg, 0.234 mmol) in H2O (0.2 mL) and dioxane (1 mL) was added K2CO3 (49 mg, 0.351 mmol) and Pd(dtbpf)Cl2 (8.0 mg, 0.012 mmol). The reaction mixture was diluted with water (10 mL) and extracted with EA (10 mL×3). The combined organic layer was washed with brine (20 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by preparative TLC to give Example 117. LCMS: 402.2 [M+H] + ; 1 H NMR: (400MHz, DMSO-d6) δ12.65(s,1H),9.32(s,1H),8.38(s,1H),8.15(s,1H),8.00(s,1H),7.00(d,J=8. 2Hz,1H),6.85(dd,J=16.3,4.9Hz,2H),4.81(s,1H),4.09(s,2H),1.87(s,3H),1.79(s,3H),1.11(s,6H).

[0757] The following Examples 118-122 were prepared according to the method described in Example 117 using similar starting materials.

[0758]

[0759] Example 121: Preparation of (S)-5-(3-hydroxy-2,6-dimethylphenyl)-2-(1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile

[0760] The title compound was prepared according to the following synthetic procedure.

[0761]

[0762] Step 1: Preparation of Example 121

[0763] A mixture of compound 117-4 (50 mg, 0.146 mmol) and compound 121-1 (101.0 mg, 1.461 mmol) was stirred at 140°C for 18 hours. The reaction mixture was diluted with water (10 mL), which was extracted with EA (10 mL×3). The combined organic layer was washed with brine (20 mL), dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel column chromatography to give Example 121. LCMS: 331.1 [M+H] + ; 1 H NMR: (400MHz, DMSO-d6) δ13.62(s,1H),9.44(s,1H),9.37(s,1H),8.43(s,1H),8.21(s,1 H),7.07(s,1H),7.02(d,J=8.2Hz,1H),6.85(d,J=8.2Hz,1H),1.87(s,3H),1.80(s,3H).

[0764] Example 122: Preparation of (S)-5-(3-hydroxy-2,6-dimethylphenyl)-2-(1H-imidazol-1-yl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile

[0765] The title compound was prepared according to the following synthetic procedure.

[0766]

[0767] Step 1: Preparation of Example 122

[0768] A mixture of compound 117-4 (40 mg, 0.117 mmol) and compound 122-1 (119.4 mg, 1.753 mmol) was heated to 140° C. for 16 hours. The mixture was purified by preparative TLC to give Example 122. LCMS: 330.2 [M+H] + ; 1 H NMR: (400MHz, DMSO-d6) δ13.37(s,1H),9.36(s,1H),8.56(s,1H),8.14(s,1H),8.01(s,1 H),7.23(s,1H),7.01(d,J=6.4Hz,2H),6.85(d,J=8.2Hz,1H),1.87(s,3H),1.79(s,3H).

[0769] Example 123: Preparation of (S)-5-(3-hydroxy-2,6-dimethylphenyl)-2-(1H-pyrazolo[3,4-b]pyridin-5-yl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile

[0770] The title compound was prepared according to the following synthetic procedure.

[0771]

[0772] Step 1: Preparation of compound 123-2

[0773] A mixture of compound 123-1 (1000 mg, 5.051 mmol), 3,4-dihydro-2H-pyran (1274 mg, 15.152 mmol) and PPTS (127 mg, 0.505 mmol) in CH3CN (8 mL) and DCM (8 mL) was stirred at 50 °C for 16 hours. The mixture was concentrated. The residue was purified by silica gel column chromatography to give compound 123-2 (1200 mg, 4.254 mmol, 84.2%) as a yellow solid. LCMS: 282.1 [M+H] + .

[0774] Step 2: Preparation of compound 123-3

[0775] To a solution of compound 123-2 (150 mg, 0.532 mmol) in dioxane (2 mL) was added 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolan (270 mg, 1.063 mmol), KOAc (130 mg, 1.329 mmol) and Pd(dppf)Cl2 (39 mg, 0.053 mmol). The mixture was stirred at 90 °C for 16 hours. The reactant was directly carried to the next step. LCMS: 330.2 [M+H] + .

[0776] Step 3: Preparation of compound 123-4

[0777] To a solution of compound 123-3 (87 mg, 0.263 mmol) and compound 117-4 (50 mg, 0.146 mmol) in dioxane (2 mL) and water (0.4 mL) was added K2CO3 (60 mg, 0.438 mmol) and Pd(dtbpf)Cl2 (10 mg, 0.015 mmol). The mixture was stirred at 100°C for 3 hours. The mixture was concentrated. The residue was purified by preparative TLC to give compound 123-4. LCMS: 465.4 [M+H] + .

[0778] Step 4: Preparation of Example 123

[0779] A mixture of compound 123-4 (20 mg, 0.043 mmol) and hydrogen chloride (4 mL, 16.000 mmol) in MeOH (4 mL) was stirred at room temperature for 4 hours. The mixture was concentrated. The crude product was diluted with water (10 mL) and adjusted to pH about 8 with Na2CO3 (aqueous solution). The mixture was extracted with EA (40 mL). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by preparative TLC to give Example 123. LCMS: 381.1 [M+H] + ; 1 HNMR: (400MHz, DMSO-d6) δ13.87(s,1H),12.98(s,1H),9.33(s,1H),9.25(d,J=2.0Hz,1H),8.89(d,J=1.8Hz,1H),8.2 9(s,1H),8.14(s,1H),7.31(d,J=1.9Hz,1H),7.01(d,J=8.1Hz,1H),6.85(d,J=8.1Hz,1H),1.89(s,3H),1.81(s,3H).

[0780] The following examples were prepared according to the method described in Example 123 using similar starting materials.

[0781]

[0782]

[0783]

[0784] Example 126: Preparation of (S)-2-(2-aminothiazol-5-yl)-5-(3-hydroxy-2,6-dimethylphenyl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile

[0785] The title compound was prepared according to the following synthetic procedure.

[0786]

[0787] Step 1: Preparation of compound 126-2

[0788] At -78 ° C, to a solution of compound 126-1 (300.0 mg, 1.498 mmol) in THF (6 mL) was added n-BuLi (1.26 mL, 3.151 mmol). The mixture was stirred at -78 ° C for 0.5 hours. Then (n-Bu) 3 SnCl (536.4 mg, 1.648 mmol) was added and the mixture was stirred at -78 ° C for 0.5 hours, the reactants were allowed to warm to room temperature and stirred for 3 hours. The mixture was diluted with water (40 mL) and extracted with EA (40 mL×3). The combined organic layers were washed with brine (40 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by silica gel column chromatography to obtain compound 126-2. 1 H NMR: (400MHz, CDCl3) δ12.27 (s, 1H), 7.23 (d, J = 7.3Hz, 1H), 1.52 (s, 9H), 1.49-1. 43(m,6H),1.26(dd,J=14.7,7.3Hz,6H),1.07-0.98(m,6H),0.82(t,J=7.3Hz,9H).

[0789] Step 2: Preparation of compound 126-3

[0790] Compound 32-4 (69.1 mg, 0.194 mmol), LiCl (16.4 mg, 0.387 mmol) and Pd(PPh3)4 (44.8 mg, 0.0388 mmol) were added to a solution of compound 126-2 (190.0 mg, 0.388 mmol) in dioxane (5 mL). The mixture was stirred at 100 ° C for 5 hours. The mixture was diluted with water (30 mL) and extracted with EA (30 mL×3). The combined organic layer was washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by preparative TLC to give compound 126-3. LCMS: 476.3 [M+H] + .

[0791] Step 3: Preparation of Example 126

[0792] To a solution of compound 126-3 (60.0 mg, 0.126 mmol) in DCM (4 mL) was added BBr3 (315.7 mg, 1.26 mmol) at 0°C. The mixture was stirred at room temperature for 1 hour. The reaction was quenched with MeOH (10 mL). The mixture was concentrated to dryness and purified by preparative HPLC to give Example 126. LCMS: 362.1 [M+H] + ; 1H NMR: (400MHz, DMSO-d6) δ12.69(s,1H),9.33(s,1H),8.00(s,1H),7.74(s,1H),7.54(s,2 H),6.99(d,J=8.2Hz,1H),6.83(d,J=8.2Hz,1H),6.52(s,1H),1.86(s,3H),1.78(s,3H).

[0793] The following Example 132 was prepared according to the method described in Example 126 using similar starting materials.

[0794]

[0795] Example 127: Preparation of (S)-2-(3-amino-1,2,4-triazine-6-yl)-5-(3-hydroxy-2,6-dimethylphenyl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile

[0796] The title compound was prepared according to the following synthetic procedure.

[0797]

[0798] Step 1: Preparation of Compound 127-1

[0799] To a solution of compound 29-1 (3.0 g, 6.952 mmol) in THF (75.0 mL) was added dropwise LDA (7.0 mL, 13.905 mmol) under N2 at -78 °C. The mixture was stirred at -78 °C for 30 minutes. Then (n-Bu)3SnCl (4.53 g, 13.905 mmol) was added. The mixture was stirred at -78 °C for 1 hour, then warmed to room temperature for 0.5 hours. The mixture was quenched by saturated NH4Cl aqueous solution (30 mL) and extracted with EA (40 mL×3). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography to give compound 127-1 (1.28 g, 1.776 mmol, 25.5%). 1H NMR: (400MHz, CDCl3) δ8.18(s,1H),8.07(d,J=8.3Hz,2H),7.30(d,J=8.3Hz,2H),7.10(d,J=8.4Hz,1H),6.90-6.83(m,2H),3.85(s,3 H),2.41(s,3H),1.90(s,3H),1.83(s,3H),1.70-1.56(m,6H),1.41(dd,J=14.6,7.3Hz,6H),1.35-1.25(m,6H),0.94(t,J=7.3Hz,9H).

[0800] Step 2: Preparation of compound 127-3

[0801] Compound 127-2 (97.1 mg, 0.555 mmol), Pd(PPh3)4 (64.1 mg, 0.056 mmol) and CuI (21.1 mg, 0.111 mmol) were added to a solution of compound 127-1 (400.0 mg, 0.555 mmol) in toluene (6.0 mL). The mixture was stirred at 120 ° C for 1 hour under N2. The reaction mixture was diluted with water (20 mL) and extracted with EA (30 mL×3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by silica gel column chromatography to give compound 127-3. LCMS: 526.3 [M+H] + .

[0802] Step 3: Preparation of compound 127-4

[0803] A mixture of compound 127-3 (172.0 mg, 0.327 mmol) and NaOH (130.9 mg, 3.272 mmol) in EtOH (6.0 mL) was stirred at 60 ° C for 1 hour under N2. The pH of the reaction mixture was adjusted to 7 with HCl (1M aqueous solution) at 0 ° C. The mixture was extracted with EA (20 mL×3). The combined organic layers were washed with brine (90 mL), dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel column chromatography and further purified by SFC to obtain compound 127-4. LCMS: 413.1 [M+H+CH3CN] + .

[0804] Step 4: Preparation of Example 127

[0805] To a solution of compound 127-4 (30.0 mg, 0.081 mmol) in DCM (3.0 mL) was added BBr3 (0.04 mL, 0.404 mmol) at 0°C. The mixture was stirred at room temperature for 1 hour. The reaction mixture was carefully added to MeOH (2 mL) while stirring, and diluted with water (10 mL), and its pH was adjusted to 8 with NaHCO3. The mixture was extracted with DCM (30 mL) and EA (20 mL×2). The combined organic layers were dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by preparative HPLC to give Example 127. LCMS: 358.0 [M+H] + ; 1 H NMR: (400MHz, DMSO-d6) δ9.35(s,1H),9.08(s,1H),8.16(s,1H),7.66(s,2H),7.3 4(s,1H),7.01(d,J=8.2Hz,1H),6.85(d,J=8.2Hz,1H),1.88(s,3H),1.80(s,3H).

[0806] Example 128: Preparation of 3-(6-(2-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl)pyrimidin-5-yl)-5H-pyrrolo[2,3-b]pyrazin-2-yl)-2,4-dimethylphenol

[0807]

[0808] Step 1: Preparation of Example 128

[0809] A mixture of compound 128-1 (165.0 mg, 0.746 mmol), compound 128-2 (274.3 mg, 1.119 mmol), K3PO4 (190.1 mg, 0.896 mmol) and Pd(dtbpf)Cl2 (19.5 mg, 0.030 mmol) in dioxane-water (3 mL) was stirred at 90 ° C for 3 hours under N2. The reaction mixture was diluted with water (20 mL) and extracted with EA (30 mL×3). The combined organic layer was washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by preparative HPLC to give Example 128. LCMS: 415.2 [M+H] + ; 1H NMR: (400MHz, DMSO-d6) δ12.49(s,1H),9.21(s,1H),9.00(s,2H),8.02(s,1H), 7.06(s,1H),6.94(d,J=8.2Hz,1H),6.79(d,J=8.1Hz,1H),5.04(s,1H),4.72(s, 1H),3.84(d,J=7.2Hz,1H),3.72(d,J=7.3Hz,1H),3.56(d,J=10.6Hz,1H),3.47( d,J=10.9Hz,1H),1.98(d,J=8.5Hz,1H),1.92(s,1H),1.88(s,3H),1.80(s,3H).

[0810] Example 133: Preparation of (S)-2-(4-amino-1H-pyrazol-1-yl)-5-(3-hydroxy-2,6-dimethylphenyl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile

[0811] The title compound was prepared according to the following synthetic procedure.

[0812]

[0813] A mixture of 2-bromo-5-(3-hydroxy-2,6-dimethylphenyl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile (70 mg, 0.205 mmol), 1H-pyrazol-4-amine (34.0 mg, 0.409 mmol), methyl[(1S,2S)-2-(methylamino)cyclohexyl]amine (5.8 mg, 0.041 mmol), t-BuONa (59.0 mg, 0.614 mmol) and CuI (7.8 mg, 0.041 mmol) in DMF (0.5 mL) was heated to 100 ° C. under N2 atmosphere for 16 hours. The mixture was purified by preparative HPLC to give compound 133. LCMS: 345.1 [M+H] + ; 1 H NMR(400MHz,DMSO-d6)δ13.71–12.17(br s,1H),9.29(s,1H),7.96(s,1H),7.84(s,1H),7.44(s,1H),6.99(d,J=8.1Hz,1 H),6.83(d,J=8.0Hz,1H),6.61(s,1H),4.41(s,1H),1.87(s,3H),1.79(s,3H).

[0814] Example 135: Preparation of 5-(3-hydroxy-2,6-dimethylphenyl)-2-(4H-1,2,4-triazol-3-yl)-1H-pyrrolo[2,3-b]pyridine-4-carbonitrile

[0815]

[0816] Step 1: Preparation of compound 135-2

[0817] To a solution of compound 29-1 (2000 mg, 4.635 mmol) in THF (50 mL) was added LDA (4.63 mL, 9.270 mmol) at -78 °C. The mixture was stirred for 0.5 hours, and then a solution of methyl chloroformate (876.0 mg, 9.27 mmol) in THF (15 mL) was added. The mixture was stirred at -78 °C for 2 hours, quenched with aqueous NH4Cl solution (50 mL), diluted with water (200 mL), and extracted with EA (100 mL×3). The combined organic phases were washed with brine (150 mL×2), dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography to give compound 135-2 (1.0 g, 44.1% yield) as a white solid. LCMS: 489.8 [M+H] + .

[0818] Step 2: Preparation of compound 135-3

[0819] A mixture of compound 135-2 (200 mg, 0.409 mmol) in ammonia (7.0 M MeOH solution, 10 mL, 70.0 mmol) was stirred at 65° C. for 10 hours. The mixture was concentrated to give compound 135-3. LCMS: 321.2 [M+H] +

[0820] Step 3: Preparation of compound 135-4

[0821] A solution of compound 135-3 (100 mg, 0.312 mmol) in N,N-dimethylformamide dimethyl acetal (5 mL) was stirred at 90 ° C for 1 hour. The mixture was concentrated and dissolved in EtOH (10 mL) to give P1. P1 was added to a solution of hydrazine hydroxide (1 mL, 20.559 mmol) in AcOH (3 mL) at 0 ° C. The mixture was stirred at room temperature for 1 hour and concentrated. The residue was purified by silica gel column chromatography to give compound 135-4. LCMS: 345.1 [M+H] + .

[0822] Step 3: Preparation of Example 135

[0823] To a mixture of compound 135-4 (15 mg, 0.044 mmol) in DCM (5 mL) was added boron tribromide (0.25 mL) at 0°C. The mixture was stirred for 1 hour, quenched with NH3 / MeOH (7 M) at 0°C and concentrated. The residue was purified by preparative TLC (MeOH:DCM=1:10) to give Example 135. LCMS: 331.1 [M+H] + ; 1 H NMR(400MHz,DMSO-d6)δ14.52(s,1H),13.14(s,1H),9.35(s,1H),8.72(s,1H),8 .19(s,1H),7.20–6.94(m,2H),6.85(d,J=8.2Hz,1H),1.87(s,3H),1.80(s,3H).

[0824] Example A: PKMYT1 HTRF assay

[0825] Compounds were serially diluted by Echo and the final concentrations varied from 10 μM to 0.5 nM. Filled by adding 5 μL / well of enzyme solution to the assay plate containing the compound. The plate was centrifuged at 1000 rpm for 1 minute and incubated at 25°C for 15 minutes. Then 5 μL / well of tracer solution (Tracer 178) was added to initiate the reaction and incubated at 25°C for 60 minutes. Next, 5 μL of GST-Tb was added to the assay plate, the plate was centrifuged at 1000 rpm for 1 minute, and incubated at 25°C for 15 minutes. The assay plate was read on Envision.

[0826] The data for Example A is shown in Table 3.

[0827] Table 3

[0828]

[0829]

[0830]

[0831]

[0832]

[0833] MYT1 HTRF IC 50 (nM): 0 <A≤10;10<B≤50;50<C≤500;500<D≤5000;5000<E

[0834] Example B: WEE1 ADP-Glo ​​Assay

[0835] Compound serial dilutions were performed by Echo and the final concentrations varied from 10 μM to 0.5 nM. The assay plates were filled by adding 5 μL / well of enzyme solution to the assay plates containing the compounds. The plates were centrifuged at 1000 rpm for 1 minute and incubated at 25 °C for 15 minutes. Then 5 μL / well of substrate solution was added to initiate the reaction and incubated at 25 °C for 60 minutes. Next 10 μL of kinase detection reagent was added to the assay plates, the plates were centrifuged at 1000 rpm for 1 minute, and incubated at 25 °C for 60 minutes. The US LUM of the assay plates were read as RLU on Envision.

Claims

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof: in: Ring A is cycloalkyl, heterocycloalkyl, aryl or heteroaryl; Each R 1 are independently halogen, -CN, -NO 2 、-OH、-OR a 、-OC(=O)R a 、-OC(=O)OR b 、-OC(=O)NR c R d , -SH, -SR a 、-S(=O)R a 、-S(=O) 2 R a 、-S(=O) 2 NR c R d 、-NR c R d 、-NR b C(=O)NR c R d 、-NR b C(=O)R a 、-NR b C(=O)OR b 、-NR b S(=O) 2 R a 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl, C 1 -C 6 Heteroalkyl, C 2 -C 6 Alkenyl, C 2 -C 6 wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently optionally replaced by one or more R 1a replace; or two R on the same atom 1 Together they form an oxo group; Each R 1a are independently halogen, -CN, -NO 2 、-OH、-OR a 、-OC(=O)R a 、-OC(=O)OR b 、-OC(=O)NR c R d , -SH, -SR a 、-S(=O)R a 、-S(=O) 2 R a 、-S(=O) 2 NR c R d 、-NR c R d 、-NR b C(=O)NR c R d 、-NR b C(=O)R a 、-NR b C(=O)OR b 、-NR b S(=O) 2 R a 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl, C 1 -C 6 Heteroalkyl, C 2 -C 6 Alkenyl, C 2 -C 6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently optionally substituted with one or more R; or two R on the same atom 1a Together they form an oxo group; n is 0-6; R 2 It is hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl, C 1 -C 6 heteroalkyl, cycloalkyl or heterocycloalkyl; W is N or CR W ; R W It is hydrogen, halogen, -CN, -OH, -OR a , -SH, -SR a 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl, C 1 -C 6 Heteroalkyl, C 2 -C 6 Alkenyl, C 2 -C 6 wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted by one or more R Wa replace; Each R Wa are independently halogen, -CN, -NO 2 、-OH、-OR a , -SH, -SR a 、-S(=O)R a 、-S(=O) 2 R a 、-S(=O) 2 NR c R d 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl, C 1 -C 6 Heteroalkyl, C 2 -C 6 Alkenyl, C 2 -C 6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently optionally substituted with one or more R; or two R on the same atom Wa Together they form an oxo group; X is N or CR X ; R X It is hydrogen, halogen, -CN, -OH, -OR a 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl, C 1 -C 6 Heteroalkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted with one or more R; Y is N or CR Y ; R Y It is hydrogen, halogen, -CN, -OH, -OR a 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl, C 1 -C 6 Heteroalkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted with one or more R; Z is N or CR Z ; R Z It is hydrogen, halogen, -CN, -OH, -OR a 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl, C 1 -C 6 Heteroalkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted with one or more R; R 3 Halogen, C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl or C 1 -C 6 heteroalkyl, cycloalkyl or heterocycloalkyl; R 4 Halogen, C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl or C 1 -C 6 heteroalkyl, cycloalkyl or heterocycloalkyl; R 5 It is hydrogen, halogen, -CN, -NO 2 、-OH、-OR a 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl, C 1 -C 6 Heteroalkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, cycloalkyl or heterocycloalkyl; R 6 It is hydrogen, halogen, -CN, -NO 2 、-OH、-OR a 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl, C 1 -C 6 Heteroalkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, cycloalkyl or heterocycloalkyl; Each R a Independently C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl, C 1 -C 6 Heteroalkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C 1 -C 6 Alkylene (cycloalkyl), C 1 -C 6 Alkylene (heterocycloalkyl), C 1 -C 6 Alkylene (aryl) or C 1 -C 6 Alkylene(heteroaryl), wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently optionally substituted with one or more R; Or two R a taken together with the atoms to which they are attached form heterocycloalkyl optionally substituted with one or more R; Each R b are independently hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl, C 1 -C 6 Heteroalkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C 1 -C 6 Alkylene (cycloalkyl), C 1 -C 6 Alkylene (heterocycloalkyl), C 1 -C 6 Alkylene (aryl) or C 1 -C 6 Alkylene(heteroaryl), wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently optionally substituted with one or more R; Or two R b taken together with the atoms to which they are attached form heterocycloalkyl optionally substituted with one or more R; R c and R d are independently hydrogen, C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl, C 1 -C 6 Heteroalkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C 1 -C 6 Alkylene (cycloalkyl), C 1 -C 6 Alkylene (heterocycloalkyl), C 1 -C 6 Alkylene (aryl) or C 1 -C 6 Alkylene(heteroaryl), wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently optionally substituted with one or more R; or R c and R d taken together with the atoms to which they are attached form heterocycloalkyl optionally substituted with one or more R; and Each R is independently halogen, -CN, -OH, -S(=O)CH 3 、-S(=O) 2 CH 3 、-S(=O) 2 NH 2 、-S(=O) 2 NHCH 3 、-S(=O) 2 N(CH 3 ) 2 、-NH 2 、-NHCH 3 、-N(CH 3 ) 2 、-C(=O)CH 3 , -C(=O)OH, -C(=O)OCH 3 , C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, C 1 -C 6 Haloalkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl, C 1 -C 6 Heteroalkyl or C 3 -C 6 Cycloalkyl; Alternatively, two R's on the same atom form an oxo group.

2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein X is N.

3. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein X is CR X . 4 . The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein Y is N.

5. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, wherein Y is CR Y .

6. The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein W is N.

7. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 5, wherein W is CR W .

8. The compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein Z is N.

9. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 7, wherein Z is CR Z .

10. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound has formula (Ia):

11. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound has formula (Ib):

12. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound has formula (Ic):

13. A compound according to any one of claims 1 to 12 or a pharmaceutically acceptable salt thereof, wherein R 3 Halogen, C 1 -C 6 Alkyl or C 1 -C 6 Halogenated alkyl.

14. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 13, wherein R 3 It is C 1 -C 6 alkyl.

15. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 14, wherein R 4 Halogen, C 1 -C 6 Alkyl or C 1 -C 6 Halogenated alkyl.

16. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 15, wherein R 4 It is C 1 -C 6 alkyl.

17. A compound according to any one of claims 1 to 16 or a pharmaceutically acceptable salt thereof, wherein R 5 It's hydrogen.

18. A compound according to any one of claims 1 to 17 or a pharmaceutically acceptable salt thereof, wherein R 6 It's hydrogen.

19. A compound according to any one of claims 1 to 18 or a pharmaceutically acceptable salt thereof, wherein R 2 is hydrogen or C 1 -C 6 alkyl.

20. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 19, wherein R 2 It's hydrogen.

21. A compound according to any one of claims 1 to 20, or a pharmaceutically acceptable salt thereof, wherein R X It is hydrogen, halogen, C 1 -C 6 Alkyl or C 1 -C 6 Halogenated alkyl.

22. A compound as claimed in any one of claims 1 to 21 or a pharmaceutically acceptable salt thereof, wherein R X is hydrogen, halogen or C 1 -C 6 alkyl.

23. A compound as described in any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, wherein R X is hydrogen or a halogen.

24. A compound as described in any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof, wherein R X It's hydrogen.

25. A compound as described in any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, wherein R Y is hydrogen, halogen, C 1 -C 6 Alkyl or C 1 -C 6 Halogenated alkyl.

26. A compound as described in any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, wherein R Y It's hydrogen.

27. A compound as described in any one of claims 1 to 26, or a pharmaceutically acceptable salt thereof, wherein R Z is hydrogen, halogen or C 1 -C 6 alkyl.

28. A compound as described in any one of claims 1 to 27, or a pharmaceutically acceptable salt thereof, wherein R Z is hydrogen or a halogen.

29. A compound as described in any one of claims 1 to 28, or a pharmaceutically acceptable salt thereof, wherein R Z It's hydrogen.

30. A compound as described in any one of claims 1 to 29, or a pharmaceutically acceptable salt thereof, wherein R W It is hydrogen, halogen, -OH, -OR a 、-NR c R d , C 1 -C 6 Alkyl, C 1 -C 6 wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl groups are optionally substituted with one or more R.

31. A compound as described in any one of claims 1 to 30, or a pharmaceutically acceptable salt thereof, wherein R W is hydrogen, halogen, -OR a , C 1 -C 6 Alkyl, C 1 -C 6 wherein the alkyl, cycloalkyl and heterocycloalkyl are optionally substituted with one or more R.

32. A compound as described in any one of claims 1 to 31, or a pharmaceutically acceptable salt thereof, wherein R W is hydrogen, -OR a , C 1 -C 6 wherein the alkyl and heterocycloalkyl are optionally substituted with one or more R.

33. A compound as described in any one of claims 1 to 32, or a pharmaceutically acceptable salt thereof, wherein R W It's hydrogen.

34. A compound as described in any one of claims 1 to 32, or a pharmaceutically acceptable salt thereof, wherein R W is heterocycloalkyl optionally substituted by one or more R.

35. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 34, wherein ring A is cycloalkyl or heterocycloalkyl.

36. The compound or pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 35, wherein ring A is a heterocycloalkyl group.

37. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 36, wherein ring A is a 5-membered or 6-membered heterocycloalkyl group.

38. The compound or pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 37, wherein Ring A is tetrahydropyridinyl.

39. The compound or pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 34, wherein ring A is aryl or heteroaryl.

40. The compound of any one of claims 1 to 34 or 39, or a pharmaceutically acceptable salt thereof, wherein Ring A is a heteroaryl group.

41. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 34 or 39 or 40, wherein ring A is a 5-membered or 6-membered heteroaryl group.

42. The compound of any one of claims 1 to 34 or 39 or 40, or a pharmaceutically acceptable salt thereof, wherein Ring A is a monocyclic heteroaryl.

43. A compound as described in any one of claims 1 to 34 or 39 or 40, or a pharmaceutically acceptable salt thereof, wherein Ring A is a bicyclic heteroaryl.

44. The compound of any one of claims 1 to 34 or 39 or 40, or a pharmaceutically acceptable salt thereof, wherein Ring A is pyridinyl.

45. A compound as described in any one of claims 1 to 44, or a pharmaceutically acceptable salt thereof, wherein each R 1 are independently halogen, -CN, -OH, -OR a 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 Hydroxyalkyl, C 1 -C 6 Aminoalkyl, C 1 -C 6 wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently optionally replaced by one or more R 1a replace.

46. ​​A compound as described in any one of claims 1 to 45, or a pharmaceutically acceptable salt thereof, wherein each R 1 are independently halogen, -OR a 、-NR c R d 、-C(=O)R a , C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 1 -C 6 wherein each alkyl, cycloalkyl and heterocycloalkyl group is independently optionally substituted by one or more R 1a replace.

47. A compound as described in any one of claims 1 to 46, or a pharmaceutically acceptable salt thereof, wherein each R 1 are independently halogen, -OR a 、-NR c R d 、-C(=O)R a , C 1 -C 6 Alkyl, C 1 -C 6 wherein each alkyl and heterocycloalkyl group is independently optionally substituted by one or more R 1a replace.

48. A compound as described in any one of claims 1 to 47, or a pharmaceutically acceptable salt thereof, wherein each R 1a are independently halogen, -CN, -OH, -OR a 、-NR c R d 、-C(=O)R a 、-C(=O)OR b 、-C(=O)NR c R d , C 1 -C 6 Alkyl, C 1 -C 6 haloalkyl, cycloalkyl or heterocycloalkyl; wherein each alkyl, cycloalkyl, heterocycloalkyl is independently optionally substituted with one or more R.

49. A compound as described in any one of claims 1 to 48, or a pharmaceutically acceptable salt thereof, wherein each R 1a are independently halogen, C 1 -C 6 Alkyl or C 1 -C 6 wherein each alkyl group is independently optionally substituted with one or more R groups.

50. A compound as described in any one of claims 1 to 49, or a pharmaceutically acceptable salt thereof, wherein each R 1a are independently halogen, C 1 -C 6 Alkyl or C 1 -C 6 Halogenated alkyl.

51. A compound as described in any one of claims 1 to 50, or a pharmaceutically acceptable salt thereof, wherein n is 0-2.

52. A compound as described in any one of claims 1 to 51, or a pharmaceutically acceptable salt thereof, wherein n is 1 or 2.

53. A compound as described in any one of claims 1 to 52, or a pharmaceutically acceptable salt thereof, wherein n is 1.

54. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the compounds present in Table 1 or Table 2.

55. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 54 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

56. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a compound as described in any one of claims 1 to 54, or a pharmaceutically acceptable salt thereof.

57. A method of modulating PKMYT1 in a subject, the method comprising administering to the subject a compound of any one of claims 1 to 54, or a pharmaceutically acceptable salt thereof.

58. A method of inhibiting PKMYT1 in a subject, the method comprising administering to the subject a compound of any one of claims 1 to 54, or a pharmaceutically acceptable salt thereof.

59. The method of claim 57 or 58, wherein the subject has cancer.

60. The method of claim 56, wherein the cancer is dependent on the activity of PKMYT1.

61. The method of any one of claims 56 or 60, wherein the cancer overexpresses CCNE1.

62. The method of any one of claims 56 or 60 or 61, wherein the cancer has an inactivating mutation in the FBXW7 gene.

63. The method of any one of claims 56 or 60 to 62, wherein the cancer is a solid tumor.

64. The method of any one of claims 56 or 60 to 63, wherein the cancer is breast cancer, colorectal cancer, endometrial cancer, esophageal cancer, glioblastoma, hepatocellular carcinoma, lung cancer, neuroblastoma, ovarian cancer, prostate cancer, gastric cancer, or uterine cancer.

Citation Information

Patent Citations

  • Inhibitors of Akt Activity

    US20080318947A1

  • Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use

    WO2021195781A1

  • Methods of using MYT1 inhibitors

    WO2021195782A1